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SUMMARY
The antitumour activities of 18 benzoic acid and 2-hydroxybenzoic acid 
analogues were investigated in HT-1080 fibrosarcoma cell line. Several 
approaches were used to identify the most effective apoptotic agents 
capable of inhibiting cell population expansion of HT-1080 cells mostly at a 
concentration of 0.4mM. Techniques used in this study included: cell 
viability assays (MTT, direct count and time-lapse tracking images), 
morphology (DAPI, haematoxylin-eosin, methyl green-pyronin y, and 
SEM), immunocytochemistry (Annexin V, caspase-3) and pharmacology 
(2-hydroxybenzoate uptake). The results indicated that most of these 
compounds showed antiproliferative activities at specific concentrations 
(range 0.025-8mM), with an incubation time of 2-180 hours. It is evident 
that zinc 2-hydroxybenzoate was the most effective antiproliferative agent 
at 0.3 and 0.4mM. Other analogues, mainly calcium, also showed 
antiproliferative activities but at higher concentrations (up to 8mM).
The growth inhibitory effect on HT-1080 cells population after treatment 
with either calcium or zinc 2-hydroxybenzoates was identified as the 
occurrence of apoptosis. This was confirmed by the morphological 
techniques as well as by immunoassay including annexin V and caspase- 
3, measured by flow cytometry. Although strong evidence has been 
presented here for apoptosis, the genetic mechanism remains uncertain. 
Neither the expression of the six proteins p53, p21, Bax, Bcl-2, histones 
and TNF-a, nor the cell cycle analysis was able to fully elucidate the 
mechanism of action of calcium and zinc 2-hydroxybenzoate on HT-1080 
cells. Nonetheless, calcium and zinc 2-hydroxybenzoate-induced 
apoptosis clearly involved caspase-3 through Bax and p53/p21, 
respectively, and displayed the properties of potentially therapeutic 
compounds.
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Chapter One 
General Introduction
CHAPTER ONE
General Introduction 
1.1 Introduction
It has been found that certain natural products are good sources for new 
chemotherapeutic agents (Stellman, 1995; Chung et al., 2001). Many 
more natural and synthetic biologically active compounds are being 
investigated as potential anticancer agents. Among these are the benzoic 
acid analogues, including salicylates. These have been shown to exert 
anticancer activities, particularly against colorectal cancer cells (Hector et 
al., 2001). The role of 2-hydroxybenzoates (salicylates) in cancer has 
been largely based on epidemiological studies which showed that the 
regular use of aspirin could reduce the risk of developing colorectal cancer 
by 40-50 % (Ruschoff et al., 1998; Stark et al., 2001). The data were 
obtained by comparing people who regularly take aspirin with matched 
controls. Although many studies have been published on the effects of 2- 
acetylbenzoic acid, very few appear to have exploited its precursor, 2- 
hydroxybenzoic acid and its metal ion benzoates. The current work aims 
to screen and assess the anticancer activities of a total of 18 compounds, 
including benzoic acid, 2-hydroxybenzoic acid, 2-acetylbenzoaic acid 
(aspirin) and their corresponding lithium (Li), potassium (K), magnesium 
(Mg), calcium (Ca) and zinc (Zn) benzoate, 2-hydroxybenzoate, and 2- 
acetylbenzoate salts, respectively. The goal was to study the effect of a 
range of benzoate concentrations on HT-1080 cells viability and 
proliferation, their morphological characteristics, and changes in molecular 
biology.
1.2 Cell Death by Apoptosis
Most living cells undergo recurring cycles of cell growth and division under 
strictly controlled conditions. This fundamentally occurs in 4 phases (G1, 
S, G2 and M; see Chapter 4). In a healthy living system, cell population
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growth is precisely balanced with apoptosis to maintain homeostasis of the 
living system. Apoptosis is a genetically controlled programmed cell death 
that forms part of the normal development of multicellular organisms. It 
serves two functions: remodelling of tissues during embryogenesis and 
elimination of damaged cells (Roger, 2000). It is functionally defined as an 
equal and opposite force to mitosis (Bowen et al., 1997). Integration of 
proliferation and death is essential for normal developing tissues. 
Apoptosis usually involves single isolated cells rather than a confluent 
portion of a tissue (Roger, 2000). It occurs in two stages; a commitment to 
cell death and an execution phase characterised by morphological 
changes in cell structure (Wong eta!., 1999).
In cancer cells, the level of mitosis is elevated, compared to the level of 
apoptosis due mainly to defective cell cycle checkpoints (see Chapter 4). 
Therefore, several natural and synthetic molecules have been investigated 
to readjust the kinetic relationship between proliferation and cell death.
Beside apoptosis, living cells may also die by necrosis, or massive 
accidental cell death. Necrotic cell death can result from diseases, acute 
toxins or lethal external force. This type of death is characterised by an 
increase in plasma membrane permeability, resulting in cellular oedema, 
and eventually leads to osmotic lysis of the cell and spilling of the cellular 
contents, instigating an inflammatory response (Mitton, 2000). Therefore, 
inducing apoptosis is a therapeutic possibility. Many studies have 
elucidated the characteristic features of apoptosis, both morphological and 
molecular, employing different techniques (see Chapters 3 and 4). The 
metabolic machinery necessary for the completion of apoptosis already 
exists in the cell. The signal transduction required to activate the pre­
existing death machinery often entails novel protein synthesis. It is 
generally understood that there are 3 types of gene product involved in 
apoptosis. The first type includes gene products that generate the death- 
activating signal transduction process in healthy cells during physiological 
cell death. These products can result in either cell proliferation or 
apoptosis, depending on the differentiation status of the cell. An example
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is the transformating growth factor-beta (TGF-p), which is a cell type- 
specific type-1 gene that can stimulate cell proliferation in mesenchymal 
cells, but causes apoptosis in certain epithelial cells (La Monica et al., 
2003). The second kind of apoptotic gene product establishes the 
sensitivity of the cell to the activation of apoptosis in response to damage. 
This includes p53 and Bcl-2. The expression of p53 increases the 
sensitivity of the cells to apoptosis, and Bcl-2 reduces this sensitivity 
(Adams and Cory, 1998). The third type of gene product makes up the 
actual machinery of apoptosis e.g. the caspases.
The major machinery for the execution of apoptosis is a family of serine 
proteases called caspases (see Chapter 4). They are initially synthesised 
as procaspases, and are activated by cleavage at an aspartic acid 
residue. Once a caspase is activated, it cleaves other procaspases, 
resulting in an amplifying proteolytic cascade. Certain caspases, when 
activated, can cleave other proteins in the cell, such as nuclear lamins and 
the proteins that hold DNA-degrading enzymes in an inactive form. The 
caspase cascade is destructive, self-amplifying and irreversible. Adaptor 
proteins initiate activation of procaspases; they aggregate specific initiator 
procaspases together to form a complex. Initator procaspases have a 
small amount of protease activity, and when they are brought together, 
they can cleave each other, initiating their reciprocal activation. Once the 
caspase on the top of the cascade is triggered, it will begin cleaving 
downstream procaspases (Thornberry and Lazebnik, 1998).
Caspase activation can also be triggered extracellularly by the activation 
of death receptors. Cytotoxic killer lymphocytes, for instance, trigger 
apoptosis by producing a Fas ligand protein that binds to the Fas cell 
surface receptor. The Fas proteins can employ intracellular adaptor 
proteins, which bind to and aggregate procaspase-8 molecules. 
Procaspase-8 molecules subsequently cleave and activate each other and 
other downstream procaspases. When cells are under great stress, they 
may commit suicide by producing both Fas ligand and the Fas protein 
(Wajant, 2002)
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Apoptosis can also be triggered by inducing mitochondria to release 
cytochrome c (an electron carrier) into the cytosol. Cytochrome c binds, 
activates and aggregates protein Apaf-1 which then binds and aggregates 
procaspase-9 molecules, triggering the caspase cascade (Green and 
Reed, 1998). The Bcl-2 family of proteins help regulate the activation of 
procaspases. Bcl-2 and Bcl-X inhibit apoptosis by preventing the release 
of cytochrome c from the mitochondria. Some members of the Bcl-2 
family, however, promote apoptosis, for instance Bad functions by binding 
and inactivating the death inhibitor members of the Bcl-2 family. Bax and 
Bak stimulate the release of cytochrome c. If genes encoding Bax and Bak 
are inactivated, cells become extremely resistant to apoptotic agents. 
Other apoptotic-inducing members of the Bcl-2 family such as Bid activate 
Bax and Bak (Wei et al., 2001). The inhibitors of apoptosis (IAP), a family 
of intercellular apoptotic regulators, inhibit apoptosis in two ways. They 
can bind to procaspases and prevent their activation, or they bind to 
caspases to directly inhibit their activity. When mitochondria release 
cytochrome c to activate Apaf-1, they also release proteins that block IAP, 
assisting the induction of apoptosis.
Extracellular signals may also promote or inhibit apoptosis, by regulating 
the activity of the Bcl-2 and IAP families (Nicholson and Thornberry,
2003).
1.3 Cancer
It is generally accepted that cancer is a complex disease evolving from 
permanent damage, mainly to cells' DNA. Humans have 22 pairs of 
chromosomes plus the sex chromosomes (XX in the female, XY in the 
male). Each human has about 6 billion base pairs of DNA capable of 
encoding about 30,000-40,000 different proteins (Pennisi, 2001; Wu and 
Morris, 2001) that undergo different types of interactions and subsequent 
modifications. Although cells have the mechanism to correct any defective 
molecular interactions, it is becoming increasingly apparent that aberrant
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cells have the same complexity of interactions as normal cells. Cancer is a 
complex disease arising from normal cells whose nature is permanently 
altered, forming a malignant neoplasm, such as carcinoma, sarcoma or 
others. The main problem in cancer cells is the regulation of the cell cycle 
which directs mitosis and/or apoptosis.
Disruption of restriction point control in the cell cycle is a common 
biological feature in human cancer. Cancer cells are characterised by their 
unregulated proliferation, their lower requirements for growth factors, and 
their negative response to signals. Alterations in cyclins and CKI genes 
are important for the genesis of certain cancers (Roger, 2000). A number 
of hereditary syndromes exist, in which DNA repair is defective. Ataxia 
telangiectasia syndrome is one of these disorders, which results from the 
failure of G1/M checkpoint delay (Dennis, 1998). Many tumours are 
formed because the rate of cell division exceeds that of cell death.
Two well-known types of primary genes that regulate apoptosis and cell 
division, that could be responsible for cancer include proto-oncogenes 
(e.g. Bcl-2) and tumour suppressor genes (e.g. p53) (Harrington 1994; 
Daniel, 2002). Bcl-2 blocks apoptosis in tumours and therefore allows the 
propagation of abnormal cells. Overexpression of Bcl-2 has been reported 
in a number of human tumours, e.g. adenocarcinoma of the prostate, 
squamous carcinoma of the lung, and nasopharyngeal carcinoma 
(Sherbet and Lakshmi, 1997). The two genes that are most frequently 
altered in cancers are p53 and Rb genes. Mutations in the p53 gene are 
found in 50% of human cancers, which are in the form of deletion, 
rearrangement, and base substitution mutations (Spence and Johnston, 
2001). Some sporadic cancers such as bladder and breast cancer are the 
result of mutation in the Rb gene (Bowen, 1999).
Cancers can be treated in several ways: surgery, radiotherapy, 
chemotherapy, or combined treatments. The objective of any treatment is 
to control proliferation (cytostatic effect) and to kill cancer cells (cytotoxic 
effect). Apoptosis is an important factor in determining the response to
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treatment and a major determinant of size of tumours, with individual cells 
being eliminated in about three hours (Roger, 2000).
1.4 Biological Activity of 2-Hydroxybenzoate Analogues
Naturally occurring monoaromatic compounds, such as 2-acetylbenzoic 
acid (aspirin) and 2-hydroxybenzoic acid (salicylic acid), have significant 
biological activities such as anti-oxidative and anti-inflammatory 
properties. Since early civilisation, many plants containing monoaromatic 
constituents were used as a remedy for different ailments. Different parts 
of the willow tree, for example, were exploited by Sumerians, Babylonians, 
Egyptians, and Greeks, and later, in the middle of the previous millennium, 
Europeans explored the active ingredient responsible for the remedy for 
relieving pain and controlling inflammation (Mahdi et al., 2004). The active 
compound appeared to be salicin which hydrolyses and oxidises to give 2- 
hydroxybenzoic acid, the precursor of the common drug known as aspirin 
(Mahdi et al., 2004).
Inflammation is closely associated with carcinogenesis, therefore it might 
be expected that substances with anti-inflammatory properties would exert 
anti-tumour activity (Zhou et al., 2001). Many tumours, especially gastric 
carcinomas, contain high levels of prostaglandin, which promote cellular 
proliferation, tumour growth and angiogenesis (the formation of new blood 
vessels).
It has been illustrated that 2-acetylbenzoic acid and other non-steroidal 
anti-inflammatory drugs (NSAIDs) can restore proper function to cell death 
pathways in some types of tumours (Kim, 2001). NSAIDs have been 
shown to inhibit cell proliferation and induce apoptosis in a number of cell 
lines in vitro, and are therefore anticipated to have a potential role in the 
treatment and prevention of carcinogenesis (Zhou eta!., 2001).
The effects of 2-acetylbenzoate analogues on the population growth of 
cancer cells in culture have been actively studied, and they have been 
shown to interfere with cell proliferation (Marra and Liao, 2001). 2-
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Acetylbenzoic acid has been shown to inhibit proliferation of human 
colorectal cancer cells by inhibiting cell population growth, DNA synthesis 
and protein synthesis (Marra and Liao, 2001). 2-Acetylbenzoic acid has 
also been shown to induce cell cycle arrest in the G0/G1 phase, thus 
blocking progression from G1 to S phase (Marra and Liao, 2001; Sharma 
et a/., 2001).
2-Acetylbenzoic acid and other NSAIDs have been shown to induce 
apoptosis in many cancer cell lines, exhibited by the extemalisation of 
phosphatidyl serine and nuclear chromatin condensation, a characteristic 
of typical apoptosis, in colorectal cancer cells (Stark et al., 2001).
There is general consensus in the literature about the anti-tumour activity 
of NSAIDs, arising from their inhibition of prostaglandin synthesis. 
Prostaglandins are signalling molecules and are responsible for regulating 
a number of cellular functions, including gene expression, growth and 
differentiation (Towndrow et al., 2000). The enzyme cyclooxygenase (Cox) 
is involved in the synthesis of prostaglandins, and there is strong evidence 
to suggest that prostaglandins and Cox play an important role in a number 
of malignancies (Munkarah et al., 2002). Two isoforms of Cox exist, Cox-1 
and Cox-2. The latter is found in some cancers and its expression is linked 
to tumour promotion (Husain et al., 2001). Overexpression of Cox-2 leads 
to elevated levels of prostaglandins, which promote cellular proliferation, 
tumour growth and angiogenesis, events that contribute to the emergence 
of the neoplastic phenotype (Husain et al., 2001; Munkarah et al., 2002). 
High levels of Cox-2 may also have the ability to confer programmed cell 
death-resistance to some cancer cells by turning on genes that promote 
cell survival (Kim, 2001).
Thus NSAIDs exert their anti-carcinogenic properties by Cox-2 inhibition 
and subsequent inhibition of prostaglandin formation, which may result in 
the induction of apoptosis and/or inhibition of cellular proliferation (Husain 
et al., 2001). However, NSAIDs have shown chemoprevenitive properties 
in cell lines that do not express either Cox-1 or Cox-2. Also, 2-
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acetylbenzoic acid induced the same anti-tumour effect on cancer cells as 
that of aspirin, despite being a poor inhibitor of Cox-2. These findings 
suggest that Cox is not the only target for NSAIDs (Stark et al., 2001).
The nuclear factor-kappa beta (NF-kp) signalling pathway required for anti­
tumour activity has been identified as a target for the activity of NSAIDs 
(Stark et al., 2001). NF-kp is a transcription factor crucial for the 
expression of many genes that regulate proliferation, immunity, 
inflammatory response and cellular adhesion, as well as playing an 
essential role in apoptotic cell death (Sharma et al., 2001; Stark et al., 
2001). NF-kp normally exists in the inactive state, bound in the cytoplasm 
by the inhibitor protein IkB (Stark et al., 2001). Upon stimulation of the cell 
by a number of cytokines, oxidative stress, or pathogens, IkB is 
phosphorylated and degraded to release NF-kp, which is subsequently 
translocated to the nucleus, where it binds to regulatory elements within 
the promoter region of target genes (Sharma et al., 2001; Stark et al., 
2001). Activation of NF-kp has been shown to inhibit apoptosis, and 
dysregulation of the NF-kp pathway, resulting in abnormally high NF-kp 
activity, has been observed in cancer cell lines (Stark et al., 2001). NF-kp 
is known to regulate several growth regulatory genes, including p53 and 
Cox-2, and therefore is a strong potential target for the anti-tumour effects 
of NSAIDs (Stark et al., 2001). Both aspirin and salicylate have been 
shown to interfere with NF-kp activation by inhibiting the IkB kinase 
complex, and it has been shown that aspirin can induce apoptosis in 
cancer cell lines (Sharma et al., 2001). Inhibition of NF-kp activation may 
down-regulate genes involved in the promotion and progression of the 
carcinogenic process by restoring the sensitivity of cells to apoptotic 
stimuli (Sharma e ta i,  2001).
The anti-oxidant properties of naturally occurring benzoate compounds are 
thought to have anti-tumour promoting effects. Numerous epidemiological 
studies have shown an inverse relationship between the dietary intake of 
antioxidants (found in fruit, vegetables and cereals) and the incidence of
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certain cancers. The anti-oxidant (free radical scavenging) activity is 
thought to provide the protective mechanism (Rice-Evans et al., 1997). 
Free radicals, a highly reactive chemical species, have been found to be 
involved in the initiation and promotion of carcinogenesis. Free radicals 
can act as inhibitors and/or promoters, cause DNA damage, activate 
procarcinogens and alter the normal cellular antioxidant defence system 
(Dizdaroglu et al., 2002). Anti-oxidants act as free radical scavengers and 
have been shown to be anti-carcinogens, functioning as inhibitors at both 
the initiation and promotion/transformation stages of the carcinogenic 
process by offering cells protection against oxidative damage (Sun et al., 
1989; Thomberry and Lazebnik, 1998; Salvi et al., 2001). Various 
antioxidant enzymes, such as manganese superoxide dismutase, zinc 
superoxide dismutase, catalase, glutathaione peroxidase and glutathione 
reductase, have shown lower levels of activity in tumour cells compared 
with normal cells. Other enzymes, such as glutathione S-transferase 7-7, 
glucose-6-phosphate dehydrogenase have shown increased levels of 
activity in tumour cells (Sun, 1990).
1.5 Biological Activity of Metal Ions
A number of different metal ions exist within cells, including calcium, 
magnesium, potassium and zinc. These play an important role in both the 
functional and structural aspects of cellular molecules. They are often 
incorporated in various forms in proteins to perform specialised functions 
(Luchinat, 2003). These ions can form ionic bonds with almost any 
molecule in the cell, for example DNA, RNA, and any other protein or 
molecule with a negative charge, such as oxygen or nitrogen. The folded 
structure of proteins is stabilised by non-covalent interactions between the 
different parts of the polypeptide chain, and is important for obtaining the 
correct conformation and specificity of an active site. The biological activity 
of a protein depends on its active site, a cleft or crevice on the surface 
responsible for binding the substrate and initiating catalysis. Some
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enzymes only function in the presence of a specific cofactor, such as 
Mg2+, Ca+2 or Zn2+, which are required for the activity of certain conjugated 
enzymes. Intracellular calcium, for example, plays a critical role in cell 
survival and cell death: apoptosis or necrosis (Schanne et al., 1979; 
Nicotera and Orrenius, 1998; Choi, 1988). The distinction between these 
two types of death pathways depends on the calcium ion concentration. 
The increase of calcium ion by 4 times damages the signalling and 
mitochondrial function, as well as plasma membrane, giving the 
morphological signs of necrosis (Choi, 1988; Dawson, 1994; Hyrc, 1997; 
Yu et al., 2001). In contrast, an early physiological elevation of calcium ion 
may not per se induce cellular damage, but rather it may serve as a 
component of a signalling cascade culminating in triggering apoptosis (Yu 
et al., 2001).
Furthermore, magnesium and zinc ions are also known to exert a variety 
of other biological functions. An increase in the levels of intracellular free 
magnesium ion is characteristic of the early stages of apoptosis, and 
accumulating evidence suggests a role for magnesium in cell cycle 
regulation, proliferation, differentiation and apoptosis (Hartwig, 2001). In 
particular, magnesium is an essential cofactor in almost all enzymatic 
systems involved in DNA processing, including the removal of damaged 
DNA, and acts as an intracellular regulator of the cell cycle and apoptosis 
(Hartwig, 2001). Zinc also has a diverse role in many physiological 
systems, and has been shown to be an important regulator of apoptosis 
(Truong-Tran et al., 2001).
The majority of evidence suggests that zinc is a physiological suppressor 
of apoptosis, although when present in high concentrations which exceed 
the capacity of homeostatic control, zinc may trigger programmed cell 
death in a number of mammalian cell lines (Beyersmann and Haase, 
2001). Very high concentrations of zinc have also been shown to induce 
necrotic cell death (Troung-Tran et al., 2001). It has been reported that 
relatively high concentrations of zinc (200-500 jiM) can induce necrosis in 
human prostate carcinoma cells, and in other studies, zinc has been
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shown to induce both necrosis and apoptosis (Hamatake eta!., 2000). The 
mechanisms of how zinc may induce apoptosis are not yet well 
understood, and there are many other aspects of zinc functions that 
require further elucidation (Beyersmann and Haase, 2001).
1.6 Benzoates Significance and Structure
Benzoic acid, 2-hydroxybenzoic acid and 2-acetylbenzoic acid (Figure 1.1) 
belong to the monoaromatic acid group of compounds found naturally in 
plants. They play a significant role in the plant’s defence system 
(Matthews, 1991; Ryals et al., 1996; Shirano et al., 2002). 2- 
hydroxybenzoic acid, for example, plays a vital role in plant responses to 
pathogens and stress (Raskin, 1992; Hammond-Kosack and Jones, 1996; 
Ryals et al., 1996; Dumer et al., 1997; Wildermuth et al., 2001). 
Furthermore, these compounds (commonly, 2-acetylbenzoic acid) also 
exert important pharmacological characteristics as effective agents in the 
treatment of pain, fever, rheumatic disease and cardiovascular problems, 
and as a therapeutic agent against cancer (Levesque and Lafont, 2000), 
as well as being an anti-microbial agent (Amborabe et al., 2002; Shabir,
2004).
The simplest example is benzoic acid, which is widely used as a 
preservative in food, cosmetic and pharmaceutical products (FDA, 1973; 
Amborabe et al., 2002; Shabir, 2004) with low toxicity (LD50: 1700 mg/kg; 
LC50 rat > 26,000mg/L/Hr; MSDS, 2003). Other examples are the 
hydroxylated monoaromatic acids, or the phenolic acids such as salicylic 
acid, chemically known as 2-hydroxybenzoic acid, and its acetylated 
analogue, or aspirin, chemically known as 2-acetylbenzoic acid.
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Figure 1.1 Chemical structures of benzoate analogues.
In this work 18 analogues of benzoic acid were tested and screened for 
anticancer activities. Table 1.1 shows the names, structures, 
abbreviations, and the molecular weights of these compounds which are 
used in this study.
Table 1.1 Chemical characteristics of benzoate analogues.
Name Abbreviation Structure Molecular
Weight
Benzoic Acid BA 121‘OH
O
Lithium Benzoate BnLi 127
o
Potassium Benzoate BnK 159
o
Magnesium Benzoate BnMg 264
o
Calcium Benzoate BnCa 280,02Ca
Zinc Benzoate BnZn 305
Continued
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Table 1.1 Continued
Name Abbreviation Structure Molecular
Weight
2-Hydroxybenzoic add 2HBA P>
-
0 1 138
Lithium 2- 
Hydroxy benzoate
2HBnLi 144
Potassium 2- 
Hydroxy benzoate
2HBnK 176
Magnesium 2- 
Hydroxy benzoate
2HBnMg i f f
2
298
Caldum 2- 
Hydroxy benzoate
2HBnCa a !r c?22 314
Zinc 2-Hydroxy benzoate 2HBnZn z?2
2
339
2-Acetylbenzoic add 2AcBA c 6 180
Lithium 2-Acetylbenzoate 2AcBnLi CC^1'
O’^ C H j
186
Potassium 2- 
Acetyl benzoate
2AcBnK
O ^ C H j
218
Magnesium 2- 
Acetylbenzoate
2AcBnMg o f"
O ^ C H j 2
382
Continued
13
Table 1.1 Continued
Name Abbreviation Structure Molecular
Weight
Calcium 2- 
Acetyl benzoate
2AcBnCa
O ^ ^ C H j
©2
Ca
2
398
Zinc 2-Acetyl benzoate 2AcBnZn cd"
O ^ C H ,
7©2Zn
2
423
1.7 Aims, Objectives and Approach of this Study
The current study not only aims to elucidate the cytotoxic effect of 18 
benzoate analogues on HT-1080 fibrosarcoma cell line, but also to 
determine their effects on the morphological and molecular constitution of 
the cell at mostly 0.4mM, based on the preliminary experiments. The 
specific objectives can be summarised as follows:
1 To investigate cell viability. Three techniques are used to measure 
cell viability. First, MTT cytotoxicity assay to quantify dose and time- 
dependent treatment; second, direct count of cells using a 
haemocytometer, and third, time-lapse tracing of images of growing 
HT-1080 cells.
2 To investigate the changes in cell morphology. The 
light/fluorescence and scanning electron microscope are used to 
evaluate the changes in cell morphology (membrane, nucleus, and 
cytoplasm) resulting from benzoate treatments. Four staining 
techniques are used; haematoxylin-eosin, methylgreen-pyronin y, 
observed by light microscope; and DAPI and Annexin V, observed 
by fluorescence microscope.
14
3 To investigate cell cycle analysis. The treated/untreated HT-1080 
cell cycle is evaluated by time-lapse tracking images to measure 
the duration and percentages of mitotic cells, as well as measuring 
the cell cycle duration. Cell cycle phases are also investigated by 
flow cytometry after staining with propidium iodide.
4 To investigate molecular changes. Flow cytometric analyses of 
Annexin V and caspase-3 are conducted in this study to evaluate 
their distribution and define the method of cell death (apoptosis or 
necrosis). Furthermore, the expressions of six proteins are also 
investigated, using Western blotting. These comprise p21, p53, 
Bax, Bcl-2, histones, and TNF-a.
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CHAPTER TWO
Effect of Benzoate and 2-Hydroxybenzoate Analogues on the HT- 
1080 Cell Line: Cell Population Growth and Cell Viability 
2.1 Introduction
Many natural and synthetic biologically active compounds are being 
investigated as potential anticancer agents. Several have been found to 
exhibit therapeutic and pharmacological advantages. 2-hydroxybenzoate, 
2-acetylbenzoate (aspirin), taxol and others are among these therapeutic 
agents (Ackerknecht, 1973; Sumner, 2000; Dewick, 2002). This Chapter 
focuses on the assessment of the cytotoxic effects of 18 benzoate and 2- 
hydroxybenzoate analogues (see chapter 1) on HT-1080 cell viability and 
proliferation at different concentrations and incubation periods.
In order to investigate the cytotoxic effects of these compounds, the 3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay for 
cell viability and proliferation was used. Other techniques to screen the 
cytotoxic activities of these compounds were also applied, using direct 
counts and capture-image time-lapse microscopy.
2.2 Cell Viability and Proliferation
All living cells are commonly propagated by cell division, during which cells 
replicate their molecular contents and divide into two at the right time. This 
process is tightly regulated and coordinated by several genes to ensure 
that cell proliferation occurs precisely and successfully. The whole process 
of cell division is organised and governed by the cell cycle (see Chapter 
4), which is divided into four distinct phases (i.e. G1, S, G2, M) (see 
Chapter 4). Various physiological and environmental factors may alter the 
way in which healthy or abnormal cells divide. It is advantageous that the 
cell cycle of abnormal cells, like cancer cells, is altered to slow or stop its 
proliferation. This process forms part of the physiological response to 
chemotherapeutic drugs. Cancer cells undergoing the cell cycle attempt to
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repair chemotherapy-induced DNA damage, and then may undergo 
apoptosis. In this respect, the investigation of new chemical compounds or 
candidates is an essential process in drug discovery. One approach for 
evaluating a drug candidate is to study its effects on cell population growth 
and cell viability. The measurements of these parameters are important for 
assessing the activity of chemicals and other materials in many fields, 
such as medicine, the pharmaceutical industry and agriculture. Therefore, 
a great deal of effort has been made to establish methods to evaluate 
these parameters quantitatively.
Many assays are commonly used to measure cell proliferation and cell 
death, and these assays form the in vitro screening process. This offers 
the potential to screen a large number of chemical compounds in a 
reasonable time-scale. For example, measurement of proliferation by 
counting cells under the microscope using a haemocytometer is the 
simplest method which is commonly used to study cell viability and 
proliferation in cell populations. Incorporation of trypan blue helps identify 
the viable cells (unstained) from non-viable cells (blue-stained). 
Furthermore, cell proliferation can also be monitored using time-lapse 
microscopy, where cell population growth can be tracked by video image 
(Feeney et ai, 2003).
Although these methods are efficient for assessing viable cell numbers, 
they are however time-consuming and are impractical when many 
samples have to be analysed. Therefore, a concerted effort has been 
made to establish methods that are able to assess a large number of 
samples. The 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide 
(MTT) colourimetric assay, first developed by Mosmann in 1983, is a 
reliable and simple assay to measure cell viability, proliferation, or 
cytotoxicity colorimetrically. It is an assay that is suitable for high 
throughput screening of candidate drugs since it is carried out entirely in 
96-well microtiter plates (Cole, 1986). Thus, drug concentration, time of 
exposure to drug, length of assay, and cell density can be varied and 
tested at the same time. As a consequence, this method is used
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extensively by many researchers to study in vitro chemosensitivity in 
various cancer cell lines and to quantify cell proliferation and cell toxicity 
(Cole, 1986; Carmichael et a!., 1987; 1988; Twentyman and Luscombe, 
1987; Pieters et at., 1989; Twentyman et ai, 1989; Huveneers-Oorsprong 
e ta i, 1997; Kudo eta i, 2003).
The MTT assay measures the cellular metabolic activity of viable cells 
colorimetrically. The tetrazolium bromide salt, MTT, is a yellow dye which 
can be metabolised by viable cells, in part by the action of dehydrogenase 
enzymes, into a water-insoluble dark blue formazan by reductive cleavage 
of the tetrazolium ring (Mosmann, 1983). Figure 2.1 shows the 
biochemical pathway of the reduction process of MTT to formazan. The 
cellular reactions involved in MTT reduction are not completely 
understood, but the mitochondrial succinate dehydrogenase system 
seems to be primarily involved (Mosmann, 1983; Slater, 1963). The 
resultant formazan can be dissolved and quantified by measuring the 
absorbance of the solution at 570nm. The resultant absorbance value 
reflects the number of living cells. Both replicates and multi-well 
spectrophotometer are used to facilitate measuring a large number of 
samples and provide a rapid measurement of cell viability. One 
disadvantage in the use of MTT is that the resulting coloured formazan 
product is insoluble, precluding direct spectrophotometric absorbance 
measurements without first dissolving the crystals (Liu et ai., 2004). 
Nonetheless, several tetrazolium salts analogues such as 2,3-bis(2- 
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium 
hydroxide (XTT) (Scudiero et ai, 1988; Roehm et a i,  1991), and 3-(4,5- 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium, inner salt (MTS) (Cory, 1991) have been developed and 
become commercially available. The advantage of these three dyes is that 
viable cells convert them into a water-soluble formazan. Thus, a metabolic 
assay with any of these compounds requires one step less (i.e. 
solubilisation of formazan) than an assay with straightforward MTT.
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Figure 2.1 Structure of MTT and XTT, also showing biochemical reduction 
of MTT.
2.3 Cell Proliferation Responses to Benzoate Analogues
The biological activity of molecules in modulating cell proliferation is an 
important determinant of chemopreventive activity. Experimental data 
suggest that 2-hydroxybenzoates retard cell population growth of various 
cancer cell lines in vitro (Shiff et ai., 1996; Marra, 2000; Brooks et ai., 
2003) and in vivo (Moorghen et ai., 1988). Table 2.1 lists, for example, the 
effect of 2-acetylbenzoic acid on the proliferation and population growth of 
different cell lines at different concentrations and incubation times.
Furthermore, 2-acetylsalicylic acid induced a pronounced concentration- 
dependent reduction in the proliferation rate of HT-29 cells (Qiao et ai.,). 
For example, at 0.4mM, 2-acetylbenzoic acid reduced cell proliferation by 
1.5-fold compared to controls following incubation for 96 hours. At higher 
concentrations (1 and 1.5mM), the reduction in cell proliferation was also 
apparent at 48, 72 and 96 hours (Shiff et ai., 1996). Sodium 2- 
acetylbenzoate (Na+ 2-acetylbenzoate) also significantly inhibited the 
cellular proliferation of human pancreatic cancer cell lines (BxPC3 and
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Panc-1) in a dose-dependent manner (Perugini et a i, 2000). Goel et a!,. 
(2003) found similar effects with 2-acetybenzoic acid on the population 
growth of three different human colon cancer cells (HCT116, 
HCT116+chr3 and SW480), but at different rates. At 72 hours, incubation 
with 2-acetylbenzoic acid (acetylsalicylic acid or aspirin) treatment, the 
proliferation rate of HCT116+chr3 cells was significantly less than 
inhibition of HCT116 cells at 0.1mM (14.3% versus 40.7%) and 2.5mM 
(27.2% versus 47.9%). All other published investigations have concluded 
that the inhibitor effects of 2-hydroxybenzoate analogues, particularly 2- 
acetylbenzoic acid (or aspirin), on cell population growth and cell 
proliferation were concentration- and time-dependent (Qiao et a i, 1998; 
Zhu e ta i, 1999; Zhou e ta i, 2001; Kim e ta i, 2003).
Table 2.1 Effect of 2-acetylbenzoic acid on Cell Proliferation and Cell
Population Growth.
Concentration
(mM)
Cell line Max incubation 
time (Hour)
% of Growth 
inhibition*
Reference
1-3 HeLa TG - 18-55 Kim et ai, 2003
0.1-10 AGS 72 21-47 Zhu etai, 1999
0.4-3 HT-29 73 70-75 Qiao eta.I, 1998
1 AGS and 
MKN-28
60 37-40 Zhou etai, 2001
* Cells population Growth inhibition at highest incubation time, relative to control
These results have encouraged the revival of interest in the clinical and 
pharmacological effects of 2-acetylbenzoate in terms of cancer treatment 
(Funkhouser and Sharp, 1995; Wong et a i, 1999; Smith et ai, 2000; 
Hector et ai, 2001; Claudia, 2003). This is particularly true for colon 
cancer with the potential for the use of 2-acetylbenzoates and other 
nonsteroidal antiinflammatory drugs (NSAIDs) as chemopreventive 
molecules.
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Generally, the biological activity of a natural and synthetic compound is 
defined by a classic dose-response relationship, where the response is 
either therapeutic or toxic. The difference between the therapeutic and 
toxic effect of a chemical is dose-dependent. Most chemicals are 
therapeutic over a narrow range of doses, and are toxic at higher doses 
(Wedge and Camper, 2000). This concept is not new and can be traced 
back to Parcelsus in 1541, as he stated: All substances are poisons; there 
is none which is not a poison (quoted by Wedge and Camper, 2000).
2.4 Materials and Methods 
2.4.1 Materials
2.4.1.1 General
T-flasks (25, 75 cm2), well plates (6, 12, 24, 96-well), pipettes, obtained 
from Coster, Cambridge, MA, USA.
2.4.1.2 Chemicals
2-Aceylbenzoic acid (2AcBA) (aspirin), benzoic acid (BA), 2- 
hydroxybenzoic acid (2HBA), staurosporine, triton X-100 (Sigma, UK). 
Lithium, potassium, magnesium, calcium and zinc salts of benzoate, 2- 
hydroxybenzoate and 2-acetyl benzoate were available in the laboratory, 
designed and prepared by Dr. J. Mahdi.
Sodium pyruvate, ascorbic acid, 3-(4,5-dimethylthiazol-2yl)-2,5-
diphenyltetrazolium bromide (MTT), and trypan blue were obtained from 
Sigma, UK. DMEM medium, L-glutamine, D-glucose, foetal calf-serum 
(FCS), gentimycin solution, Hepes buffer, and trypsin were obtained from 
Gibco, UK.
2 1
2.4.1.3 Cell Line
The human fibrosarcoma cell line HT-1080 was available in our laboratory 
at passage 9. Originally cells were kindly obtained from Dr. Steve 
Luckman, Biomedical Section, Cardiff University. These cells are 
characterised as adherent fibroblast sarcoma cells that grow in a 
monolayer (see Paragraph 5.2).
2.4.2 Methods
2.4.2.1 General
The handling of the human cancer cell line was performed in an enclosed 
sterile class II laminar flow hood. The laminar flow work surface was 
sterilised and kept free of contamination through the spraying of 70% 
industrial methylated spirits (IMS) and Virusolve anti- microbial agent 
before and after use. An aseptic technique was employed during all work 
with human cell cultures to avoid microbial contamination.
The optimal cell population growth media for HT-1080 human cell line 
culture was prepared from 500ml DMEM (Gibco, UK), 10% (v/v) foetal calf 
serum (Gibco, UK), gentimycin solution 1 ml/100ml media (Gibco, UK), 1% 
(v/v) L-glutamine (Gibco, UK), 0.1% (v/v) Hepes buffer (1M), 0.1% (v/v) 
sodium pyruvate (100mM), and 0.1% (w/v) ascorbic acid (Sigma, UK). The 
medium was stored at 4°C and was used within three weeks of being 
made up.
2.4.2.2 Cells and in vitro Culture Conditions
HT-1080 cells were cultured in optimal DMEM medium to about 80% 
confluence in T-flask (25 or 75 cm2) under a humidified atmosphere of 
95% air and 5% CO2 at 37°C. Splitting of cells was carried out by 
removing the medium, cells were trypsinised for 3-5 minutes to detach the 
adherent cells, and these were subjected to microscopic examination. The 
detached cells were then transfered into a 50ml centrifuge tube and
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centrifuged at 120g for 4 minutes (Supermax Lorius centrifuge, U.K.). 
Supernatant was decanted and the cell pellet was resuspended in 10ml of 
warm (37°C) medium, gently resuspended, and cell number/ml was 
counted. The cell suspension was sub-divided into T-75 flasks by 1.8- 
2.5x106/flask, which already contained 13ml of media. The cells were then 
incubated in the appropriate standard conditions.
In the current work, the liquid nitrogen frozen-HT-1080 cell sample was 
thawed and cultured in 3 x T-75 flasks in an optimised DMEM and under 
standard growth conditions. After cells reached about 70% confluence, 
they were gently detached by trypsinisation and centrifuged, before being 
transferred into sterile 34 Nunc tubes, each holding approximately 1x106 
cells in 1ml of DMEM medium containing dimethylsulfoxide (DMSO) to a 
5% final concentration, which was quickly added, mixed and frozen at - 
70°C for 8 hours or overnight, before being transferred into a liquid 
nitrogen storage. The liquid nitrogen frozen HT-1080 cell samples were 
used in this work.
The following procedure was used in the culturing of HT-1080 cells. The 
medium was first decanted from the T-75 culturing flask before adding the 
trypsin (5ml) to detach cells and transfer them into another vessel(s). The 
T-75, containing cell line HT-1080 and trypsin, was incubated for 3-5 
minutes. After this time, the T-75 was gently tapped to assist in the 
dissociation of cells. Dissociation of at least 90-95 % of cells was required 
(this was ensured by observing cells in the light and under the light 
microscope). The buffer (and cells) were aspirated into a tube suitable for 
centrifuging, with a 10ml pipette, and centrifuged at 1800 rpm for 4-5 
minutes. The supernatant was decanted carefully, so as not to lose the 
pellet. The pellet was gently resuspended in 10ml of optimal DMEM 
medium. Finally, cells were counted using a haemocytometer.
The number of cells in the four chambers of the haemocytometer were 
counted and averaged. The number of cells present in 1ml of cell
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suspension was then calculated, and the total cell number determined, 
according to the total volume of fluid from which the sample was derived.
2.4.2.3 HT-1080 Cells population Growth Curve
HT-1080 cells (4x104 cells/T-25 flask) were seeded in 5ml full medium. 
The flasks were set up in triplicate for 13 days and incubated at standard 
conditions. The cells were harvested each day at the same time by 
detaching the cells with 3ml trypsin, then immediately 3ml medium was 
added and the cells were transferred into a centrifuge tube. The flask was 
washed out with 3ml PBS, and this was added to the centrifuge tube 
before centrifuging at 1000g for 4 minutes. The cells were resuspended in 
10ml PBS and were counted using a haemocytometer every 24 hours for 
13 days. Throughout the experiment, the medium was changed with 5ml 
of fresh medium every three days, ensuring an adequate supply of 
nutrients was maintained at all times. Three flasks were counted every day 
with the aid of a haemocytometer for the 13-day period.
The population growth curve of HT-1080 was measured with and without 
the incorporation of the benzoic/benzoate compounds. Cells were seeded 
in a T-25 flask in the optimal growth medium and under standard growth 
conditions at an initial cell density (4x104 cells/T-25 flask), unless 
otherwise stated in each figure legend in the results section. For the first 5 
days, HT-1080 cells were cultured without the benzoic/benzoate 
compounds, where cell number was measured by the haemocytometer 
method, as described above. The population growth curves were 
continued but with the incorporation of benzoate compounds at a range of 
concentrations and experimental conditions, as stated in the legends. 
Cells were again counted by haemocytometer but every 12 hours for the 
first 3 days.
Note that in all the experiments in Chapters 2-4, HT-1080 cells were 
cultured to the exponential phase (3-4 days post the initial cell seeding) 
specified by the population growth curve experiment above before any
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drug treatment, unless otherwise specified. This was to ensure the 
consistency of any effect induced by the 2-hydroxybenzoate analogues.
2.4.2.4 Preparation of Benzoate Solutions
Concentrated stock solutions of each compound were prepared by 
dissolving a known mass of the compound in a certain volume of 
deionised water. For example, the concentration of a stock solution of 
36mg 2-acetylsalicylic acid in 10ml deionised water can be calculated as 
follows:
Mass
Number of Moles = --------------------------
Molecular Weight
=  2.0x10"* mole
Concentration of 2-acetylsalicylic acid in 10ml is 2.0 x 10'2 M, or equivalent 
to 20,000mM.
The stock solution was diluted to certain concentrations in the optimal 
DMEM medium, according to the following equation:
Concentration of stock solution x required volume = new concentration x 
required volume
Or
C1 x V1 = C2 x V2
Thus, by adding 40pl of 2-acetylbenzoic acid solution to 1960jil of the 
optimal DMEM medium this would equal the maximum drug concentration 
(typically 0.4mM) to be tested. 40jj.I stock drug volume was selected due to 
its insignificant volume, which should result in negligible dilution effects on 
the DMEM. Compounds that proved difficult to dissolve in water, like 2- 
acetylbenzoic acid, were heated in a water bath at 50°C overnight.
0.036g
180
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After the addition of 40pl of stock drug solution to 1960pl of DMEM 
medium, the final concentration of the drug solution in the medium will be 
0.4mM. A serial dilution of each drug was performed to the required 
concentration.
To ensure equality between DMEM/drug solutions and DMEM/deionised 
water solutions, 40^1 of deionised water was also added to 2000pl of 
DMEM medium for the control sample.
2.4.2.5 MTT Assay Procedure
A 96-well plate (Costar, Cambridge, MA, U.S.A) was seeded with HT-1080 
cells at a density of 2x104 cells/ml equating to 20,000 cells/well.
After that, each plate was examined under the light microscope to ensure 
equal distribution and density of cells within each well. Plates were left 
overnight in the incubator at standard culture conditions so that the cells 
would settle and attach to the bottom of the wells. Cells were allowed to 
proliferate for another 2 days before the plate was removed from the 
incubator and placed into a laminar flow class II fume hood, and then the 
medium was replaced with fresh medium containing the compound(s).
For each 96-well plate, 1.0ml of pre-warmed MTT reagent (5mg/ml stock 
solution in PBS, filter sterilised through a 0.22pM filter) was mixed 
thoroughly with 10ml of pre-warmed free FCS DMEM in a universal bottle. 
As a negative control, 4-8 wells were lysed by addition of Triton X-100 to a 
final concentration of 0.1% (1 pil of 10% stock in PBS) immediately prior to 
addition of MTT reagent.
The old medium was aspirated from all wells and replaced with 110pl of 
the MTT medium mixture, which was homogenised by gentle pipetting in 
and out. Plates were then incubated at standard conditions for 1 hour.
After the incubation period, the plate was examined under the light 
microscope to determine the progress of the MTT reaction.
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Viable cells contained insoluble formazan salt which could be clearly 
observed under the microscope. Cells treated with Triton X-100 or 
staurosporine showed no formazan salt. However, cells treated with 
staurosporine exhibited the typical morphological features of apoptosis, 
whereas cells treated with Triton X-100 did not. Cells treated with drugs 
presented varying amounts of formazan depending on the cytotoxic effect 
of the drug.
The absorbance of formazan in the 96-well plate was then measured by a 
Labsystems Multiskan MS Version 3.0 (Helsinki, Finland) at 575nm.
2.4.2.6 Time-Lapse Microscopy
HT-1080 cells were seeded and cultured in the optimal DMEM medium 
with an initial cell density of 1x103 cells per well in standard plastic 12-well 
plates. The plates were incubated at standard culture conditions for 3 days 
in an optimal DMEM medium prior to treatments. HT-1080 cell populations 
were treated with calcium or zinc 2-hydroxybenzate compounds at a range 
of different concentrations as indicated in the legends. The plates were 
then incubated for 22 hours on the stage of a Zeiss Axiovert 100 
microscope (Zeiss, Welwyn Garden City, UK) fitted with a temperature- 
regulating incubator system and CO2 supply (Solent Scientific, 
Portsmouth, UK). The camera, stage (xy) and focus (z) were PC computer 
controlled using AQM 200 software (Kinetic Imaging, Wirral, UK). Tiff- 
format Images (512x512 pixels) were played back for analysis as movies 
using the AQM 2000 software. The motorised xy microscope stage was 
from Prior Scientific (UK), and the phase transmission images (x10 
objective lens) were captured every 5 minutes over 22 hours (264 frames 
per field), using an Orca I ER charge-coupled device camera 
(Hammamatsu, Welwyn Garden City, UK). The image sequences taken by 
the time-lapse microscope were viewed and analysed manually by 
counting the start and the end numbers of cells every one hour, using 
Lucida Analyse- 6 software (Kinetic Imaging, Wirral, UK).
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2.4.2.7 Statistical Analysis
Cell viability assays were conducted using three replicates, unless 
otherwise indicated in each figure legend. The resulting average was used 
to calculate mean ±SE. To determine the effect of drug treatment, data 
were calculated as percentage of control and expressed as means ±SE. 
One-Way Analysis of Variance statistical analysis was performed using the 
Minitab statistical program. A value of p<0.05-0.001 was considered 
significant.
2.5 Results
2.5.1 Determination of population Growth Curve of HT-1080 by Total 
Cell Count
The standard growth curve for cell line HT-1080 was used to determine 
the population growth characteristics of the cells in the culture, and cell 
counts were performed, using a haemocytometer. Figure 2.2 shows the 
growth curve characteristics for HT-1080 cell line. The first 4 days of 
culturing represent the lag phase of population growth. The cells enter the 
exponential phase from about 4 days post-seeding, and between this time 
and about 8 days post-seeding the cumulative cell number in the culture 
vessel can be seen to increase linearly with time.
After the exponential phase, the cell population growth rate declines, 
occasionally reaching a plateau level where there is not net population 
growth of cells in the culture. This phase represents a point where the cell 
density in the culture limits either the available area or volume for growth 
or becomes limiting in respect to nutrient supply. Generally, observing the 
culture vessel indicated that HT-1080 reached about 40-50% confluence 
after about 4 days of seeding. However, this period changes according to 
the seeded cell density. In the current work, the exponential phase was 
taken as a reference to treat cells with various benzoate and 2- 
hydroxybenzoate compounds.
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Figure 2.2 Ppopulation growth profile characteristic for human 
fibrosarcoma HT-1080 cell line seeded into a culture vessel. Cells were 
cultured at initial seeding density of 4x104 in 3xT-25 flasks in optimal 
DMEM growth medium under standard conditions. Cell numbers counted 
by haemocytometer at 1-day interval for 13 days. Medium was changed 
every 3 days. Data represent mean ±SE of three replicates.
2.5.2 Cell Viability by MTT Assay
The effect of a total of 18 benzoic acid analogues, including the 2- 
hydroxybenzoic, 2-acetylbenzoic acids and their lithium, potassium, 
magnesium, calcium and zinc analogues, on the viability of HT-1080 cell 
line was assessed by a standard MTT assay. Staurosporine was used in 
each experiment as an internal cytotoxic standard drug. Cell viabilities 
were calculated relative to the control experiment with no drug 
incorporation in the HT-1080 cells culture. Results were expressed in 
percentages.
2.5.2.1 Response of HT-1080 to Benzoic and 2-Hydroxybenzoic Acids 
Analogues
The MTT cell proliferation assay for HT-1080s cell was conducted to study 
the effects of three monoaromatic acids, namely benzoic acid, 2- 
hydroxybenzoic acid and 2-acetylbenzoic acid (or Aspirin). Results of 
these experiments indicated that no antiproliferative properties were 
exerted by the incorporation of most of these acids at the following 
concentrations (0.025, 0.05, 0.1, 0.2, 0.4mM), and following incubation for
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Figure 2.2 Ppopulation growth profile characteristic for human 
fibrosarcoma HT-1080 cell line seeded into a culture vessel. Cells were 
cultured at initial seeding density of 4x104 in 3xT-25 flasks in optimal 
DMEM growth medium under standard conditions. Cell numbers counted 
by haemocytometer at 1-day interval for 13 days. Medium was changed 
every 3 days. Data represent mean ±SE of three replicates.
2.5.2 Cell Viability by MTT Assay
The effect of a total of 18 benzoic acid analogues, including the 2- 
hydroxybenzoic, 2-acetylbenzoic acids and their lithium, potassium, 
magnesium, calcium and zinc analogues, on the viability of HT-1080 cell 
line was assessed by a standard MTT assay. Staurosporine was used in 
each experiment as an internal cytotoxic standard drug. Cell viabilities 
were calculated relative to the control experiment with no drug 
incorporation in the HT-1080 cells culture. Results were expressed in 
percentages.
2.5.2.1 Response of HT-1080 to Benzoic and 2-Hydroxybenzoic Acids 
Analogues
The MTT cell proliferation assay for HT-1080s cell was conducted to study 
the effects of three monoaromatic acids, namely benzoic acid, 2- 
hydroxybenzoic acid and 2-acetylbenzoic acid (or Aspirin). Results of 
these experiments indicated that no antiproliferative properties were 
exerted by the incorporation of most of these acids at the following 
concentrations (0.025, 0.05, 0.1, 0.2, 0.4mM), and following incubation for
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12, 24, 48 and 72 hours. Figure 2.3 shows the most effective acids when 
cells were incubated for 24 hours or 72 hours at 0.4mM. 2-hydroxybenzoic 
acid at 0.4mM, following 48 hours' incubation, showed the highest 
decrease (21.7%) in cell viability compared to the control, while 
staurosporine decreased cell viability by about 80% at 1.0jaM 
concentration compared to the control. It must be noted that the cell 
viability of HT-1080 was slightly higher at 72 hours' incubation (83.3%) 
compared to 48 hours incubation (78.3%) at the same drug concentration 
(Figure 2.3). The percentage cell death is partly an inverse function of the 
amount of cell division going on in the cultures.
The responses of cells to different concentrations and incubation periods 
generally were inconsistent with the increase of both concentrations and 
incubation periods. In other words, the cell viability did not gradually 
decrease as the drug concentration or the incubation period increased. 
The cytotoxic responses of the rest of the compounds which show 
proliferative responses are presented in Appendix A. Figure 2.4, for 
example, indicates that HT-1080 cell viability increased by about 10-17% 
compared to control upon incorporation of the 2-acetoxybenzoic acid.
The same pattern was also observed with both benzoic acid and 2- 
hydroxybenzoic acid treatments (Appendix A). Generally, the cytotoxic 
effect of these compounds may be a specifically concentration and/or 
incubation dependent (see results for all drugs in Appendix A).
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Figure 2.3 Concentration- and time-dependent effects of benzoic and 2- 
hydroxybenzoic acids as well as staurosporine on viability of HT-1080 cell 
line grown in 96-well plate for different periods and drug concentrations 
(Cell seeding density = 2 x104 cells/well, 100pl of optimal DMEM medium, 
population growth under standard growth conditions). Data represent 
mean ± SE of three replicates. Cell viability was measured by MTT assay.
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Figure 2.4 Concentration- and time-dependent effects of 2-acetylbenzoic 
acids on viability of HT-1080 cell line grown in 96-well plate for different 
periods and drug concentrations (Cell seeding density in = 2 x104 
cells/well, 100pl of optimal DMEM medium, growth under standard growth 
conditions). Data represent mean ±SE of three replicates. Cell viability 
measured by MTT assay.
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2.5.2.2 Response of HT-1080 to Benzoate and 2-Hydroxybenzoate 
Monovelant Metal Ions
The viability responses of HT-1080 cell to different concentration of lithium 
and potassium benzoate, 2-hydroxybenzoate and 2-acetylbenzoate 
analogues were also investigated using the MTT assay. HT-1080 cells 
were cultured under the standard conditions and incubated for different 
periods (12, 24, 48, and 72 hours). Results of cell viability assay clearly 
indicated that these 2-hydroxybenzoate analogues showed different 
cytotoxic activities to HT-1080 cells depending on the counter ion (i.e. Li+ 
or \C) present in the benzoate molecule. Generally, all potassium salts 
showed anti-proliferative effect at 0.025, 0.05 and 0.1 mM concentrations, 
and at 12, 24, 48, and 72 hours' incubation periods (Figures 2.5). 12 hours 
after treatment with potassium benzoate, 2-hydroxybenzoate or 2- 
acetylbenzoate, inhibition of the proliferation rate of HT-1080 cells ranged 
between 18% and 30%. The maximum reduction in the proliferation was 
due to the incorporation of 0.1 mM potassium benzoate or 0.05mM 
potassium 2-acetylbenzoate, both at 12 hours' incubation (Figure 2.5).
Although the viability of HT-1080 treated with benzoate and potassium 2- 
hydroxybenzoate analogues (0.025-0.1mM for 72 hours, 12 hour intervals) 
was maintained below 100% compared to control (Figure 2.5), it is clear 
that these results showed both concentration and incubation period- 
dependency, as indicated by both the increase and the decrease patterns 
of the HT-1080 cell viability. This increase/decrease pattern of cell viability 
during the course of the experiment may be more pronounced when the 
other concentrations (0.2 and 0.4mM) of potassium analogues are 
included (see Appendix A).
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Figure 2.5 Concentration- and time-dependent effects of (A) potassium 
benzoate, (B) potassium 2-hydroxybenzoate, and (C) potassium 2- 
acetylbenzoate on viability of HT-1080 cell line grown in 96-well plate for 
different periods and drug concentrations (Cell seeding density in = 2 x104 
cells/well, 10Opil of optimal DMEM medium, under standard growth 
conditions). Data represent mean ± SE of three replicates. Cell viability 
measured by MTT assay.
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Figure 2.6 shows the typical effect of benzoate, 2-hydroxybenzoate and 2- 
acetylbenzoate of lithium analogues at different concentrations and 
incubation times (See Appendix A for the rest of the results). The 
responses of HT-1080 cells to lithium benzoate analogues, however, were 
mitogenic for almost all treatments. The HT-1080 cells' viability was higher 
than control by a maximum of 40% (see Appendix A).
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Figure 2.6 Concentration- and time-dependent effects of lithium benzoate, 
lithium 2-hydroxybenzoate and lithium 2-acetylbenzoate on the viability of 
HT-1080 cell line grown in a 96-well plate for different periods and drug 
concentrations (Cell seeding density in = 2 x104 cells/well, 1 OOjj.1 of optimal 
DMEM media, growth under standard growth conditions). The data 
represents the mean ± SE of three replicates. Cell viability was measured 
by MTT assay.
The highest cell viability was 140.7% caused by 0.2mM of 2- 
acetylbenzoate lithium salt when cells were treated for 72 hours (see 
Appendix A). It is generally accepted that the HT-1080 cell viability 
responses were positively related to the incubation periods in each lithium 
salt (see Appendix A). It is worth noting that there is a gradual increase in 
cell viability due to the incorporation of lithium 2-hydroxybenzoate at 
0.025mM or lithium 2-acetylbenzoate at 0.4mM, but this is not significant 
(p< 0.5) (Figure 2.6). The three lithium 2-hydroxybenzoate analogues
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increased the proliferation of HT-1080 cells by a maximum of 31.7% 
(0.2mM Li benzoate) compared to the control.
2.5.2.3 Response of HT-1080 to Benzoate and 2-Hydroxybenzoate 
Divalent Metal Ions
Divalent salts of benzoate, 2-hydroxybenzoate and 2-acetylbenzoate 
(salicylates) refer to compounds that contain magnesium or calcium 
counter ions (i.e. Mg+2, Ca+2, respectively). The cytotoxic effects of these 
compounds were also examined using MTT assay. Figure 2.7 shows the 
cytotoxic responses of HT-1080 cells to the most effective treatments, 
including incubation periods (12, 24, 48, 72 hours), different
concentrations (0.025, 0.05, 0.1, 0.2, 0.4mM), and 6 different compounds 
(see also Appendix A). The highest antiproliferative response was induced 
by 0.2mM calcium benzoate compound after 12 and 24 hours' incubation 
with cell viability of 81.1% and 85.9%, respectively, compared to the 
control (Figure 2.7A). The other antiproliferative, calcium benzoate, also 
induced cytotoxic effects after 12 and 24 hours, mostly at higher 
concentrations (0.2mM and 0.4mM) (Figure 2.7A). Furthermore, 
magnesium benzoate compound induced its antiproliferative effect after 24 
hours at 0.025mM and 0.05mM concentration, whereas no antiproliferative 
effects were induced by concentration of the higher magnesium benzoate 
analogue (Figure 2.7A).
Figure 2.7B shows that 0.05 and 0.4mM magnesium 2-acetylbenzoate 
induced the highest antiproliferative effects after 12 hours' incubation. 
Results showed that the highest antiproliferative effect was induced by 
0.05mM and 0.4mM magnesium 2-acetylbenzoate after 12 hours' 
incubation: cell viabilities were 87.8% and 88.3%, respectively. 
Nonetheless, the other treatments (0.025, 0.05mM BnMg, 0.025, 0.05mM 
2HBnMg and 0.025mM 2-AcBnMg) also induced cytotoxic effects of 
between 7 and 10% (Figure 2.7B), but were not significantly (P< 0.05) 
different from each other (Figure 2.7B).
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Figure 2.7 Concentration- and time-dependent effects of benzoic, 2- 
hydroxybenzoic and 2-acetylbenzoic acids on viability of HT-1080 cell line 
grown in 96-well plate for different periods and drug concentrations (Cell 
seeding density in = 2 x104 cells/well, 100pl of optimal DMEM medium, 
under standard growth conditions). Data represent mean ± SE of three 
replicates. Cell viability measured by MTT assay.
It is interesting to note that most magnesium and calcium 2- 
hydroxybenzoate analogues exerted their cytotoxic effects at the earlier 
incubation periods (12, 24 hours), and at lower concentrations (0.025, 
0.05mM), similar to the effect of potassium benzoate or 2-
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hydroxybenzoate analogues (see Figure 2.5). Results of the effect of other 
magnesium and calcium treatments generally showed no antiproliferative 
responses by HT-1080 cells (see Appendix A).
Further investigations were also conducted to see whether the effect of the 
higher concentrations of calcium 2-hydroxybenzoate analogues on the cell 
viability of HT-1080 human fibrosarcoma cancer cell line, using MTT 
assay. Three 2-hydroxybenzoate analogues were used: calcium 2- 
acetylbenzoate or calcium 2-hydroxybenzoate as well as 2-acetylbenzoic, 
acid at 0.4, 0.8, 2, 4, 6, and 8mM concentrations and for 24, 48 and 72 
hours' incubation time. Figure 2.8 shows that all benzoate compounds 
induced a concentration and time-dependent reduction in the proliferation 
of HT-1080 cells.
The proliferation gradually decreased as the 2-hydroxybenzoate 
analogues' concentration increased. Although the three 2- 
hydroxybenzoate analogues at 0.4-2mM had no appreciable effects, they 
were profoundly cytotoxic at 6 and 8mM concentrations. 2-Acetyl benzoic 
acid (aspirin) increased the antiproliferative activity of HT-1080 cells by 
approximately 25% and 36% at 6 and 8mM, respectively, after 48' hours 
incubation, compared to the control. The antiproliferative activity of 2- 
acetylbenzoic acid was further increased to 47% and 60%, respectively, 
after 72 hours of incubation (Figure 2.8A). In contrast to the 
antiproliferation effect of 2-acetylbenzoic acid, calcium 2-acetylbenzoate 
reduced cell proliferation by approximately 24% and 35% after 48 hours' 
incubation, which increased to 40% and 63% after 72 hours' incubation at 
6mM and 8mM concentration, respectively (Figure 2.8B). For calcium 2- 
acetylbenzoate, under the same concentrations and incubation times, the 
increase in the antiproliferation was 34% and 46% after 48 hours, and 
52% and 69% after 72' hours incubation (Figure 2.8C).
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Figure 2.8 Concentration- and time-dependent effects of higher 
concentration of 2-acetylbenzoic acid (A), Calcium 2-acetylbenzoate (B) 
Calcium 2-hydroxybenzoate (C) on HT-1080 cell viability, and (D) a 
comparison between the three compounds at 6mM and 8mM after 72 
hours' incubation. Cells seeded at density 15x103 cells/well containing 
100pl of optimal DMEM medium, in 96-well plate, for different periods and 
drug concentrations. The MTT assay used to measure cell viability. Data 
represent mean ±SE of 4 replicates. Cell viability measured by MTT assay. 
One-Way ANOVA (Fisher's pairwise comparisons, see Appendix A) for (D) 
showed statistical differences for p< 0.001 between the 3 compounds at 
same concentration and between concentrations with each compound.
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Although, 8mM calcium 2-hydroxybenzoate showed the highest 
antiproliferative activities of the three benzoate analogues, this 
concentration may not be relevant physiologically (Raz, 2002; see also 
Chapter 5). Therefore, the mechanism by which these drugs induce 
antiproliferation in vitro may not reflect the actual mechanism of benzoate, 
particularly the 2-acetylbenzoic acid, or aspirin, as protective agents 
against cancers. The main focus in the current project was to investigate 
the effect of 2-hydroxybenzoates at lower concentration (mostly 0.4mM) 
than normally reported in the literature (5-1 OmM; Marra and Liao, 2001).
2.5.2.4 Response of HT-1080 to Benzoate and 2-Hydroxybenzoate 
Zinc Salts
The cytotoxic effect of zinc benzoate, zinc 2-hydroxybenzoate and zinc 2- 
acetylbenzoate compounds were investigated at different concentrations 
(0.025, 0.05, 0.1, 0.2, 0.4mM) and incubation times (3, 6, 12, 24, 48 and 
72 hours). The MTT assay demonstrated that of zinc-containing 
compounds produced a significant cytotoxic activity against HT-1080 
cancer cell line compared to the corresponding lithium, potassium, 
magnesium and calcium salts analogues (see previous sections), at the 
same concentrations and incubation periods. It is clear that there is a 
negative correlation between cell viability and the incubation period. Figure 
2.9, shows, for example, that zinc benzoate at 0.2mM gradually inhibited 
cell viability of HT-1080 from 98.7% at 6 hours' incubation to 29.8% at 72 
hours' incubation or by 70%. A similar cytotoxic effect was also observed 
when cells were incubated at 0.4mM concentration.
Figure 2.10 shows the cytotoxic effect of the zinc 2-hydroxybenzoate and 
2-acetylbenzoate. Both zinc 2-hydroxybenzoate analogues showed 
cytotoxic effect at 0.2 and 0.4mM concentrations, with a similar pattern to 
zinc benzoate compound (Figure 2.9). Furthermore, the effect of zinc 2- 
hydroxybenzoate analogues at the lower concentrations (0.025-0.1 mM) 
showed no cytotoxic or antiproliferative effect on HT-1080 cell line. The 
cell viabilities under these treatments increased by an average of
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approximately 10% in most cases, especially at the earlier incubation 
periods. Nevertheless, zinc 2-hydroxybenzoate analogues at longer 
incubation periods induced some cytotoxicity in HT-1080 cells (see Figure 
2-10).
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Figure 2.9 Concentration- and time-dependent effects of zinc benzoate on 
the viability of HT-1080 cell line grown in 96-well plate for different periods 
and drug concentrations (Cell seeding density in = 2 x104 cells/well, 10Ojul 
of optimal DMEM medium, under standard growth conditions). Data 
represent mean ±SE of three replicates. Cell viability measured by MTT 
assay.
The effects of higher 0.2mM zinc 2-hydrocybenzoate on the HT-1080 cell 
indicated that viability decreased from 92.1% after 12 hours to 33.9% after 
72 hours’ incubation, or by 63% over 36 hours of incubation compared to 
control (Figure 2.10A). At 0.4mM concentration of the same zinc 
compound and the same incubation period, cell viability was decreased 
further from 66.2% to 16% compared to the lower concentrations of the 
same zinc compound (Figure 2.10A).
Figure 2.10B shows the effect of zinc 2-acetyl benzoate on the viability of 
HT-1080 cells. MTT assay showed that zinc 2-acetyl benzoate was more 
cytotoxic, especially at higher incubation period. Results in Figure 2.10B 
indicate that 0.2mM zinc 2-acetylbenzoate decreased the cell viability from
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94.9% after 12 hours to 25.7% after 72 hours' incubation, while at 0.4mM 
concentration, the viability decreased from 99.6% to 11.5% over 36 hours' 
incubation (Figure 2.1 OB).
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Figure 2.10 Concentration- and time-dependent effects of A- zinc 2- 
hydroxybenzoate and B- zinc 2-acetyl benzoate on viability of HT-1080 cell 
line grown in a 96-well plate for different periods and drug concentrations 
(Cell seeding density in = 2 x104 cells/well, 100pl of optimal DMEM 
medium, under standard growth conditions). Data represent mean ±SE of 
three replicates. Cell viability measured by MTT assay.
2.5.3 Cell Viability by Haemocytometer Count
Results of the MTT assay in the previous section indicated that the 3 zinc- 
containing compounds elicited significant cytotoxic effects compared to the 
other 15 benzoic acid analogues which generally showed a similar pattern 
of effects on cell viability of HT-1080. The purpose of studying cell viability
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by direct count was to double-check the effect of 2-hydroxybenzoate 
analogues on HT-1080 cell line. Only 5 compounds were used: calcium 2- 
hydroxybenzoate, potassium 2-hydroxybenzoate, zinc 2-hydroxybenzoate, 
zinc 2-acetylbenzoate and 2-acetylbenzoic acid. These compounds, 
according to the MTT assay results (see previous sections) showed 
appreciable cytotoxic activities. Figure 2.11 shows the progression of 
population growth of HT-1080 cells pre- and post-treatments.
The cells showed slow proliferation rate in the first 96 hours of culture. 
Furthermore, the overall proliferation in the pre-treatment was slow, which 
agreed with the results obtained from the standard population growth 
curve in Figure 2.1. The cells were undergoing proliferation in the lag 
phase at a slow rate of increase in cell number, as illustrated in Figure 
2.11. However, the knowledge gained through the initial HT-1080 
population growth curve experiments meant an anticipation of the cells 
initiating the exponential phase of population growth around the fourth day 
after seeding (see Figure 2.1). The start of the exponential phase of 
population growth is the ideal point in time to inoculate the cells with the 
three-individual test samples. Figure 2.11 clearly shows that calcium 2- 
hydroxybenzoate, potassium 2-hydroxybenzoate and 2-acetylbenzoic acid 
at 0.4mM concentration did not exert significant cytotoxic effects on cell 
proliferation of HT-1080 cell line compared to the control (Figure 2.11 A). 
Nevertheless, both calcium and potassium 2-hydroxybenzoate elicited 
some antiproliferative characteristics compared to control during the 
second day of benzoate treatments (i.e. 168 and 180 hours' culturing, 
Figure 2.11 A).
Both zinc 2-hydroxybenzoate and zinc 2-acetylbenzoate showed an anti­
proliferative cytotoxic effect 12 hours after adding the drug at 0.4mM 
concentration, compared to control and to 2-acetylbenzoic acid (Figure 
2.11B). This effect perpetuates with time until no significant viable cells 
were counted at 72 hours' incubation. Furthermore, both zinc compounds 
elicited a similar pattern of cytotoxic effect on HT-1080 cells treated for 72 
hours (Figure 2.10).
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Figure 2.11 Concentration- and time-dependent effects of (A) calcium, 
potassium 2-hydroxybenzoates, and 2-acetylbenzoic acid, (B) zinc 2- 
hydroxybenzoate and zinc 2-acetylbenzoate at 0.4mM concentration on 
HT-1080 cell viability. Cells seeded at density of 4x104/T-25 flasks in 5ml 
optimal growth medium for three days before being arrested at G1 phase 
with serum-free medium for 24 hours. Cells then activated by replacing 
serum-free medium with optimal growth medium (containing serum), and 
cells allowed to grow for 8-10 hours before drug treatment. Cells counted 
every 24 hours using haemocytometer direct assay in pre-drug cell culture 
treatment, while in post-drug treatment, cells counted every 12 hours. 
Data represent mean ±SE of three replicates.
Further investigations were also carried out on the effect of calcium 2- 
hydroxybenzate but using higher concentrations. Figure (2.12) shows that
43
HT-1080 cell viability was dependent on calcium benzoate concentrations 
(0.4, 0.8mM) more than incubation time. Results also showed that calcium 
2-hyroxybenzoate is more cytotoxic than 2-acetylbenzoic acid (or aspirin) 
compared to the control.
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Figure 2.12 Concentration- and time-dependent effects of calcium 2- 
hydroxybenzoate and 2-acetylbenzoic acid on population growth rate of 
HT-1080 cells. Cells seeded at density of 4x104/T-25 flasks in 5ml optimal 
growth medium for three days before being arrested at G1 phase with 
serum-free medium for 24 hours. Cells then activated by replacing the 
serum-free medium with optimal growth media (containing serum), and 
allowed to grow for 8-10 hours before drug treatment. Cells counted every 
24 hours using haemocytometer direct assay in pre-drug cell culture 
treatment, while in post-drug treatment, cells counted every 12 hours. 
Data represent mean and ±SE of four replicates.
2.5.4 Time-lapse Tracking Assay of Cell population Growth 
Progression
The proliferation of HT-1080 cells was also studied using time-lapse 
analysis to investigate the effect of both calcium (Figure 2.13) and zinc 2- 
hydroxybenzoate (Figure 2.14) analogues, but at shorter incubation 
periods. This experiment aimed to study the effects of these compounds 
on cell division characteristics, which will be elaborated in Chapter 4. The 
effect of the 2-hydroxybenzoate compound on the cell proliferation is 
shown in Figure 2.13. Generally, calcium 2-hydroxybenzoate and 2-
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acetylbenzoic acid did not exhibit cytotoxic effects at different 
concentrations (0.4, 0.8 and 1.2mM) during 22 hours' incubation compared 
to the control. However, these exhibited a mitogenic effect, where the 
proliferation increased by a maximum of 28%. Nonetheless, calcium 2- 
hydroxybenzoate at 0.8mM concentration showed about 6% reduction in 
the proliferation compared to control. The mitogenic effect of these 
compounds is consistent with the MTT assay discussed in the previous 
sections.
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Figure 2.13 Concentration- and time-dependent effects of calcium 2- 
hydroxybenzoate and 2-acetylbenzoic acid on population growth rate of 
HT-1080 cells. HT-1080 cells at 1x103 cell per well incubated on 
microscope stage in standard plastic 12-well culture plate. Instrument 
comprised Zeiss Axiovert 100 microscope fitted with temperature- 
regulating incubator system and CO2 supply. Motorised xy microscope 
stage and phase transmission images (x10 objective lens) set to capture 
each field every 5 minutes over 22 hours (264 frames per field) using Orca 
I ER charge-coupled device camera. Camera, stage (xy) and focus (z) PC 
computer controlled using AQM 2000 software (Kinetic Imaging, Wirral, 
UK). Tiff-format Images (512 x 512 pixels) played back for analysis as 
movies using AQM 2000 software.
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In comparison with calcium 2-hydroxybenzoate and 2-acetylbenzoic acid, 
however, zinc 2-hydroxybenzoate showed a concentration- and time- 
dependent relationship with HT-1080 cell proliferation patterns (Figure 
2.14).
The three different methods: MTT, haemocytometer and time lapse image 
tracking have shown broadly consistent viability measurements that 
identify the antiproliferative benzoate analogues.
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Figure 2.14 Concentration- and time-dependent effects of zinc 2- 
hydroxybenzoate on the population growth rate of HT-1080 cells. HT-1080 
cells at 1x103 cell per well incubated on microscope stage in standard 
plastic 12-well culture plate. Instrument comprised Zeiss Axiovert 100 
microscope fitted with temperature-regulating incubator system and CO2 
supply. Motorised xy microscope stage and phase transmission images 
(x10 objective lens) set to capture each field every 5 minutes over 22 
hours (263 frames per field) using Orca I ER charge-coupled device 
camera. Camera, stage (xy) and focus (z) were PC computer controlled 
using AQM 2000 software (Kinetic Imaging, Wirral, UK). Tiff-format Images 
(512 x 512 pixels) were played back for analysis as movies using AQM 
2000 software.
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2.6 Summary and Conclusion
The results of this chapter focus on the antiproliferative activities of 18 2- 
hydroxybenzoate analogues measured by two methods: MTT and cell 
count either by haemocytometer or through recorded time-lapse capture 
microscopy. A range of concentrations (0.025-8mM) and different 
incubation times (2-180 hour) were used, unless otherwise specified in 
each experiment. Results demonstrated the differences in the 
antiproliferative properties of the 18 benzoate analogues. It is evident that 
zinc benzoate, zinc 2-hydroxybenzoate and zinc 2-acetylbenzoate induced 
significant antiproliferative activities compared to other compounds and 
control. The induction of the antiproliferative properties, particularly at 0.3 
and 0.4mM concentrations, showed concentration- and incubation time- 
dependency. Furthermore, MTT viability measurements showed that both 
potassium and calcium 2-hydroxybenzoate analogues treatments have 
induced a certain concentration and time-dependency related to the 
inhibition of proliferation rates in HT-1080 fibrosarcoma cancer cells. For 
example, potassium benzoate, potassium 2-hydroxybenzoate and 
potassium 2-acetylbenzoate compounds, each induced a reduction in the 
proliferation at certain concentrations and incubation times. The results of 
these compounds showed a reduction of 10-30% at low concentrations 
(0.025-0.1mM) (see Figure 2.5).
The interest in 2-acetylbenzoate (acetylsalicylates), particularly in respect 
of cancer research has increased in the last three decades. These studies 
have demonstrated that 2-acetylbenzoates (particularly, aspirin), at 
concentrations ranging between 0.5mM to 10mM, inhibit cell population 
growth, DNA and various proteins synthesis, as well as G1-S phase 
progression of the cell cycle (Aas et a!., 1995; Ricchi et a\., 1997; Marra 
and Liao, 2001; Sharma eta!., 2001).
The effects of 2-hydroxybenzoate analogues on cellular function, 
particularly cell cycle progression may impact on cell population growth at 
a therapeutic level for cancer. The mechanism of antiproliferative activity
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by 2-hydroxybenzoate can be attributed to the modulation of growth- 
regulatory pathways, via genes such as p53, p21, Bax, Bcl-2, and others.
The use of high concentrations of these molecules to induce 
antiproliferative effect in vitro may not be physiologically relevant. 
However, the induction of the significant amount of inhibition supported 
here might be expected to be translated in vivo without further side effect 
on the normal biological system. The effects of these compounds on the 
cell viability may result from stimulation of extracellular and/or intracellular 
signalling pathway(s). Generally, cellular proliferation is governed by 
complex molecular interactions induced by extracellular and intracellular 
signalling pathways which determine the accurate reproduction of cells in 
a way that suits the developmental needs of the organism (Pumin, 1999). 
Eukaryotic cell division occurs in a series of steps which determine the cell 
population growth and cell proliferation that occurs in a precisely regulated 
cell cycle, comprising four distinct phases (Go/G1, S, and G2) (Zetterberg 
and Larsson, 1995). Thus several compounds with the potential to restore 
control of cell division in human cancers have been developed through the 
understanding of the cell cycle regulation by various regulatory protein 
families (Charles, 2004). The effect of some of these benzoate 
compounds will be elaborated further in Chapter 4.
In conclusion some of the antiproliferative 2-hydroxybenzoate analogues 
used in this study were concentration- and time-dependent in reducing the 
proliferation rates of HT-1080 cell line. The next chapter will focus on the 
effect of 2-hydroxybenzoate analogues on the morphology of HT-1080 cell 
line.
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CHAPTER THREE
Effect of 2-Hydroxybenzoate Analogues on the HT-1080 Cell Line: 
Morphological and Immunocytochemical Evidence for Apoptosis
3.1 Introduction
This chapter aims to assess the effect of 2-hydroxybenzoate analogues on 
the morphological characteristics of the HT-1080 fibrosarcoma cell line. 
Generally, eukaryotic cells undergo either natural or induced 
morphological changes as a result of, for example, cellular differentiation, 
proliferation or drug-induced apoptosis. These morphological observations 
are important to distinguish changes that might occur in the nucleus, 
cytoplasm, and/or cell surface, in order to understand the normal functions 
of cells. Acquiring this knowledge is also necessary to understand 
diseases and their treatments. For example, normal cellular morphology 
can differ from that of cancer cells, as tumour cell morphology is often 
characterised by aneuploidy. Furthermore, both types of cell death, 
programmed cell death (apoptosis) and necrosis, are often distinguishable 
by their morphological characteristics.
Changes in cellular morphology can be attributed to various biochemical 
molecular biological processes, and can be observed by light, 
fluorescence and electron microscopy. These techniques have been used 
by many researchers as an initial observation strategy during many 
studies (Zhang e ta i, 1997; Willingham, 1999; Barrett et aL, 2001). Thus, 
this chapter focuses on the application of a number of morphological and 
molecular techniques to visualise the changes in the HT-1080 cells 
induced by various treatments with 2-hydroxybenzoate analogues. Light, 
fluorescence and electron microscopy are used with or without certain 
dyes, including haematoxylin and eosin, methyl-green and pyronin, DAPI 
and Annexin-V. These dyes are mainly aimed at the detection of apoptotic 
HT-1080 cells. The apoptotic effects of 2-acetylbenzoic acid and calcium, 
magnesium, potassium and zinc 2-hydroxybenzoate analogues were 
assessed.
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3.2 Morphological Techniques
Several techniques have been developed and systematically used in the 
literature to investigate morphological changes resulting from the 
treatment of cancer cells with both synthetic and natural biologically active 
compounds (Bowen and Ryder, 1976; Stevens, 1977; Wyllie et ai, 1980; 
Kerr et ai, 1987; Drachenberg et a i, 1997). Light microscopy is the 
simplest technique that can detect the morphological changes in cancer 
cells with or without staining. Specific dyes have been used to elucidate 
certain changes in the cell. Haematoxylin and eosin, for example, stain the 
cell nuclei blue to black, whilst the eosin stains cell cytoplasm and most 
connective tissue fibres in varying shades and intensities of pink, orange 
and red (Stevens, 1977). This technique is routinely used in diagnostic 
and clinical research for the enhancement of cellular and nuclear 
structures, together with the recognition of apoptotic bodies. Haematoxylin 
is an adequate nuclear stain only in the presence of a mordant, such as 
aluminium, iron, tungsten, and on occasions, lead salts (Stevens, 1977). 
The mordant in most widespread use is alum haematoxylin in the form of 
aluminium potassium sulphate. The nuclei are initially stained a red colour, 
which is then converted to a blue-black colour when washed in tap water, 
which is a weak alkali.
Eosin is widely used, together with alum haematoxylin, to enhance the 
general histological structure of a cell or tissue. The eosins are xanthene 
dyes, of which eosin Y is the most commonly used. As a cytoplasmic stain, 
it is used as 0.5-1 % solution in deionised water with a crystal of thymol to 
prevent fungal growth (Stevens, 1977). Tap water washing differentiates 
the eosin stain in the cytoplasm and the subsequent intensity of both the 
haematoxylin and eosin stain.
Methyl-green and pyronin y are other common dyes that have been used 
in cytology to stain nuclear morphology, specifically of DNA and RNA, 
respectively (Elias 1969; Bancroft and Stevens, 1977; Bowen, 1984). The 
combination of these two dyes was used first by Pappenheim in 1899, and
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later modified by Unna in 1902 (cited by Moffit, 1994). The technique 
appears to be specific under certain conditions for DNA, and the pyronin y 
specific for RNA when used in an acidic environment. Thus methyl-green 
might emphasise apoptotic cells due to the staining of pyknotic nuclei, 
while the pyronin y may highlight apoptotic cells due to increases in RNA 
levels (Bowen et ai, 1993). Non-apoptotic (necrotic) cells may also be 
'negatively* highlighted due to the loss of RNA and thus lack of pyronin y 
stain.
Fluorescence dyes like 4',6-diamidino-2-phenylindole (DAPI) have also 
been used to illustrate the nuclear morphology of cells. DAPI is a 
fluorescent dye that interacts with the double stranded helix of the DNA at 
A-T clusters when it is excited at a wavelength of 460nm to give a blue 
fluorescence colour. The interaction between the DNA helix and DAPI 
increases the intensity of fluorescence twenty-fold giving enough blue 
colour to be observed.
In addition to the techniques used for nuclear and cytoplasmic staining, 
the immunohistochemical analysis of phosphatidylserine offers an earlier 
detection of changes on the cytoplasmic membrane. The Annexin-V assay 
is widely used to detect cells undergoing apoptosis and is an excellent 
indicator of the onset of apoptosis in many cell types. In healthy cells, 
most of the phosphatidylserine is localised to the interior (cytoplasmic) 
face of the cytoplasmic membrane, but within one hour after the induction 
of apoptosis, it rapidly redistributes to the outer leaflet of the lipid bilayer 
by a mechanism that is unclear, However, Martin et al. (1995) postulated 
that phosphatidylserine externalisation is an active process (e.g a flippase) 
needing a threshold presence of energy in the form of ATP. During the 
process of apoptosis, high levels of ATP are present within the cell to carry 
out the signal transduction cascades (e.g caspase cascade) of cell death 
(Fadok et ai, 1992; Martin et a i, 1995). Thus, during apoptosis ATP is 
available for the active process of phosphatidylserine translocation. 
However, during necrosis, a decrease in ATP levels prevents the energy- 
thirsty phosphatidylserine translocation (Leist et ai, 1997). Intracellular
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ATP concentration is a switch deciding between apoptosis and necrosis 
thus the assay is apoptotic-specific. The function of phosphatidylserine 
externalisation is unclear, but it may serve as a 'tag' to single out apoptotic 
cells for recognition by macrophages (Fadok et ai, 2000). However, once 
on the cell surface, phosphatidylserine can be easily detected by staining 
with an FITC conjugate of annexin-V, a protein that has a strong, natural 
affinity for phosphatidylserine. Other immunohistological techniques have 
also been developed to study cell death and the changes that occur in 
cells naturally or induced by drugs. The enzyme-linked immunosorbant 
assay (ELISA) techniques, for example, use both antihistone and 
complementary DNA base binding to detect both DNA fragmentation and 
histone released by nucleosomes (Trauth etal., 1995). The technique has 
been used successfully at both light and electronic microscope levels to 
detect histones and DNA localisation (Gregorc and Bowen, 1997; Al- 
Hazzaa and Bowen, 1998).
In addition to the morphological changes detectable by light and fluoresce 
microscopy, electron microscopy can reveal more detailed changes to the 
intracellular membrane compartments, including the endoplasmic 
reticulum, mitochondria, and Golgi apparatus (Bowen et ai, 1996; Leek 
and Albertsson, 2000). The loss of microvilli observed by electron 
microscopy, in many cases may be considered as a common feature of 
cell death (Fernandez-Segura et a i, 1990; Nagata, 1996; Kondo et al., 
1997). Loss of microvilli has been shown to occur downstream of caspase 
activation, and along with dephosphorylation of proteins which normally 
stabilise microvilli to the actin skeleton (Kondo et al., 1997).
3.3 Cell Morphology Changes and Cell Death
Cell death may occur naturally (e.g. apoptosis) as part of cell turnover, 
during involution of tissue as part of normal embryological development, or 
pathologically (e.g. apoptosis or necrosis). While apoptosis occurs in both 
pathological conditions (e.g. Parkinson’s and Alzheimer’s disease) and
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normal conditions (at the end of the natural cellular life-span), necrosis is 
always pathological (e.g. as a result of an infection), and is usually 
accompanied by an inflammatory reaction. Both modes of cell death have 
distinctive morphological characteristics that can be detected by 
microscopic techniques. Figure 3.1 shows the comparison between the 
morphological characteristics of both apoptosis and necrosis modes of cell 
death.
Apoptosis is associated with a distinct set of biochemical and 
morphological changes involving all components of the cell, including the 
cytoplasm, nucleus and plasma membrane (Kerr et al., 1972; Wyllie, 
1980; Arends and Wyllie, 1991). The early stage of morphological change 
in cells undergoing apoptosis is characterised by cell rounding-up, losing 
microvilli, and subsequently the contact with the neighbouring cells. The 
cells finally shrink and fragment into apoptotic bodies with intact 
membranes. During apoptosis, the cytoplasm condenses, but the plasma 
membrane, ribosomes, Golgi apparatus, and mitochondria remain intact. 
The endoplasmic reticulum dilates, and the cistemae swell to form 
vesicles and vacuoles that fuse with the surface membrane, giving a 
characteristic blebbing or bubbling appearance (Figure 3.1). In the 
nucleus, the chromatin condenses at the nuclear membrane and 
aggregates into dense compact masses, and is fragmented 
intemucleosomally by endonucleases, which can be analysed by the 
typical ‘DNA ladder1 formation of apoptosis, for which DNA is extracted 
from the cells and separated by gel chromatography (Kerr, 1994; Nagata, 
2000; Vaux, 2002). The cells at this stage separate into apoptotic bodies 
that are surrounded by an intact plasma membrane to prevent any 
interaction with biological fluids and normal cells. These fragmented cell 
bodies or apoptotic bodies are easily recognised and are digested by 
macrophages or epithelial cells, usually without inflammation. This is why 
apoptosis induction has been considered as one possible strategy in 
cancer therapy. Indeed, several anticancer molecules have been shown to
restore the missing programmed cell death which proceeds through 
apoptosis (Vaux, 2002).
It is not clear whether the detectable morphological alterations are 
subsequently due to a single pathway or multiple interrelated pathways; 
however, it can be assumed that caspases play a crucial role in the 
appearance of these alterations. But, in vitro the chemical inhibition of 
caspases only partially inhibits the alterations. An example being when 
caspase-3 was removed from both mice and human breast cancer cells 
(Janicke et ai., 1998, and Zheng et al., 1998, respectively), only a 
reduction and not a total elimination of blebbing was observed. 
Nevertheless this implies that structural events are indeed the 
consequence of caspase activation, and although blebbing appears to 
require caspase-3 activity in order to be initiated, once initiated, it can 
continue even in the presence of caspase inhibitors, implying that 
caspases activate downstream mechanisms, which mediate the 
appearance of blebs.
Mitochondrial morphological preserved
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Figure 3.1 Morphological structure of apoptosis and necrosis modes of cell 
death. Adapted from Duvall and Wyllie (1985) (1986).
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This form of physiological cell death is morphologically quite different from 
the necrotic mode of cell death (Figure 3.1), in which the cell swells and 
disintegrates in an unordered manner, eventually leading to the 
destruction of the cellular organelles, and finally rupture of the plasma 
membrane and leakage of the cell content. During necrosis, the 
permeability of the plasma membrane increases, the endoplasmic 
reticulum dilates, the cell alters shape, the mitochondria become denser, 
the nuclear chromatin flocculates. The disintegration of the plasma 
membrane and the leakage of cell contents, mainly lysosomal enzymes, 
often provoke inflammation. A secondary necrosis can also be the final 
result in situations where there is too much apoptosis occurring for 
phagocytotic cells to cope with, or in cell culture (Trump et al., 1997) 
where phagocytotic cells are usually lacking.
3.4 Materials and Methods
3.4.1 Materials and Instruments
6-well plate (Coster, Cambridge, MA, USA), Vectashield mounting medium 
for fluorescence (Vector Laboratories, Inc., Burlingame, USA), Leitz 
fluorescence microscope (Leitz Laboratory 12, Leica, Milton Keynes, UK); 
attached FS camera (MCA Leitz Neoplan system, Tucson, AZ, USA) with 
CoolSnap image analysis software V1.2 (Rofer Scientific, UK); Leitz light 
microscope (Leitz Laborlux 12; Leica, Milton Keynes, UK) connected to 
image analysis software V2.3 (Rofer Scientific, UK); Scanning Electron 
Microscope (Philips XL 20 high vacuum scanning electron microscope, 
fitted with some computerised imaging facilities)
Annexin-V (Costar, Cambridge, MA, USA), cell dissociation buffer; 1X 
binding buffer (Clontech laboratories Inc., East Meadow Circle, Palo Alto, 
USA); propidium iodide; methyl green (Sigma-Aldrich, UK); pyronin y 
(Sigma-Aldrich, UK); 4',6-Diamidino-2-phenylindole dihydrochloride 
Diamidoino-2-Phenylindole (DAPI) (Sigma-Aldrich, UK); haematoxylin (R A 
Lamb Limited, UK), Eosin (R A Lamb Limited, UK); xylene, ethanol, 
chloroform, and formaldehyde (Sigma-Aldrich, UK).
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Preparation of Methyl green-pyronin y Stain The methyl green 
component is supplied in an impure form that contains traces of methyl 
violet which is soluble in chloroform. Methyl green-pyronin y stain was 
prepared according to Moffit (1994), where 0.75g of methyl green was 
added to 150ml of acetate buffer at pH 4.9 (4.4g sodium acetate dissolved 
in 160ml deionised water, pH adjusted to 4.9). The solution was then 
washed with chloroform (150ml x 4) to remove methyl violet impurities, till 
the chloroform layer became translucent. 200mg of pyronin y was 
dissolved in 100ml of purified methyl green, and then the methyl 
green/pyronin y mixture was filtered. This solution was kept as a stock 
solution, at 4°C, and used within 5 days.
The haematoxylin and eosin stain was prepared according to Stevens 
(1977).
3.4.2 Cells and in vitro Culture Conditions
HT-1080 cells were grown in 6-well plates containing coverslips at the 
density described previously, unless otherwise stated, in DMEM optimal 
growth medium (see Chapter 2, Materials and Methods). After 48 hours, 
the medium was replaced with fresh medium containing one of the 
benzoate or 2-hydroxybenzoate analogues under investigation, unless 
otherwise stated. These compounds were prepared as described in 
Chapter 2. Two control samples were incorporated in each experiment: no 
treatment and cell treated with a standard apoptosis-inducing drug 
(staurosporine) at a final concentration of 1pM. Treated cells were 
incubated under standard culture conditions for 48 hours, unless otherwise 
indicated, washed with PBS, and finally stained with one of the dyes 
outlined above. In each experiment, both apoptotic and non-apoptotic cells 
were counted in 2 fields of each slide, using a Leitz Laborlux 12 
microscope.
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3.4.3 Immunoassay- Annexin-V for Apoptosis Detection
HT-1080 cells were seeded into 6-well plates at an initial density of 
1.25x105 per well and cultured for 48 hours, as described in Section 3.4.2. 
The optimum DMEM growth medium was then replaced with the same 
medium containing 2-hydroxybenzoate at different concentration. After 
treatment for 48 hours, unless otherwise stated, the medium containing 
non-adherent cells was aspirated into centrifuge tubes, the cells 
dissociated with 1 ml/well of warm (37°C) cell dissociation buffer 
(previously diluted with 2ml of warm DMEM medium), and incubated for 5- 
10 minutes. Adherent cells were gently scraped and pooled with the non- 
adherent cells using a cell scraper. Cells were then pelleted by 
centrifugation at 200g for 5 minutes, the supernatant removed, and the 
cells homogenised with 0.5ml of 1X binding buffer (Clontech Laboratories 
Inc, East Meadow Circle, Palo Alto, USA). The cell suspensions were 
transferred into Eppendorf pipettes and centrifuged at 200g for 5 mintes, 
the supernatant was removed, and the homogenised cells resuspended in 
50pl of 1X binding buffer. Subsequently, 3pl of Annexin-V -FITC was 
added to each tube, and these were incubated for 15 minutes at room 
temperature, in the dark. Immediately after incubation, 2pl of propidium 
iodide (50ng/ml of 1X binding buffer) was added and incubated for a 
further 5 minutes at room temperature, in the dark and mounted in 
vectashield (Vector Laboratories, Inc, Burlingame, USA). Slides were 
examined using a fluorescence microscope (Leitz Laborlux 12; Leica, 
Milton Keynes, UK). Five random fields, each of 100 cells, were counted 
per slide, and the percentage of apoptotic cells was assessed based on 
nuclear morphology (Rogers et al., 1996). Representative photographic 
images were taken using a photometries FS camera (MCA Leitz; Neoplan 
system, Tucson, AZ, USA) and CoolSnap image analysis software V1.2 
(Rofer Scientific, UK).
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3.4.4 Diamidoino-2-Phenylindole (DAPI) Staining
HT-1080 cells were seeded into 6-well plates containing coverslips, at an 
initial density of 2x105 per well, as described in Section 3.4.2. After 48 
hours or unless otherwise stated, the cells in each well were washed with 
2ml PBS and incubated for 10 minutes at room temperature before fixing 
with 2ml of 4% formaldehyde in PBS for 10 minutes at room temperature 
while cells became attached to the coverslips in the wells. After fixation, 
cells were washed again with PBS, stained for 20 minutes with 2.5mg/ml 
DAPI solution and each coveslip was mounted in Vectashield mounting 
medium for fluorescence. The DAPI-stained HT-1080 cells were examined 
using a fluorescence microscope at 460nm maximum wavelength. Four 
fields were selected from each sample. Representative photographic 
images were taken using a photometries FS camera and CoolSnap image 
analysis software V1.2.
3.4.5 Haematoxylin and Eosin Staining
HT-1080 cells were seeded into 6-well plates containing coverslips at an 
initial density of 1.25x10s per well, and grown for 48 hours, as described in 
Section 3.4.2. The optimum DMEM culture medium was then replaced 
with the same medium, but containing 2-hydroxybenzoate compounds at 
concentrations, unless otherwise indicated for each experiment (see 
legend of each Figure in Results and Discussion Section). Cells were 
allowed to grow for a further 24 hours. HT-1080 cells were then washed 
with PBS, fixed with formaldehyde solution, and washed again with PBS 
for 1 minute at room temperature, as described in the previous section. 
Cell samples were washed again in 2ml of PBS for 1 minute at room 
temperature, and stained with Mayer’s haematoxylin for 1 minute, followed 
by three washes in tap water and one in distilled water. The sections were 
counterstained with 1% eosin for 3-5 minutes, followed by another 3 
washes in tap water and one in distilled water. Gently, the converslip 
containing stained cells was lifted from the well using forceps, and
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immersed in the following solvents: deionised water; 70 % alcohol; 95 % 
alcohol; 100% alcohol twice; xylene twice (xylene vapour is toxic and may 
be carcinogenic, therefore this step was carried out in a fume cupboard). 
Excess liquid was removed from the coverslip by gently tapping it on a 
piece of rolled tissue paper. Finally, the coverslip was air dried and 
mounted on a labelled slide using a small amount (several drops) of DPX 
(a synthetic resin). Forceps were used to gently press the coverslip down 
on the slide. Images of treated and untreated HT-1080 cells were viewed 
under Leitz light microscope. The significant images were recorded 
through the use of Analysis Image, Analysis software V2.3.
3.4.6 Methyl-green/pyronin y Staining
HT-1080 cells were seeded into 6-well plates containing coverslips, at 
initial density of 1.5x104 per well, and grown for 48 hours as described in 
Section 3.4.2. The optimum DMEM culture medium was then replaced 
with the same medium but containing 2-hydroxybenzoate analogue at 
different concentrations, (see legend of each Figure in Results and 
Discussion Section). After 48 hours, the DMEM optimal growth medium 
was replaced with fresh medium containing 2-hydroxybenzoate analogue 
unless otherwise stated. After treatment for 48 hours, the old medium was 
aspirated and the adherent cells were washed in 2ml of PBS and 
incubated for 10 minutes at room temperature before fixing with 2ml of 4% 
(v/v) formaldehyde in PBS for 10 minutes at room temperature. The 
samples were washed again in 2ml of PBS for 1 minute at room 
temperature, and incubated for 45 minutes in methyl-green/pyronin y 
staining solution at room temperature. The coverslips were removed from 
the wells, then washed by dipping for 3-4 seconds in deionised water at 
1°C. Coverslips were air dried and mounted with DPX. The coverslips 
were viewed under a light microscope and images recorded through the 
use of Analysis Image, Analysis software V2.3.
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3.4.7 Scanning Electron Microscopy
HT1080 cells were seeded in a 12-well plate containing microscope 
coverslips at density of 1.5 x 104 cells per well, and incubated for 24 hours 
under standard growth conditions in the optimal DMEM growth medium, 
before being treated with salicylates at different concentration and 
incubation periods (see Section 3.4.2). Cells were then treated with the 
fixative (0.8% glutaraldehyde, 0.6% osmium tetroxide, 2 mM CaCb, and 
0.2M sucrose in 0.1M sodium cacodylate buffer pH 7.4) for one hour, 
washed several times in PBS buffer, and dehydrated with different alcohol 
concentrations (30%, 50%, 70%, 90%, each for 5 minutes, and 100% for 
10 minutes, twice). The dehydrated samples were then dried to the critical 
point in a Blazers CPD 030 using CO2 . Cell samples were then mounted 
onto 12 mm 'Philips type' aluminium stubs, using silver paint, and then 
gold sputter-coated in an Edwards S150B sputter coater. Finally, the 
samples were imaged using a Philips XL20 SEM under various 
magnifications ranging from x500 up to x5000.
3.5 Statistical Analysis
The immunohistochemical detection of the number of labelled cells with 
Annexin-V was obtained from 2-3 slides. The resulting average was used 
to calculate mean ±SE. To determine the effect of drug treatment on the 
induction of apoptosis, data were calculated as a percentage of control 
and expressed as means ±SE. One-Way Analysis of Variance was 
performed using Minitab statistical program. A value of p<0.01 was 
considered significant.
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3.6 Results and Discussion
3.6.1 Morphology of Untreated HT-1080 Cell Line
The fibrosarcoma HT-1080 cells showed an irregular shape with a distinct 
microvilli as revealed by scanning microscopy. The dimensions of HT- 
1080 cells ranged between 10-15pm wide and 20-30pm long (Figure 
3.2A). Cells also appeared in a flat monolayer structure (Figure 3.2A) and 
retained their attachment to the surface, as well as their plasma 
membrane processes. The control cells of HT-1080, stained by DAPI and 
observed under a phase contrast of fluorescence/light and scanning 
electron microscope, indicated that these cells were viable, as confirmed 
by the above-mentioned features and the presence of cell connection 
fibres (Figure 3.2B). It is possible to identify the nucleus of HT-1080 cells 
by DAPI staining as a blue colour (Figure 3.2B), or as a dark colour when 
cells were stained by haematoxylin (Figure 3.2D) or methyl green (Figure 
3.2C). Furthermore, the cytoplasm of HT-1080 cells showed responses to 
pyronin y and eosin to give, respectively, pink or red colours to the RNA of 
the cells (Figures 3.2C and 3.2D). It appeared that there were a few cells 
either apoptotic (Figure 3.2C, blue arrows) or mitotic (Figure 3.2D, black 
arrows).
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Figure 3.2 HT-1080 fibrosarcoma cell images: A SEM revealing distinctive 
filaments and filopodia (white arrows); B Phase contrast image showing 
cell connections (green arrows) and fluorescent DAPI blue stained 
nucleus; C Methyl green-pyronin y stained HT-1080 cells, blue indicates 
DNA in the nucleus, while pink colour indicates RNA rich cytoplasm. 
Apoptotic cells (blue arrows), and normal HT-1080 cells (white arrows) 
(magnification x200). D Haematoxylin-eosin-stained HT-1080 cells, 
nucleus dark-stained by haematoxylin, and cytoplasm red- stained by 
eosin, filopodial attachment (white arrows), and mitotic cells (black arrows) 
(magnification x200).
These cells were treated with both 2-acetylbenzoic acid, and 2- 
hydroxybenzoate calcium, magnesium, potassium and zinc analogues at 
different concentrations and incubation periods unless otherwise indicated
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in the following sections. The effect of these compounds in inducing cell 
death was investigated by light, fluorescence and electron microscopy.
3.6.2 Morphological Changes Induced by Standard Drugs
Figure 3.3 shows the morphological characteristic of HT-1080 treated with 
an apoptotic control agent, the staurosporine at 0.001 mM concentration 
for 24 hours. DAPI staining of treated cells indicated that they progressed 
through apoptosis as cells showing various apoptotic bodies and pyknotic 
nuclei. In some treated cells, signs of blebbing were observed Figure 3.3A. 
Both haematoxylin-eosin and methyl green-pyronin y staining techniques 
have also clearly showed cells signs of apoptotic morphology, blebs and 
apoptotic bodies Figures 3.3B and 3.3C. These signs are clearer in the 
fine structure of benzoate analogues-treated HT-1080 cells when 
examined under the scanning electron microscope, as illustrated in Figure 
3.3D. Further examination of microscopic images of cells treated with 
0.001 mM staurosporine did not find chromatin condensation, but a few 
swollen cells which may be indicative of an early stage of necrosis.
HT-1080 cells treated with 0.4mM and 0.8mM 2-acetylbenzoic acid 
showed signs of apoptosis when stained with DAPI. Cell treated with 
0.8mM 2-acetylbenzoic acid showed more cells undergoing blebbing 
compared to 0.4mM treatment (Figure 3.4A, 3.4B) and control sample 
(Figure 3.2B). Both apoptotic bodies and blebs as evidence of distinct 
signs for cells undergoing apoptosis were clearly observed by the 
microscopic examination when HT-1080 cells treated with 0.4mM 2- 
acetylbenzoic acid and stained by haematoxylin-eosin (Figure 3.4C) or 
methyl green-pyronin y (Figure 3.4D). Furthermore, the effect of 2- 
acetylbenzoic acid on the morphological features of HT-1080 cells was 
also examined by SEM.
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Figure 3.3 Microscopic images of HT-1080 cells treated with 0.001 mM 
staurosporine and examined by (A) DAPI staining, white arrows refer to 
apoptotic bodies, red arrows to blebs and stars to pyknotic nuclei, B 
Haematoxilin-eosin staining, green arrows refer to apoptotic body, blue 
arrows for blebs, and star for apoptotic cells (magnification x200), C 
Methyl-Green-pyronin y staining, labelling as in B (magnification x200) and 
(D) SEM, red arrows refer to apoptotic bodies.
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The effect of different concentrations of 2-acetyl benzoic acid (0.4, 2 and 
8mM) also confirms the results of the previous cytological techniques 
about the presence of apoptotic cells, and apoptotic bodies. Examining the 
morphology of HT-1080 indicates 0.4mM (Figure 3.4E1) caused less 
cytotoxic effects compared to 2mM (Figure 3.4E2). The number of 
apoptotic cells increased dramatically at 8mM concentration (Figure 
3.4E3).
3.6.3 Effect of Calcium 2-Hydroxybenzoate on HT-1080 Cell Death
The morphological effect of calcium 2-hydroxybenzoate and 2- 
acetylbenzoic acid on HT-1080 cells was studied at 0.4mM and 24 hours' 
incubation, to determine whether these compounds elicited significant cell 
death compared to control. Treated and untreated HT-1080 cells were 
cultured under standard conditions prior to immunolabelling with Annexin- 
V. The results in Figure 3.5 indicate that the benzoate analogues induced 
apoptosis, as indicated in the positive responses to the Annexin-V 
immunoassay. The percentages of both the positively and negatively 
immunolabelled phosphatidylserine on the cell surface of HT-1080 cells is 
shown in Figure 3.5A.
Statistical analysis indicated that both benzoates induced significantly 
more apoptosis than the control at 0.01% (Figure 3.5A). The percentage of 
cells positively labelled with Annexin-V were 16.5% by 2-acetylbenzoic 
acid and 25.3% by calcium 2-hydroxybenzoate. Figure 3.5B1-B3 shows 
the morphological characteristics of HT-1080 cells undergoing cell death 
at the early stages, as elucidated by the labelling of the flagged 
phosphatidylserine (green arrows) and at the later stages (white arrows) of 
death, as indicated by the cell shrinkage and nuclear condensation during 
24 hours and at 0.4mM concentration.
Further investigations of the effect of calcium 2-hydroxybenzoate on the 
nuclear morphology of HT-1080 cells were also carried out at different 
concentrations (0.4, 0.8 and 1.2mM) (Figure 3.6). Treated HT-1080 cells
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were cultured under optimal conditions for 24 hours before staining with 
DAP I.
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Figure 3.4 Microscopic images of HT-1080 cells treated with (A) 0.4 and 
(B) 0.8mM 2-acetylbenzoic acid and examined by DAPI staining, blebs 
(white and blue arrows). C HT-1080 cells treated with 0.4mM 2- 
acetylbenzoic acid and stained with Haematoxylin-eosin, apoptotic body 
(green arrows); blebs (blue arrows), (magnification x200). D HT-1080 cells 
treated with 0.4mM 2-acetylbenzoic acid and stained methyl-green-pyronin 
y staining, labelling as in C, (magnification x200). E1-E3 SEM of effect of 
2-acetylbenzoic acid at (E1) 0.4mM, (E2) 2.0mM, and (E3) 8mM. Apoptotic 
bodies (blue arrows) and apoptotic cells (white arrows) respectively.
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Annexin-V positiveAnnexin-V negative
Figure 3.5 Immunohistochemical illustration for effect of 2- 
hydroxybenzoate analogues. A Percentage of apoptotic HT-1080 cells 
after treatment with 2-acetylbenzoic acid or calcium 2-hydroxybenzoate for 
24 hours. Data represent mean ±SE of eight readings. One-way ANOVA; 
control significantly different from 2-AcBA and 2-HBnCa at P< 0.000. 2- 
AcBA significantly different from 2-HBnCa at P< 0.003 (Appendix B). B I­
BS HT-1080 Cells labelled with Annexin-V. B1 Control, B2 treated with 
0.4mM 2-acetylbenzoic acid, and B3 treated with 0.4mM calcium 2- 
hydroxybenzoate. Early apoptotic cells (green arrows), late apoptotic cells 
(white arrows). Magnification X40.
The fluorescence/light phase contrast microscopic images of the treated 
cells clearly showed that the 1.2mM concentration of calcium 2- 
hydroxybenzoate (Figure 3.6C) induced more apoptotic cells compared to 
the control HT-1080 cells (Figure 3.2B) and the other treatments of the
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lower calcium 2-hydroxybenzoate concentrations (i.e. 0.4 and 0.8mM) 
(Figures 3.6A and 3.6B).
50um
Figure 3.6 Fluorescence/light phase contrast microscopic images of 
calcium 2-hydroxybenzoate treated HT-1080 cells, and after 24 hours 
stained with DAPI, A at 0.4mM, B at 0.8mM, and C at 1.2mM 
concentration. Blebbings of HT-1080 cells (white and blue arrows), and 
pyknotic nuclei (stars).
Cells undergoing apoptosis showed various blebs coming of the cell 
surface of HT-1080 cell line (Figure 3.6, note white and blue arrows). The 
microscopic images of treated cells showed clear morphological changes,
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like blebbing and apoptotic bodies, as a result of the incorporation of 
different concentrations of calcium 2-hydroxybenzoate (0.4, 0.8 and 
1.2mM), particularly at the highest concentration (1.2mM) (Figure 3.6C, 
note white arrows). Furthermore, haematoxylin and eosin also showed 
morphological changes when HT-1080 cells were treated with calcium 2- 
hydroxybenzoate at 0.4mM concentration for 24 hours compared to the 
control (Figure 3.2D). HT-1080 cells showed distinct morphological 
characteristics such as pyknotic cells (rounded cells) and shrinkage, 
indicating that cell death was induced through the apoptotic pathway 
(Figure 3.7A). Note that cells undergoing apoptosis also have lost their 
filopodial attachment compared to control (Figure 3.2D). The classical 
apoptotic signs appearing in Figure 3.6 and other figures are true 
representations of the overall effect of the individual treatment. Further 
examination of the effect of calcium 2-hydroxybenzoate at different 
concentrations showed no necrotic cells, indicating that the cell death is by 
apoptotic pathway.
Methyl green and pyronin y staining was next used in the morphological 
analysis of the effect of calcium 2-hydroxybenzoate. HT-1080 cells were 
treated prior to the staining procedure with 0.4mM calcium 2- 
hydroxybenzoate for 24 hours. Morphologically, the nucleus of the HT- 
1080 cells is stained dark blue with methyl green, while pyronin y stained 
the cytoplasm pink or red (Figure 3.7B). This morphological technique 
clearly showed cellular blebbing and shrinkage as evidence for apoptosis 
when cells were incubated with calcium 2-hydroxybenzoate. Note that the 
dark blue colour of some stained nuclei is due to the staining of the 
chromatin as well.
The fine structure of the treated HT-1080 cells with calcium 2- 
hydroxybenzoate at different concentrations (0.4 and 0.8mM) also 
confirms that cells were dying through apoptosis. The scanning electron 
micrographs showed many apoptotic cells at both benzoate 
concentrations (Figure 3.7C - 3.7E).
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Figure 3.7 HT-1080 cells treated with different concentrations of calcium 
2-hydroxybenzoate for 24 for hours. A Cell treated with 0.4mM and 
stained with haematoxylin-eosin, pyknotic cells (black arrows), 
magnification x200. B Cells treated with 0.4mM and stained with methyl- 
green and pyronin y staining, Chromatin staining (green arrows) and 
apoptotic cells with blebs (blue arrows), magnification x200. C-E SEM 
image of treated cells, (C) at 0.4mM, and D-E at 0.8mM, apoptotic cells in 
C-E with green arrows.
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3.6.4 Effect of Potassium and Magnesium 2-Hydroxybenzoates on 
HT-1080 Cell
The effect of potassium and magnesium 2-hydroxybenzoates on the 
morphological characteristics of HT-1080 cells were examined using the 
immunocytochemical assay for flagged phosphatidylserine when cells 
became committed to apoptosis. Figure 3.8 shows the percentage of cells 
with the negative and positive responses to Annexin-V. One-way ANOVA 
analyses indicated that 2-acetylbenzoic acid, potassium, and magnesium 
2-hydroxybenzoate induced significantly more apoptotic cells compared to 
control at p< 0.0. However, these compounds did not show statistical 
differences among themselves. Further statistical analyses between 
calcium 2-hydroxybenzoate (see Figure 3.5A) and either magnesium or 
potassium analogues (Figure 3.8A) also showed no significant difference 
in inducing of apoptosis. Figures (3.8B-3.8C) show both early and late 
apoptotic cells labelled by Annexin-V HT-1080 cells (see the control and 2- 
acetylbenzoic acid in Figure 3.5B1 and 3.5B2). Indeed, the late apoptotic 
cells show some signs of secondary necrosis, and hence, the propidium 
iodide labels nuclear materials with red fluorescence.
3.6.5 Effect of Zinc 2-Hydroxybenzoate on HT-1080 Cell Death
In comparison with calcium (Figure 3.5A), magnesium and potassium 2- 
hydroxybenzoate (Figure 3.8A), the zinc analogue showed more potency 
to induce apoptosis in the HT-1080 cell line. Figure 3.9A shows the 
percentage of cells positively and negatively labelled with Annexin-V at 
different concentrations and incubation periods. 0.3mM of zinc 2- 
hydroxybenzoate induced about 59.03% apoptosis when cells were 
cultured for 24 hours under the optimal conditions.
The number of apoptotic cells increased to 81.65% by increasing the dose 
to 0.4mM at the same incubation period, or 24 hours. Furthermore, at 
0.4mM zinc 2-hydroxybenzoate and 48 hours' incubation period, all cells 
appeared to be labelled with Annexin-V. The formal treatment showed a 
decrease in the total number of cells. The ANOVA statistical analysis
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indicated that the zinc benzoate analogue treatments induced significantly 
more (p<0.001) apoptotic cells than the control sample and the other 
benzoate analogues examined in this study. Figure 3.9B shows the 
labelled HT-1080 cells with Annexin-V after the treatment with zinc 2- 
hydroxybenzoate compound at 0.3 and 0.4mM for 24 and 48 hours.
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Figure 3.8 Immunohistochemical illustration for effect of 2- 
hydroxybenzoate analogues. A Percentage of apoptotic HT-1080 cells 
after treatment with 2-acetylbenzoic acid, potassium or magnesium 2- 
hydroxybenzoate for 24 hours. Data represent mean ±SE of eight 
readings. One-way ANOVA: control significantly different from AcBA, 
HBnK, and HBnMg at p< 0.00; No significant differences among AcBA, 
HBnK, and HBnMg at p < 0.001 (Appendix B). Cells labelled with Annexin- 
V. B1 Treated with 0.4mM potassium 2-acetyl benzoate, and B2 treated 
with 0.4mM magnesium 2-hydroxybenzoate. Early apoptotic cells (green 
arrows), and late apoptotic cells (white arrows), which also show red 
fluorescence due to propidium iodide leakage. Magnification X40.
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Figure 3.9 Immunohistochemical illustration for effect of zinc 2- 
hydroxybenzoate. A Percentage of apoptotic HT-1080 cells after treatment 
with 0.3mM and 0.4mM 2-acetylbenzoic acid, zinc 2-hydroxybenzoate for 
24 and 48 hours. Data represent mean ± SE of eight readings. One-way 
ANOVA: control significantly different from AcBA and zinc benzoate 
analogue at 0.3 and 0.4mM concentrations at p< 0.01. Both 
concentrations and incubation periods treatments significantly different at 
p < 0.001 (Appendix B), B1-B3 cells treated with zinc 2-hydroxybenzoate 
and labelled with Annexin-V; B1 treated with 0.3mM for 24 hours, B2 with 
0.4mM for 24 hours and B3 with 0.4mM for 48 hours. Early apoptotic cells 
(white arrows), Apoptotic cells (red arrows), also show red fluorescence 
due to propidium iodide leakage. Magnification x40.
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Furthermore, Figure 3.9 shows further evidence of the effect of zinc 
benzoate analogue in inducing apoptosis in HT-1080 cell. DAPI staining of 
the DNA of HT-1080 treated with 0.05mM zinc benzoate analogue (Figure 
3.10A) was less effective than at the higher concentrations (0.2, 0.3 and 
0.4mM) (Figure 3.10B-D). Note the blebs at 0.3 and 0.4mM (Figure 3.10C- 
D), and the difference in the ratio between the nucleus (blue) and the 
cytoplasm (dark-grey) when cells were treated with 0.4mM zinc benzoate 
(Figure 3.10D).
Figure 3.11 shows haematoxylin-eosin staining, methyl green-pyronin y 
and scanning electron microscope experiments. All showed that HT-1080 
cells died through apoptosis pathway when treated with zinc benzoate 
analogue at different concentrations (0.1-0.4mM) for 24 hours' incubation. 
Haematoxylin-eosin staining after treatment clearly showed signs of 
blebbing, and shrinking of cells which are typical signs of apoptosis 
(Figure 3.11 A). Staining HT-1080 with methyl green-pyronin y also 
showed cellular blebbing (Figure 3.11B). Furthermore, SEM of HT-1080 
cells treated with 0.1-0.4mM zinc benzoate analogue (Figure 3.11C1-C3) 
for 24 hours mainly showed apoptotic bodies.
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Figure 3.10 DAPI staining of HT-1080 cells treated with zinc benzoate 
analogue for 24 hours at the following concentrations (A) 0.05mM, B1-B2 
0.2mM, C 0.3mM and D 0.4mM. Apoptotic cells (white arrows).
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Figure 3.11 HT-1080 cells treated with 0.4mM zinc benzoate for 24 hours 
and stained with (A) Haematoxylin-eosin and (B) with Methyl green- 
pyronin y; green arrows indicate blebbing. Notice pronounced cell 
shrinkage (black arrows), magnification x200.
C1-C5, SEM of HT-1080 cells treated with zinc benzoate analogue, C1- 
C2 at 0.1 mM for 24 hours; C3 at 0.2mM for 24 hours; C4 at 0.4mM for 24 
hours and (C5) at 0.4mM for 24 hours. Apoptotic cells (blue arrows); 
apoptotic bodies (white arrows) and pronounced cell shrinkage (green 
stars).
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3.7 Summary and conclusion
This chapter focused on the effect of 2-acetylbenzoic acid, 2- 
hydroxybenzoate analogues of calcium, magnesium, potassium and zinc 
on HT-1080 cell morphology. The morphological and immunocytochemical 
analyses of treated HT-1080 cells were examined using Annexin-V, 
haematoxylin-eosin, methyl green-pyronin y, DAP I and scanning electron 
microscopy. These techniques are widely used for the histological and 
immunocytochemical investigations of both the nucleus (DNA) and the 
cytoplasm (RNA). Results in this chapter have shown clear morphological 
evidence for apoptosis based on the presence of the apoptotic bodies, cell 
blebbing, cell rounding and shrinkage, as well as the increased presence 
of RNA in the cytoplasm, as shown by pyronin y staining. These results 
were also supported by the immunochemical labelling of 
phosphatidylserine, using the Annexin-V assay. According to these 
techniques, the 2-hydroxybenzoate analogues can be arranged in the 
following ascending order in terms of their ability to induce apoptosis: 2- 
acetylbenzoic acid, potassium 2-hydroxynbenzoate, magnesium 2- 
hydroxynbenzoate, calcium 2-hydroxynbenzoate and zinc 2- 
hydroxynbenzoate.
In conclusion, the effect of 2-hydroxybenzoate analogues on the HT-1080 
cells clearly showed that cells die through apoptosis, as investigated by 
using both morphological and immunocytochemical techniques. The next 
chapter will focus on aspects of the molecular biology of 2- 
hydroxybenzoate-treated HT-1080 cells.
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Chapter Four
Effect of 2-Hydroxybenzoate 
Analogues on the Molecular 
Biology of HT-1080 Cell Line: 
Evidence of Apoptosis
CHAPTER FOUR
Effect of 2-Hydroxybenzoate Analogues on Molecular Biology of HT- 
1080 Cell Line: Evidence of Apoptosis 
4.1 Introduction
Results in the previous chapter have clearly demonstrated, by various 
morphological techniques, the possible role of 2-hydroxybenzoate 
analogues in the induction of apoptosis in the HT-1080 cells in vitro. The 
significant changes that were observed in these studies included the 
presence of apoptotic bodies, blebbing, and the labelling of the 
externalised phosphatidylserine by Annexin V. The focus in this chapter is 
to (1) confirm the apoptotic effects of 2-hyroxybenzoate analogues on HT- 
1080 cells, and (2) investigate further cellular and molecular changes. 
Therefore, both cell cycle analysis and molecular events occurring in 
treated HT-1080 cells were studied, including cell cycle duration, level of 
mitosis, and cell cycle phases. Changes in gene expression after 
treatment with a number of apoptosis-related proteins were also 
investigated, including p53, p21, Bax, Bcl-2, TNF-a and histones. Western 
blotting analysis was used in addition to analysis of caspase-3 and 
Annexin V by flow cytometry.
4.2 Cell Cycle: Regulatory and Function
Many eukaryotic cells often undergo frequent cell cycles distinguished by 
4 main phases or gaps: G1, S, G2 and M (Figure 4.1). The fundamental 
phases of the cell cycle are synthesis (S) where the DNA replicates and 
mitosis (M) where the cell divides into 2 daughter cells. The central task of 
the cell cycle is to ensure that the DNA is replicated precisely during S 
phase, and that identical chromosome copies are distributed equally 
between the 2 daughter cells during M phase (Heichman and Roberts, 
1994; Grana and Reddy, 1995; Wuarin and Nurse, 1996; Nurse, 2000).
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The ultimate task of the process is to ensure that each mitotic cell is 
usually genetically identical to the parent cell.
The cell cycle pathway also includes three other phases: Go, G1 and G2. 
Generally, cells respond to various regulatory signalling, which either 
direct cells to divide (proliferate) or to withdraw from the cell cycle into the 
Go state, where cells are quiescent, or resting (see later in this section). 
Resting cells may remain in this state for an indefinite time, until they 
either resume proliferation or die.
GO
START orRpoirt__________
CycImD-CDK.4 & C D K 6
G2 G1
CycImA-CDK2| |Cydin E-CDK2
Figure 4.1 Eukaryotic cell division cycle and role of cyclin-CDKs in cell 
cycle control. Cycle made up of four stages: G1, S, G2 and M. Interphase 
consists of G1, G2 and S phase. Cell goes through these phases to 
replicate itself and divide into two daughter cells. Go is quiescent stage 
when the cell faces unfavourable conditions and stops the cycle. R point, 
restriction point (Diffley and Evan, 2000).
Generally, the period between one M phase and the next is known as 
interphase, during which preparations for cell division are occurring in a 
closely ordered sequence. Interphase consists of three sub-phases: G1, S 
and G2 (Baserga, 1985). During G1, cells are preparing for S phase and 
the cell 'decides' whether to commit itself to DNA replication and 
proliferation. DNA replication occurs during the S (synthesis) phase of the 
cell cycle (Murray and Hunt, 1993).
The progression from the G1 to S-phase is a key regulation point during 
the cell cycle. Mitogenic and anti-mitogenic signals converge at the 
restriction point (R-point) in the late G1 -phase, and 'make the cell continue 
the cycle or not. Once the cells pass through the R-point, they no longer
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require the extracellular mitogenic signals to complete the cycle (Bartek et 
al., 1996; Blagosklonny and Pardee, 2002).
Fundamentally, the cell cycle is similar in all eukaryotic cells, hence 
research in this area has contributed to the overall understanding of how 
events are controlled and coordinated in humans. It is clearly understood, 
for example, that perturbations to cell population growth pathways are a 
basis for tumourigenesis and malignant disease. In healthy cells, the 
successful division is dependent on ensuring that the duplication and 
segregation of all cellular components is tightly and precisely coordinated. 
Coordination of cell cycle events is achieved under the control of a family 
of a highly regulated group of enzymes known as kinases, or specifically, 
cyclin-dependent kinases (Cdks). Each of these enzymes forms a complex 
with a specific subunit to regulate the cell cycle at certain phases. Table
4.1 lists the mammalian Cdks, and summarises the corresponding 
regulatory subunits necessary for the formation of the complexes, which 
function at certain phases of the cell cycle (Carnero, 2002).
Table 4.1 Cyclin-dependent kinases (Cdks), regulatory units, substrates 
and designated functions.
Cdk Regulatory subunit Substrate Function
Cdk1 cyclin A,B pRb.NF.histone H1 G2/M
Cdk2 cyclin A,E pRb,p27,histone H1 G1/S.S
Cdk3 cyclin E E2F1 G1/S
Cdk4 cyclin D1 ,D2 &D3 pRb G1/S
Cdk 5 cyclin D1 &D3,p35 NF.Tau Neuronal differentiation
Cdk6 cyclin D1,D2 &D3 pRb G1/S
Cdk7 cyclin H, MAT1 Cdk1,Cdk2/4/6 Cdk-activating kinase
Cdk8 cyclin C RNA Pol II Transcription regulation
Cdk9 cyclin T pRb.MBP G1/S
The general principles by which progression through the cell cycle is 
regulated are: (1) activation of Cdks driven by the sequential expression 
and association with cyclin subunits which bind to the active site for the 
activation of cyclin enzymes; (2) the activity of one Cdk-cyclin sets up the
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conditions needed for the activation of the next; (3) destruction of cyclins 
ensures a unidirectional cell cycle; and (4) inhibition of assembled Cdk- 
cyclin complexes, either through phosphorylation or by the binding of 
inhibitory protein delays, Cdk activation, and slow cell cycle progression in 
adverse conditions (for review on cell cycle, see: Pardee, 1989; Sherr, 
1993; Grana and Reddy, 1995; Bartek et a/., 1996; Nurse, 2000; 
Blagosklonny and Pardee, 2002).
Cell cycle progressions start with the expression of cyclin D first, when the 
cell 'decides' to enter the cell cycle, and levels remain high to the end of M 
phase. Cyclin D complexes with Cdk4 and Cdk6 to induce cell cycle 
progression. Entry into S phase correlates with the hyperphosphorylation 
of the retinoblastoma (Rb) tumour suppressor protein, resulting in its 
inactivation. This allows activation of the E2F family (a group of proteins 
that associate with phosphorylated Rb) of transcription factors and 
promotes the transcription of proteins required for G1 and S phases 
(Sherr, 1993; McGowan, 2003). Cyclin E is also expressed at G1 phase, 
accumulates at S phase, and complexes with Cdk2 to give the active 
kinase which leads to the initiation of DNA replication and a number of 
substrates that are required to carry out the task of duplicating and 
segregating cellular contents (Sherr, 1993; Hinchdiffe and Gluder, 2001; 
Hall eta l., 2001). The levels of cyclin E mRNA and protein rise significantly 
in the last quarter of G1 phase when pRb undergoes phosphorylation (Koff 
et al., 1991; Weinberg, 1995). Mouse model experiments have suggested 
that cyclin E is a downstream target of cyclin D (Fantl et al., 1995; Sicinski 
etal., 1995; Geng etal., 1999).
The expression of cyclin A lags behind that of cyclin E which occurs at the 
G1-S boundary (Norbury and Nurse, 1992). The induction of the activities 
of cyclin E-Cdk2 and cyclin A-Cdk2 are essential for the initiation and 
completion of DNA replication, and to ensure that replication occurs once 
in each cycle (Pagano et al., 1992; Ohtsubo et al., 1995). Furthermore, 
cyclin A also plays a significant role in the termination of S phase by 
increasing transcription of histone and other genes needed to
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accommodate replication (Obaya and Sedivy, 2002). Finally, cyclin B is 
expressed late in S phase, and remains high throughout G2 and M 
phases. Cyclin B complexes with Cdc2 protein to regulate the cell cycle 
G2-M phases progression (Lee and Nurse, 1988; Dalton, 1992). Three 
main isoforms have been identified: cyclin B1-3, cyclin-1 and cyclin-2, 
which are found in the cytoplasm. Cyclin-3 is in the nucleus (Pines and 
Hunter, 1991; Gallant and Nigg, 1992; 1994; Jackman etal., 1995).
The activity of Cdks at various stages of the cell cycle needs to be tightly 
regulated if uncontrolled cell proliferation is to be avoided. This is primarily 
achieved though the expression of specific Cdk inhibitors (Cdkls) which 
target a specific active Cdk complex (Morgan, 1995). Cdkl-4, for example, 
specifically inhibits the activity of both Cdk-4 and Cdk-6. The less specific 
cyclin inhibitors are represented by the Cip/Kip family (p21, p27 and p35) 
of proteins which disrupt the association between cyclin subunit and its 
corresponding Cdk of Cdk-D, CdK-E and Cdk-A (Lees, 1995). p53 also 
inhibits the progression of cell division (Milner, 1984).
Defects in cell cycle regulation and checkpoint controls often result in 
genomic instability and a pre-disposition to cancer. One of the most 
frequently mutated genes in human cancers is the p53 gene. 
Understanding the molecular mechanisms that regulate these processes 
is therefore of considerable medical as well as scientific interest.
4.3 Tumour Suppressor Protein p53
p53 plays a vital role in the regulation of the cell cycle to ensure that when 
genotoxic damage occurs, cells arrest in G1, and DNA gets repaired 
before replication (Kastan etal., 1991; Dennis, 1998). Mutations that result 
in cancer usually occur in the DNA binding domain of the p53 protein (Ko 
and Prives, 1996). In healthy cells, p53 interacts with Mdm-2 (a ubiquitin 
ligase) whose expression is induced by p53. Mdm-2 neutralises p53 
activity by binding to and inhibiting its transactivating domain (Oliner et al., 
1992). When DNA damage occurs however, a protein kinase
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phosphorylates p53 and reduces binding to Mdm-2, thus activating p53. 
The loss of p53 predisposes cells to drug-induced gene amplification and 
decreases the fidelity of the mitotic chromosome transmission. Duplication 
of the centrosomes, for example, normally occurs during the G1-S 
boundary, but in the case of p53 deficiency, multiple centrosomes are 
generated in a single cell cycle, which results in aberrant chromosomal 
segregation during mitosis.
When DNA damage is irreparable in multicellular organisms, the individual 
cell with the damaged DNA commits suicide through a programme of cell 
death (apoptosis). This mechanism is vital in protecting the organism from 
genetic damage that may lead to cancer. For example, mutation to a 
single amino acid in the Ras protein (involved in the initiation of mitosis) 
can cause it to become permanently overactive, promoting mitosis even in 
the absence of mitogenic stimuli. Another example is mutation resulting in 
the over-expression of the Myc protein, which promotes cell cycle entry, 
causing unwanted cell population growth and proliferation leading to 
cancer. The actual decision for the cell to enter apoptosis in response to 
such damage relies on the activation of p53. This apoptotic pathway, 
however does not require p21CIP1; p53 can directly activate death genes, 
like Bax, or suppress survival genes, like Bel-2. G1 arrest and apoptosis 
are two alternative p53 induced outcomes. Even though p53-induces 
p21c,P1, limiting Rb hyperphosphorylation, loss of Rb function can bypass 
p53-mediated G1 arrest. The incorporation of the Rb and p53 pathways 
determines whether p53 will induce apoptosis or cell cycle arrest (Evan 
and Littlewood, 1998). The loss of Rb activity usually causes the p53 
pathway to induce apoptosis.
Most identified proto-oncogenes function in signal transduction to 
reproduce the effects of mitogenic stimulation, which makes the cell 
insensitive to environmental controls. They function to disrupt the 
mechanism controlling the passage through the G1 phase by inducing G1 
cyclins and overriding Cdk inhibitors, consequently preventing cell cycle 
exit and disregarding checkpoint control. Despite the vast variety of
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oncogenes, it is clear that the most frequently disrupted pathways are 
those dominated by the two tumour suppressor genes Rb and p53. Other 
less direct mechanisms also contribute to p53 inactivation. The Mdm2 
protein and human papillomavirus E6 can be oncogenic, as they oppose 
p53 function. Even tumours that retain a wild type p53 accumulate 
epistatic lesions that have the same effect as loss of p53 function. 
Preventing p53-dependent apoptosis is the key to tumourogenesis. Loss 
of a vital death gene or the over-expression of a survival genes may mirror 
the effects of p53 loss (Sherr, 1996).
4.4 Apoptosis and Cancer Therapy
Apoptosis, the major mechanism of cell death in the body, is under genetic 
control, and deregulation of the pathways involved can lead to a number of 
neurodegenerative diseases such as, Huntington's, Parkinson’s and 
Alzheimer’s (Ona et al., 1999). Alternatively, inadequate apoptosis can 
lead to the survival of DNA damage that contributes to cancer (Thompson, 
1995; Evan and Littlewood, 1998; Wong et al., 1999). Two main factors 
induce apoptosis, the first is self-initiation. The activation of Fas (binding to 
FAS ligand), for example, leads to apoptosis (Nagata, 1997) which 
subsequently forms death-induced signalling complex (DISC) in the 
cytoplasm. The complex mediates activation of caspase-8 which then 
activates procaspase-3 (Kischkel et al., 1995). The second factor that 
contributes to the induction of apoptosis takes the form of protein 
molecules, such as MutS proteins. These proteins can recognise DNA 
chemical damage, caused by chemotherapy for example, and then initiate 
apoptosis through the activation of p53 or p53-related gene, p73 (Gong et 
al., 1999; Li, 1999). Therefore, a certain level of p53 is important to 
determine the cell status. Loss of p53 is implicated in the production of 50 
to 55% of human tumours, such as colorectal carcinoma and human lung 
(Levine, 1997; Giacda and Kastan, 1998).
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As indicated in Chapters 1 and 3, apoptosis is morphologically distinct 
from necrosis. Both types of cell death are also different in relation to 
genetic control. Apoptosis is usually initiated and proceeds through a 
complex sequence of gene control, while little gene control appears in 
necrosis which is mainly caused by physical effects such as high 
temperatures, anoxia, ishaemia excessive force or by infection. Generally, 
apoptosis includes two phases: an initial commitment to cell death, 
followed by an execution phase, characterised by synthetic biochemical 
and morphological changes, respectively (Wong etal., 1999).
Apoptosis is an energy-dependent process and, during the biochemical 
phase, is initiated in specific cell types by both endogenous tissue-specific 
agents (e.g. hormones) and exogenous, cell-damaging treatments or 
triggered by radiation, chemicals, and viruses (Denmeade and Issacs, 
1996). These signals act through receptors or ligands on the cell surface, 
and are transmitted to the cytosol and nucleus by signal transduction 
pathways (Wong et al., 1999). Activation of the caspase family begins the 
execution phase and their activity leads to morphological changes, first in 
the mitochondria and the nucleus, followed later by changes in the cell 
membrane. Caspases, the critical mediators of the execution phase, are 
proteases that cleave exclusively after aspartate residues, and have a 
conserved active site containing the amino acid cysteine. During 
apoptosis, upstream caspases are activated and subsequently cleave and 
activate downstream caspases. The caspases act in a cascade and 
eventually lead to the formation of membrane-enclosed apoptotic bodies, 
containing the contents of the cell, which are rapidly recognised, 
phagocytosed, and digested by macrophages or adjacent epithelial cells 
(Denmeade and Issacs, 1996).
Apoptosis is tightly regulated, and loss of this regulation is critical to the 
pathogenesis of a number of diseases. In the adult, the relationship 
between cell proliferation and death is balanced, such that neither 
regression nor excessive growth of tissue will occur under normal 
conditions. Any events that shift this equilibrium in favour of an enhanced
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survival of damaged cells promote the carcinogenic process by allowing 
the survival of potentially neoplastic cells (Denmeade and Issacs, 1996). 
Thus, cancer arises not only from increased and unregulated cell division, 
but also from a reduction in the rate of apoptosis. An abnormal cell that 
proliferates uncontrollably (i.e. exceeds the rate of cell death), results in 
the net accumulation of malignant cells, which have the ability to invade 
surrounding cells and produce the lethality of cancer (Denmeade and 
Issacs, 1996).
DNA damage can lead to cell cycle arrest at the checkpoints until the 
damage is repaired. ATM and ATR, both protein kinases, respond to 
different stresses, and thus play a role in the detection of damaged DNA. 
Expression of ATM and ATR proteins leads to phosphorylation of the 
protein p53, which eventually results in cell cycle arrest. p53 provides 
another level of regulation in healthy cells, and is active in times of 
potentially severe DNA damage. p53 comes into action when the 
checkpoints cannot cope and is able to steer the cells into apoptosis. p53 
is involved in the detection of abnormal DNA, and whether detects to 
arrest the cell cycle and initiate DNA repair or, if the damage is irreparable, 
initiates apoptosis. Usually a very short-lived protein, p53 is stabilised and 
accumulates in cells with damaged DNA or in those responding to certain 
forms of stress (Sherr, 1996). The decision on whether to commit to 
apoptosis occurs in G2.
Tumours often have a mutant form or are deficient in checkpoint proteins, 
allowing the cells to behave abnormally. Cancer cells tend to abandon 
checkpoint controls and remain in cycle, and as cell cycle exit can facilitate 
maturation and terminal differentiation, these processes are often 
abandoned too (Sherr, 1996). The p53 gene, which functions as a 
transcription factor, is the most commonly mutated gene in human 
cancers, and cancer-related mutations cluster in its binding domain (Sherr, 
1996). Mutations affecting the gene coding for other components of 
apoptosis, such as Bcl-2, Bax, Apaf-1 and p21, may also be associated 
with cancer (Bowen and Saunders, 2004)
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A successful therapy for cancer must readjust the relationship between 
mitosis and apoptosis so that cell death exceeds cancer cell proliferation 
(Denmeade and Issacs, 1996). Apoptosis has been reported in tumours by 
Kerr et al., (1987) and by Sarraf and Bowen (1986; 1988), in both 
untreated cells and in cells exposed to chemotherapeutic agents. 
“Apoptosis is arguably the most potent natural defence against cancer; 
because it eliminates premalignant cells that enter S phase inappropriately 
after genetic sabotage of restriction point controls” (Sherr, 1996).
Successful cancer therapy requires drugs that will activate apoptosis in 
tumours, with minimal side effects to normal cells. Novel apoptotic agents 
are continuously being sought.
4.5 Materials and Methods
4.5.1 Cells and in vitro Culture Conditions
HT-1080 cells were cultured in an optimal DMEM medium and under a 
humidified atmosphere of 95% air and 5% CO2 at 37°C using standard 
suitable culture vessels unless otherwise indicated (see Chapter 2, 
materials and methods). HT-1080 cells were seeded at specific density 
unless otherwise stated, and allowed to grow for 3 days, followed by 24 
hours' culturing in serum-free DMEM medium before being treated with 2- 
hydroxybenzoate analogues (for the preparation of the solutions, see 
Chapter 2), individually, at specific concentration(s) and for certain time(s). 
Cells were harvested and centrifuged at 1000g for 5 minutes before 
conducting the test by specific technique.
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4.5.2 Time lapse Microscopic Analysis of HT-1080 Cell Cycle
2-Hydroxybenzoate analogues (2HBnCa, 0.4, 0.8mM; 2HBnZn, 0.2, 0.25, 
0.3mM; 2AcBA, 0.4, 2mM) treated-HT-1080 cells were seeded in 12-well 
plate at an initial density of 1x103 per well (see Section 2.4.2.6, Chapter 2, 
for full experimental details). In addition, control experiments were 
performed parallel to the treatment experiments. The sequences for the 
cell images, captured digitally by Orca IER charge-coupled device camera 
(Hammamatsu, Welwyn Garden City, UK) were analysed by Lucida 
Analyse-6 software (Kinetic Imaging, Wirral, UK). The capture of a series 
of images for each treatment was carried out manually, and analysed for 
cell cycle and mitosis durations, as well as the percentage of mitotic cells 
in each treatment.
4.5.3 Flow Cytometric Analysis of HT-1080 Cell Cycle
HT-1080 cells were seeded in T-25 flask at an initial density of 1x104 per 
flask. Cells were cultured (see Section 2.4.2.1, Chapter 2) for 3 days post- 
seeding and 1 day in serum-free medium before being treated with 2- 
hydroxybenzoate analogues (2HBnCa, 0.4, 0.8mM; 2HBnZn, 0.25, 
0.3mM) for 2, 6, 12, or 24 hours. In addition, control experiments were 
performed in which no benzoate was incorporated in the cultures.
At the end of each treatment, HT-1080 cells were harvested by 
trypsinisation, centrifuged and resuspended in 200jil of PBS. Aliquots 
(2ml) of ice-cold 70% ethanol were then added and the cells vortexed prior 
to being cooled to -20°C for 30 min. Subsequently, 100pl of a RNase 
(Sigma, UK) at a concentration of 1 mg/ml and 100pl of propidium iodide 
(Biovision Incorporate, CA, USA) at a concentration of 400pg/ml were 
added prior to incubation at 37°C for 30 min. The cells were analysed 
using a FACSCalibur flow cytometer (Becton Dickinson, UK), and the 
percentages of cells in the different phases of the cell cycle were 
quantified using Cylchred version 1.0.2 software (Terry Hoy, University 
Hospital of Wales, UK).
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4.5.4 Flow Cytometric Analysis of Apoptosis Using Annexin V
HT-1080 cells were seeded in T-25 flasks at an initial density of 1x105 per 
flask and cultured for 3 days before being treated with zinc 2- 
hydroxybenzate (0.1, 0.2 and 0.4mM) for 48 hours. At the end of the 
treatment, 1x106 cells were harvested by centrifugation and then washed 
with phosphate buffered saline. Cells were resuspended in 10Opil of 
binding buffer and 1jil (final concentration 1 mg/ml) of FITC-labelled 
Annexin V (Dako Cytomation, UK), and then incubated in the dark for 10 
minutes at room temperature. 100pl (final concentration 1 mg/ml) of 
propidium iodide solution (Dako Cytomation, UK) was added to each 
aliquot prior to analysis by flow cytometry using CellQuest software on a 
FACSCalibur flow cytometer (Becton Dickinson, UK).
4.5.5 Flow Cytometric Analysis of Caspase-3 activation
HT-1080 cells seeded in T-25 flask at 1x103 initial density were cultured in 
optimal DMEM medium and under standard conditions, before being 
treated with zinc 2-hydroxybenzoate (0.4mM) or 2-acetylbenzoic acid 
(3.2mM) for 48 hours. In addition, control experiments were performed in 
which no benzoate was added to the cultures. Cells were subsequently 
harvested by centrifugation and incubated for a further 1 hour at 37°C, in 
the presence of the PhiPhiLux™ GID 2 substrate (Calbiochem, UK). The 
substrate contains two fluorophores separated by a quenching linker 
sequence that is specifically cleaved by active caspase-3. Once cleaved, 
the resulting products fluoresce green, and can be quantified using flow 
cytometry. For all experiments, 10,000 events were measured and were 
analysed on a FACSCalibur flow cytometer (Becton Dickinson, UK).
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4.5.6 Western Blot Analysis
4.5.6.1 Preparation of HT-1080 Cell Lysate
HT-1080 cells in 6-well plates at 3x104 initial cell density were cultured for 
3 days to reach approximately 70% confluent in a DMEM medium and 
under standard conditions (Chapter 2). The HT-1080 cell population 
growth was continued for further 24 hours but with serum-free DMEM 
medium, before they were treated with benzoate analogues (2AcBA, 
2HBnCa, 2HBnZn at 0.05 and 0.4mM each) for 24 hours. The medium 
was removed and cells were then washed with PBS to remove the 
remaining medium. Following this, 200pl of 2X sample buffer (250mM Tris- 
HCI pH 6.8, 4% SDS, 0.006% bromophenol blue, 2% p-mercaptoethanol 
(Pharmacia Uppsala, Sweden), 10% glycerol, (Sigma, U.K.) was added to 
each well, and cells were then harvested using a cell scraper. 2- 
hydroxybenzoate analogue- treated HT-1080 cells in lysate buffer were 
then transferred into a 1.5ml Eppendorph pipette, heated at 100°C for 10 
minutes, cooled to room temperature, and centrifuged at 120g for 5 
minutes. The supernatant was further centrifuged at 16,000g for 5 minutes 
to get a clear solution of protein mixture, which was used to measure the 
expression of p21, p53, Bcl-2, Bax, TNF-a, and histones by Western 
blotting.
4.5.6.2 Total Protein Determination for HT-1080 Cell Lysate
The total protein concentrations of both HT-1080 cell lysate samples and 
for the standard bovine serum albumin (BSA) curve were determined 
according to the method of Karlsson et al. (1994).
66.7pl of 60% w/v trichloroacetic acid in distilled water was added to each 
well of a 96-well plate containing a pre-warmed 100pl of the different 
concentrations (0, 50, 100, 150, 200, 250 and 300pg/100pl) of BSA 
solutions, and of HT-1080 cell lysates (diluted 15x), each in 2x sample 
buffer, and left for 15 minutes at 37°C, after which spectroscopic
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absorption was measured at 575nm. Figure 4.2 shows the albumin 
standard curve used to calculate the total protein in HT-1080 lysate 
samples (Table 4.2). Lysate samples were diluted to approximately 
10Ojug/1 OOjj.1 with lysate buffer (Table 4.2).
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Figure 4.2 Albumin standard curve (Appendix C).
Table 4.2 Total protein in benzoate analogues-treated HT-1080 cells.
Treatment
Average
(A575nm)
x = y- 
0.1139/0.0003a
p.g/100pJ of 
total proteinb
[i\ of original lysate in 
100^1 lysate buffer 
containing 100^g 
protein
Control 0.152 127 1905 5.2d
2AcBA 0.05mM 0.210 320 4805 2.1°
2AcBA 0.4mM 0.147 110 1655 6.0d
2HBnCa 0.05mM 0.178 214 3205 3.1°
2HBnCa 0.4mM 0.218 347 5205 1.9°
2HBnZn 0.05mM 0.224 367 5505 1.8°
2HBnZn 0.4mM 0.183 230 3455 2.9°
a Value of total protein (|xg/100^l) of 15-fold diluted lysate samples. 
b Value of total protein (|il/100(il) of original lysate samples.
c 500fj.l of 100jig/100(il protein solutions were prepared; d 200 nl of 100jig/1 OOjj.1 protein 
solutions were prepared.
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4.5.6.3 Gel Preparation
4.5.6.3.1 Separating Gel
The separating gel was prepared as follows: 0.5g of ammonium persulfate 
(Pharmacia Uppsala, Sweden) dissolved in 5ml of deionised water (dH20). 
Then, In a 100 ml beaker, 6.7 ml dH20, 20ml stock 2 (0.75M Tris-HCI, 
0.2% w/v SDS in dH20), and 13ml arcylamide mixture (30% acrylamide: 
0.8% bisacrylamide, 27:1 ratio; Pharmacia Uppsala, Sweden), then, just 
before the gel was poured, 25pl NNN’N’-tetramethylethylenediamine 
(TEMED, Pharmacia Uppsala, Sweden) and 300pl of pre-prepared 10% 
ammonium persulfate added. The separating gel was then poured 
between glass plates to about 1 cm below the wells of the comb, starting 
fast, then slowing down, and the gel was then left for more than 30 
minutes to set, after filling the 1 cm space with IMS.
4.5.6.3.2 Stacking Gel
The stacking gel was prepared from 5 ml stock 1 (0.25M Tris, pH 6.8, 
0.2% w/v SDS in 500ml dH20), 1.3ml of arcylamide mixture (30% 
acrylamide: 0.8% bisacrylamide, 29:1 ratio), 7.5|il TEMED, and 80pl of 
pre-prepared 10% ammonium persulfate.
The IMS was removed with dH20  before adding 5ml the stacking gel 
which was poured gently to the top of the separating gel and a 10-well 
comb immediately introduced, ensuring the two spaces in the two far ends 
were equal, the level of the comb was balanced, and that there were no 
bubbles. The gel was then left for approximately 20 minutes before 
assembly of the gel tank. The comb was gently removed, and then the gel 
with the glasses was removed from the holder and rinsed with tap water.
The gel was placed in a gel rig and then in a special tank containing 
electrophoresis running buffer (10x stock; 14.11% w/v glycine, 0.5M Tris- 
HCI, pH 8.3, 1% w/v SDS), the wells were flushed out thoroughly with the 
buffer prior to running the gel.
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Frozen lysate samples were thawed and heated at 100°C for 5 minutes to 
deactivate proteases, and each was diluted to a final concentration of 
100pg total protein/1 OOpI lysate buffer (prepared according to Table 4.2). 
20pl (100pg/100pl) of each diluted sample was loaded in each well, and 
1 Ojj.I of a molecular weight marker was added in one well (Table 4.2). The 
apparatus was connected to a Bio-Rad power pack and run with constant 
current (40 mA with voltage set at > 300 V) for approximately 1.5 hour.
4.5.6.3.3 Western Transfer
Two nitrocellulose paper sheets were cut in a size slightly bigger than the 
Western blot gel and put into two square dishes containing blotting buffer 
(0.05M Tris-HCI, 3% w/v glycine, 3.7% w/v SDS, and 25% alcohol in 
dH20). At the same time, after the electrophoresis run finished (to 
separate protein bands), the Western blotting gel was gently removed 
from the cassette with a gel knife (the well side was facing up), and finally, 
the gel was transfered into a pre-marked square dish containing blotting 
buffer.
Two 3 mm thick filter papers sheets were soaked in the blotting buffer, and 
the first was placed on the top of the gel, with the foot of the gel (bottom of 
the cassette) left uncovered. The second was transferred to the blotting 
machine, then the nitrocellulose paper underneath the gel was moved to 
the blotting machine and placed on top of the second filter paper. The 
transfer membrane was cut with a razor blade to the dimension of the gel 
and the second soaked filter paper was placed on top of the gel. Air 
bubbles were removed by gently rolling the sandwich with a 25ml tissue- 
culture plastic pipette, and the wetted anode cover placed on top. The gel 
membrane assembly was held securely between the two halves of the 
blotting module which was held together firmly in order to slide it into the 
guide rails on the lower buffer chamber. With the power turned off, the red 
and black leads were plugged into the power supply.
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The gels were blotted at 100 mA and 30 V for 1.5 hour to transfer the 
protein from the gel to the nitrocellulose membrane which was then placed 
in approximately 20 ml blocking buffer (4% w/v Marvel, Knighton, U.K, 5ml 
Tween 20, Pharmacia Uppsala, Sweden, 0.87% w/v NaCI, 1% v/v Tris-HCI 
pH 7.4, Sigma, U.K.) for 1 hour over a rotary shaker, and were then rinsed 
with 20ml of deionised water prior to immuno-detection.
4.5.6.3.4 Western Immunodetection
The blocking buffer (15ml) in the plastic container containing nitrocellulose 
membrane was replaced by the same amount of blocking buffer containing 
a specific primary antibody at pre-determined dilution (Table 4.3). The 
membrane in the blocking buffer containing the specific primary antibody 
was placed over a rotary shaker for 3 hours. The nitrocellulose membrane 
was then washed with 15 ml washing buffer (8.7% w/v NaCI, 1M Tris-HCI, 
pH 7.4, 0.5% v/v in 1 liter deionised water) three times every 15 minutes, 
before being treated with the secondary antibody, using also 15 ml of 
blocking buffer containing a specific secondary antibody (Table 4.3), and 
the nitrocellulose membrane was incubated with rocking for 1 hour.
The membranes were then washed by 3 quick rinses with washing buffer, 
followed by 4 x 15 minutes with washing buffer at room temperature. 
Finally, the membranes were incubated with a fresh 1:1 mixture of 
Enhanced Chemiluminescent (ECL) reagent (Amersham, UK) for 1 
minute, and then covered with cling film and exposed to ECL Hyper film 
(Amersham, UK) for 1-5 minute. Finally, photographic films were 
developed.
Table 4.3 Primary and secondary antibodies used and dilution factors.
Primary antibody Dilution Secondary antibody Dilution
Mouse anti-p53 
(Cambridge Bioscience, 
UK)
1:1000 Peroxidase conjugated-Anti-mouse 
1gG secondary, (Sigma, UK)
1:1000
Rabbit anti-Bax 
(Cambridge Bioscience, 
UK)
1:1500 Peroxidase conjugated-Anti-mouse 
1gG secondary, (Sigma, UK)
1:1000
Mouse anti-Human Bd-2 
(Serotec Ltd, UK)
1:1000 Peroxidase conjugated-Anti-mouse 
1gG secondary, (Sigma, UK)
1:1000
Mouse anti-P21/WAF1 
(Serotec Ltd, UK)
1:1500 Peroxidase conjugated-Anti-mouse 
1gG secondary, (Sigma, UK)
1:1000
Anti-histone Pan 
monoclonal antibody 
immunoglobulins 
(Boehringer Mannheim, 
UK
1:1500 Peroxidase conjugated-Anti-mouse 
1gG secondary, (Sigma, UK)
1:1000
Tumour Necrosis Factor 
Alpha (TNFa). 
Recombinant [E.coli], 
Human sequence 
(System, inc, 
Minneapolis, MN).
1:500 Peroxidase conjugated-Anti-goat 
1gG secondary, (DakoCytomation 
Ltd, UK)
1:5000
Marker Prestained SDS-PAGE Standard Solution for Molecular 
Weights 30,000-120,000 (Sigma, UK).
4.5.7 Pharmacological Investigations of 2-Hydroxybenzoates Uptake 
into HT-1080 Cells
Both high-pressure liquid chromatography (HPLC) and atomic absorption 
were used to investigate whether (1) 2-hydroxybenzoate analogues are 
up-taken into the HT-1080 cell’s cytoplasm, and (2) to find out if 2- 
hydroxybenzoate or 2-hydroxybenzoic acid and/or metal ion could be 
detected in HT-1080 lysate samples.
HT-1080 cells in 75-T flask at 1x106 initial cell density were cultured for 3 
days to reach approximately 70% confluence in DMEM medium and under 
standard conditions (Chapter 2). The HT-1080 cells’ population growth 
was continued for further 24 hours but with serum-free DMEM medium, 
before they were treated with benzoate analogues (2AcBA, 2HBnCa, 
2HBnZn at 0.4mM each) for 24 hours. HT-1080 cells were harvested by 
centrifugation 120g for about 10 minutes. Cells were washed with 
deionised water 0.5ml x 3, before the pellets were digested using 0.5M
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nitric acid. Samples were placed in a boiling water bath for 20 minutes. 
The digested mixture was then extracted with about 30ml x3 chloroform to 
separate benzoates (for HPLC analysis), while calcium and zinc 
separately remained in the aqueous solution as nitrate salts after they 
reacted with nitric acid. The nitrate samples were analysed using atomic 
absorption.
4.5.7.1 High-Pressure Liquid Chromatography (HPLC)
Analytical HPLC was conducted on a Hewlett Packard (HP) 1090 liquid 
chromatograph fitted with a C-18 (Latex, Eppelheim, Germany), reverse- 
phase 25 cm (5nm) column (internal diameter, 4.0 mm). Detection of the 
benzoates and/or their metabolites was by the UV detector at A 215 nm, at 
room temperature. The mobile phase was 65% double-distilled water, 35% 
HPLC grade acetonitrile (Sigma, UK) and 0.1% HPLC grade TFA 
(trifluroacetic acid, Sigma, UK). 20|nl of each sample, including control, 
was injected into the HPLC. Extracts were dissolved in the mobile phase 
prior to injection (20jal) into the HPLC. The flow rate of the mobile phase 
was 1 ml/min. Instrument control and data handling were by means of non- 
Windows-based Prime Reporter software.
4.5.7.2 Atomic Absorption Spectrophotometry (AAS)
Nitric acid digest of 2-hyroxybenzoate-treated HT-1080 cell lysate samples 
were quantified for zinc and calcium using flame (air-acetylene) AAS, in a 
Varian AA-100v atomic absorption spectrophotometer with automatic 
background adjustment. All solutions, including standards, used for 
calcium or zinc assay contained 1% lanthanum. The standard elements 
used were at 1000 ppm solution from Fisher.
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4.6 Results and Discussion
4.6.1 Cell Cycle Analysis
The effect of 2-acetylbenzoate on the growth of cancer cells in vitro has 
been actively studied. These studies have indicated that 2- 
acetylbenzoates inhibit cell population expansion, DNA and the synthesis 
of various proteins, resulting in the inhibition of G1 and S phase 
progression in a number of cell lines, including mainly human colon 
adenocarcinoma (Aas et ai., 1995; Ricchi et al., 1997). 2-acetylbenzoic 
acid has been shown to slow down or inhibit cancer cell proliferation by 
inducing arrest in the Go/G1 phase of the cell cycle (Elder et al., 1996). 
These compounds were also found to increase the susceptibility of cells at 
a late stage of neoplastic progression towards induction of apoptosis 
(Ruschoff et al., 1998). Most of these studies have used relatively high 
concentrations of 2-acetylbenzoate, ranging between 5 and 10mM (Santini 
et al., 1999; Marra and Liao, 2001). Thus, in this study, we have taken the 
initiative to investigate the effect of 2-acetylsalicylic acid and other 
analogues at much lower concentrations (mostly 0.05 and 0.4mM).
To evaluate the effects of 2-hydroxybenzoate analogues on the cell cycle 
of HT-1080 fibrosarcoma cells, the tracking of the capture images of cell 
population growth progress was used to analyse both cell cycle and 
mitosis durations. The population growth of treated HT-1080 cells was 
monitored every 5 minutes over a period of 22 hours. Figure 4.3A shows 
the mitosis process in HT-1080 cells treated with calcium 2- 
hydroxybenzoate. The series of micrographs illustrates the continuous 
process which shows the common stages of mitosis: prophase, 
metaphase, anaphase and telophase. Although the mitotic apparatus 
(spindle, microtubules) is not shown, due to the low magnification of the 
microscope lenses used, it is easy to identify the four stages from the 
sequential frames (Figure 4.3A).
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Figure 4.3 HT-1080 mitotic cell durations* and percentage of HT-1080 cells that underwent first mitosis** when cells cultured for 22 hours in presence of 2-hydroxybenzoate analogues. (A) 
Series of images illustrate sample of mitotic process with frame number and time events for different stages, (B) Representation for percentages of mitotic HT-1080 cells and duration for 
mitosis when cells cultured in presence of 2-acetylbenzoic acid (0.2, 0.4, 0.8mM), calcium 2-hydroxybenzoate (0.4, 0.8, 1.2mM), zinc 2-hydroxybenzoate (0.2, 0.25mM). Note: 0.3mM 
concentration did not induce mitosis.
* First mitosis duration refers to observed HT-1080 cells that underwent mitosis for first time during 22 hours. In this case, number of HT-1080 cells interring the first mitotic cells that were 
observed during 22 hours’ culturing are: 25,17,18, 22,18, 25, 44, 44, 29, 31, 0.0 for treatments in this graph, respectively.
% of first mitotic HT-1080 cells = No. of first mitotic cells/Total no. of first and second mitotic cells during 22 hours.
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Morphologically, towards the end of G2, chromosomes condense from 
extended diffuse form into compact, extensively folded structures, giving 
the cells a distinguishable bright appearance when they are observed 
under the light microscope. Observations of the progress of mitosis 
indicated that HT-1080 cells increased in brightness under the microscope 
as a result of the increased level of condensation in the metaphase stage. 
The brightness reaches its maximum level in the anaphase. Meanwhile, 
cells in the anaphase also started to elongate, but the elongation 
increased in the telophase stage which also showed a distinctive cleavage 
furrow visible by the light microscope (Figure 4.3A). The time between 
these two mitotic stages was approximately 15 minutes in HT-1080 
fibrosarcoma cell line (Figure 4.3A). The progress of mitosis for other 
treated-HT-1080 cells also showed the same morphological characteristics 
observed for calcium 2-hydroxybenzoate-treated cells illustrated in Figure 
4.3A.
2-hydroxybenzoate analogues exerted different effects on the first mitotic 
process, where these compounds either increased or decreased the 
duration of mitosis compared to control experiments (Figure 4.3B). For 
example, 0.8mM 2-acetylbenzoic acid (or aspirin) and 0.25mM zinc 2- 
hydroxybenzoate increased the duration of mitosis in HT-1080 about 2.1- 
and 1.9-fold, respectively, compared to control sample (26 minutes).
These treatments also induced the highest number of mitotic HT-1080 
cells during the 22 hours of treatment. Most other treatments showed 
mitotic duration close to control samples (Figure 4.3B). To examine the 
effect of combined treatment of 2-acetylbenzoc acid and zinc 2- 
hydroxybenzoate (0.2mM) on cell cycle, HT-1080 cells were treated with a 
mixture of these two drugs for 22 hours (0.4mM and 0.2mM, respectively). 
The mixture of these two drugs induced a further reduction in the mitotic 
duration of HT-1080 cells by 48% and 28% compared to cells exposed to 
0.2mM zinc 2-hydroxybenzoate or 0.4mM 2-acetylbenzoate treatments 
respectively.
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Figure 4.4 shows that both 0.2 and 0.8mM 2-acetylbenzoic acid increased 
the duration of the second mitosis about 1.4-fold. All other treatments 
showed a slightly reduced duration in the second mitotic process 
compared to the control sample (28.75 min). Generally, the overall second 
mitotic process ranged between 23 and 41 minutes (control 28.75 min). 
Although, both 2-acetylbenzoic acid and calcium 2-hydroxybenzoate 
induced a second mitosis, all the zinc treatments (0.2, 0.25, 0.3mM) 
inhibited the progression of HT-1080 cells to the second cycle of mitosis 
during the 22 hours' culture (Figure 4.4).
Further analysis of the time-lapse microscopic results indicated that 2- 
acetylbenzoic acid (0.2, 0.4, 0.8mM) and calcium 2-hydroxybenzoate (0.4, 
0.8, 1.2mM) slightly decreased the cell cycle duration, which ranged from 
13.38 to 15.25 hours compared to the cell cycle duration in control, which 
was approximately 16 hours (Figure 4.5). None of the zinc 2- 
hydroxybenzoate treatments (0.2, 0.25, 0.3mM) showed a second mitotic 
cycle, thus it was not possible to measure this cycle duration in treated 
HT-1080 cells (Figure 4.4).
The above results clearly indicate that 2-hydroxybenzoate analogues 
induced changes in cell cycle and mitosis durations in HT-1080 cells. In 
order to determine whether these analogues have any effect on cell cycle 
phases of HT-1080 cells, they were synchronised in Go/G1 phase by 
serum starvation for 24 hours before treatment with complete DMEM 
medium (i.e. with 10% FCS), containing specific 2-hydroxybenzoate 
analogue at certain concentrations. Results of the flow cytometric 
determination of cell cycle distribution indicated that the G1 phase reached 
49.9% when HT-1080 cells were allowed to grow for 24 hours in serum- 
free DMEM medium. The control experiment (culture medium contained 
10% serum) showed 31.9% for the same phase (Figure 4.6). This 
indicates that, under stress conditions, HT-1080 cells demonstrated an 
increase in G1 phase of approximately 36%.
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Figure 4.4 HT-1080 mitotic cell durations* and percentage of HT-1080 cells that underwent second mitosis** when cells cultured for 22 hours in presence of 2-acetylbenzoic acid (0.2, 0.4,
0.8mM), calcium 2-hydroxybenzoate (0.4, 0.8,1,2mM), zinc 2-hydroxybenzoate (Note 0.2, 0.25 and: 0.3mM concentration did not induce second mitosis).
* Second mitosis duration refers to observed HT-1080 cells that underwent mitosis after first mitosis during 22 hours’ culturing. In this case, number of the second mitotic cells observed
during 22 hours culturing are 9, 6, 8, 7, 7, 9, 6, 9, 0.0, 0.0, 0.0 for treatment in this graph, respectively.
** % of second mitotic HT-1080 cells = No. of 2nd mitotic cells/Total No. of first and second mitotic cells during 22 hours.
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Figure 4.5 HT-1080 cell cycle duration* and percentage of first** and second*** mitotic HT-1080 cells by total number of cells cultured for 22 hours in presence of 2-acetylbenzoic acid (0.2, 
0.4,0.8mM), calcium 2-hydroxybenzoate (0.4, 0.8,1,2mM), zinc 2-hydroxybenzoate (0.2, 0.25, 0.3mM, Note: No cell cycle durations obtained when 0.2, 0.25, 0.3mM concentrations used).
* Cell cycle duration refers to time from end of first mitosis to beginning of second mitosis.
** % of first mitosis = No. of first mitotic cells/Total No. of cells at 22 hours* culturing x 100.
*** % of second mitosis = No. of second mitotic cells/Total no. of cells at 22 hours' culturing x 100.
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To investigate the effect of calcium and zinc analogues on cell cycle, HT- 
1080 cells were cultured, arrested for 24 hours by serum-free DMEM 
medium, and treated with the individual benzoate analogue for 2, 6, 12 
and 24 hours. The aim of selecting these time points was to explain the 
effect of zinc 2-hydroxybenzoate on population growth progression of 
treated HT-1080 monitored by time-lapse capturing images (see Figure 
2.11, chapter 2). These results gave an indication that zinc benzoate 
treated cells might have an arrest at G2.
Figures 4.6-4.8 (see also Appendix C for the histograms) shows the 
distribution of the DNA content within the cell cycle of HT-1080 cell line, as 
determined by propidium iodide incorporated into DNA.
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Figure 4.6 DNA distribution in cell cycle of HT-1080 cells allowed to grow 
under standard culture condition in DMEM medium, with and without 10% 
serum, for 24 hours. DNAs of HT-1080 cells were labelled by propidium 
iodide. Data represent mean ±SE of two replicates.
Figure 4.7 shows cell cycle phase distributions of untreated HT-1080 cells 
over a 24-hour time course. The graph clearly indicates that the DNA 
content of Go/G1 phase was the highest (36.5%) at 2 hours post-serum 
cell activation, while the maximal percentage of cells in S phase was after
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12 hours. 12 hours later, percentage of cells in both of these phases 
indicated the start of another cell cycle.
As indicated from time-lapse capturing images of growing HT-1080 cells, 
the cell cycle duration was approximately 16 hours (Figure 4.5). This result 
is consistent with the results of cell cycle analysis at the 24 hours' time 
point, where the percentage of cells in Go/G1 phase increased and 
dropped in S phase (Figure 4.7). These results will be used as a reference 
for assessing the effect of 2-hydroxybenzoate analogues on cell cycle 
phases of HT-1080 cells.
G1 S G2 G1 S G2 G1 S G2 G1 S G2
CO
Incubation Period (Hour)
Figure 4.7 FACS results of cell cycle for untreated HT-1080 cells (control). 
Cells cultured under standard conditions, arrested with serum- free DMEM 
medium. Cells then harvested at indicated time points and labelled by 
propidium iodide. Results are average of two independent experiments. 
Note: see DNA histograms in Appendix C.
The results of cell cycle analysis of calcium 2-hyroxybenzoate-treated HT- 
1080 cells are shown in Figure 4.8. The calcium compound was found to
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affect HT-1080 cell cycle in a concentration-dependent manner at both 
Go/G1 and S phases, particularly between 6 and 12 hours of treatment. 
The DNA content of Go/G1 phase, at 6-hour culturing for example, 
increased by approximately 10% and 24% (control = 27.5%, 0.4mM 
treatment = 30.3%; 0.8mM treatment = 34.1%) when the treatment 
concentrations increased respectively from 0.4 to 0.8mM compared to 
control. The increase in Go/G1 was continued when cells were exposed to 
calcium compounds for 12 hours compared to control (Figure 4.8). 
Alternatively, the percentage of cells in S phase for the same period of 
exposure decreased by between 5% and 16% compared to control and 
approximately 16% from 6 hours to 12 hours' exposure of 0.4mM 
treatment, while the percentage increased by 6% for the same period at 
0.8mM. Generally, these results did not show any specific change in cell 
cycle phases.
Figure 4.9 shows the effect of zinc 2-hydroxybenzoate on the HT-1080
cells cycle phases at 2, 6, 12 and 24 hour treatments. Both 0.25 and
0.3mM zinc treatments have suppressed the level of DNA at Go/G1 by 
approximately 21-23% at 12 and 24 hours' treatment points. At S phase 
for the same treatments at the indicated time points, the DNA levels 
increased by approximately 8% for 0.3mM treatment and 23% for 0.25mM 
treatment at 12 hours' incubation. Results of S phase for the same 
treatments but at 24 hours' incubation period, indicated that the
percentage of cells increased by 16% with 0.25mM, but not with 0.3mM
zinc benzoate analogue (Figure 4.9). Analysing the cell cycle results for 
these treatments indicated that the DNA contents in G2 increased 
gradually at 6, 12 and 24 hours' time point treatments when cells were 
treated with 0.3mM zinc 2-hydroxybenzoate. The increase in the G2 phase 
was approximately 17%, compared to the control sample.
As indicated in Chapter 2, the zinc 2-hydroxybenzoate exerted the highest 
antiproliferative effects compared to other benzoate analogues, as 
measured by different techniques (see Chapter 2).
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Figure 4.8 FACS results of cell cycle for HT-1080 cells treated with 0.4 
and 0.8mM calcium 2-hydroxybenzoate for 2, 6, 12 and 24 hours. Cells 
cultured under standard conditions, arrested with serum free DMEM 
medium, treated with calcium benzoate at indicated time points and 
labelled by propidium iodide. Results average of two independent 
experiments. Note: see DNA histograms in Appendix C.
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Figure 4.9 FACS results of cell cycle for HT-1080 cells treated with 0.25 
and 0.3mM zinc 2-hydroxybenzoate for 2, 6, 12 and 24 hours. Cells 
cultured under standard conditions, arrested with serum-free DMEM 
medium, treated with zinc benzoate at the indicated time points, and 
labelled by propidium iodide. Results average of two independent 
experiments. Note: see DNA histograms in Appendix C.
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4.6.2 Detection of Apoptosis using Flow Cytometry
Apoptosis is a cell death process characterised by morphological (see 
Chapter 3) and biochemical features occurring at different stages. In this 
section of the study, changes in cell surface and detection of caspase-3 
activation were conducted flow-cytometrically. The measurements were 
based on the forward light scatter (FSC) and side light scatter (SSC) 
characteristics to quantify apoptotic and viable cell populations (Pepper et 
al., 1999; 2001; 2002). Exposure of phosphatidylserine (PS) on the 
external surface of the cell membrane may represent a hallmark (early and 
widespread) in detecting apoptotic cells. Annexin V, belonging to a 
recently discovered family of proteins, the annexins, with anticoagulant 
properties, has proven to be a useful tool in detecting apoptotic cells, since 
it preferentially binds to negatively charged phospholipids like PS in the 
presence of Ca2+, and shows minimal binding to phosphatidylcholine and 
sphingomyeline (Reutelingsperger et al., 1985; Yoshizaki et al., 1989; 
Benz and Hofmann, 1997). Changes in PS asymmetry, which is analysed 
by measuring Annexin V binding to the cell membrane, have been 
detected before morphological changes associated with apoptosis 
occurred and before membrane integrity had been lost (see Chapter 3). By 
conjugating fluorescein isothiocyanate (FITC) to Annexin V it is possible to 
identify and quantify apoptotic cells on a single-cell basis by flow 
cytometry. Staining cells simultaneously with FITC-Annexin V (green 
fluorescence) and the non-vital dye propidium iodide (red fluorescence) 
allows (bivariate analysis) the discrimination of intact cells (FITC'PI'), early 
apoptotic (FITC+PI ), and late apoptotic or necrotic cells (FITC+PI+). This 
confirms the presence of apoptotic cells in the cell cultures and validates 
the FSC/SSC quantitation method (Vermes etal., 1995)
4.6.2.1 Detection of Apoptosis through Annexin V
In order to quantify the effect of benzoate analogues on the induction of 
apoptosis in HT-1080 cells, double staining for both FITC-labelled Annexin
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V binding and cellular DNA using propidium iodide was used and 
measured by flow cytometry to substantiate the morphological results that 
showed the zinc benzoate analogue mostly induced apoptosis compared 
to others (see Chapter 3). Annexin V was used to measure surface 
changes through the labelling of the externalised phosphatidylserine (PS) 
when the cell is committed to the apoptosis pathway of death. Figure 
4.10A shows the percentage of late apoptotic (or the secondary necrotic) 
HT-1080 cells cultured in DMEM optimal population growth medium in the 
presence of zinc 2-hydroxybenzoate for 24 hours. These results clearly 
indicate the zinc analogue-induced apoptosis in a concentration- 
dependent manner, as labelled by propidium iodide (PI) (red 
fluorescence). The percentages of positively stained cells with PI 
increased 2.2-fold, 2.5-fold and 3-fold when the HT-1080 cells were 
exposed to 0.1, 0.2 and 0.4mM zinc 2-hyroxybenzoate, respectively. 
Furthermore, the FITC-labelled Annexin V and propidium iodide double 
staining show the viable cells negative (for both AV and PI, shown as dark 
blue dots), the early apoptotic cells stained (+ AV and -  PI, shown as red 
dots) and the secondary necrotic, or late apoptotic cells stained positive 
for both AV and PI, (shown as light blue dots) thus labelling both early and 
late apoptotic HT-1080 cells (Figure 4.1 OB). As with the PI positively 
stained cells, the late apoptotic cells also increased by 5.3-fold, 5.7-fold 
and 7.5-fold when HT-1080 cells were exposed respectively to 0.1, 0.2, 
and 0.4mM of zinc analogue. These results are in agreement with the 
corresponding morphological experiment with Annexin V. Other 
morphological techniques showed no HT-1080 necrotic cells.
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Figure 4.10 FACS results of concentration-dependent increase in (A) 
propidium iodide (PI) and (B) Annexin V (An-V)labelling of HT-1080 cells 
treated with 0.1, 0.2 and 0.4mM zinc 2-hydroxybenzoate for 24 hours. (C) 
% of early and late apoptotic cells labelled by PI (Green), (D) % of late 
apoptotic cells labelled by An-V (blue), and (E) % of early apoptotic cells 
labelled by An-V (red). Cells cultured under standard conditions, arrested 
with serum-free DMEM medium, treated with zinc benzoate at the 
indicated concentration points, and labelled by FITC-labelled Annexin V.
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4.6.2.2 Detection of Apoptosis through Caspase-3
Further to the early detection of apoptosis by Annexin V assay, caspase-3 
activity assay was also undertaken using the specific fluorescent 
substrate, PhiPhiLux-G1 D2. These two assays are essential to determine 
apoptosis, as the activity of caspase-3 and the externalisation of PS are 
closely associated with the downstream events of cells undergoing 
apoptosis. The externalisation of phosphatidylserine, for example, is 
thought to be a downstream event of early caspase activation (Koopman 
et al., 1994; Green and Kroemer, 1998). Furthermore, caspase-3 is the 
most important member of cysteine aspartases (caspases) family involved 
in the apoptosis of various cancer cells and the main effector of apoptosis. 
It cleaves several of the cytoplasmic and nuclear proteins (Adam et al., 
1998; Thornberry and Lazebnik, 1998; Fujino eta!., 2001).
Therefore, caspase-3 activity was measured in HT-1080 cells to 
substantiate the apoptotic-inducing activity of zinc 2-hydroxybenzoate in 
this study. The caspase-3 assay is able to detect the activity in intact cells 
undergoing apoptosis, and can be measured by flow cytometry based on 
the ability of a test drug candidate to activate or inhibit caspase-3. The 
assay is based on the reaction of the enzyme with the cell-permeable 
PhiPhiLux® G ID 2 substrate. Each substrate molecule contains two 
fluorophores and the cleaved substrate fluoresces green.
Figure 4.11 shows the caspase-3 activity in zinc 2-hydroxybenzoate and 
2-acetylbenzoic acid treated HT-1080 cells over 24 hours. Results 
indicated that both benzoate analogues induced apoptosis in HT-1080 
cells, which was significantly different from control. Note the 0.4mM of zinc 
2-hydroxybenzate induced apoptosis at a 5.9-fold increase over the level 
of apoptosis in the control sample. The 3.2mM 2-acetylbenzoic acid also 
induced apoptosis in HT-1080 cells, but at a lower level than zinc 2- 
hydroxybenzoate.
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Figure 4.11 FACS results of concentration-dependent increase in 
caspase-3 activation in HT-1080 cells treated with 3.2mM 2-acetylbenzoic 
acid or 0.4mM zinc 2-hydroxybenzoate for 24 hours. Cells cultured under 
standard conditions, arrested with serum-free DMEM medium, treated with 
zinc benzoate at indicated concentration points, and labelled by 
fluorescent substrate, PhiPhiLux-G1D2-
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Chemopreventive agents, such as 2-acetylbenzoate, have been found to 
induce apoptosis in B-cell chronic lymphocytic leukaemia cells through the 
activation of caspase-3 (Bellosillo et al., 1998). Kim et al. (2003) also 
found that 2-acetylbenzoic acid alone or combined with radiation treatment 
upregulated the expression of caspase-3, inducing apoptosis in human 
cervical cancer cells.
4.6.3 Effect of 2-Hydroxybenzoate Analogues on Gene Expression
To investigate the effect of 2-hydroxybenzoate analogues on the 
molecular biology that governs the population growth and cell cycle 
progression of HT-1080 cells, the expressions of six proteins were 
analysed by Western blotting. These proteins included p21, p53, Bcl-2, 
Bax, TNF-a and histones after cell treatment with individual agent in 
continuous exposure for 24 hours. p53 plays an important role in guarding 
the cell genome from the effects of DNA damage. p53 forms tetramers 
and binds to specific DNA sequences to activate the expression of genes 
involved in multiple cellular functions including population growth arrest 
(p21Cip1), DNA repair (p48), apoptosis (Bcl-2, Bax) and antiangiogenesis 
(TSP1/GD-AIF) (Vogelstein and Kinzler, 1992; Jacks and Weinberg, 1996; 
Hanahan and Weinberg, 2000; Malumbres and Carnero, 2003). Although, 
several human tumour suppressor genes (TSG) have been identified (e.g. 
APC in colon, BRCA1, in breast and ovary, p16 in melanoma, Rb Retina in 
bone, other), p53 is one of the most frequent TSGs subject to mutation in 
human cancer. Thus dysfunction of p53 protein has been reported in many 
tumour types (Hollstein et al., 1994; Soussi and Beroud, 2001).
4.6.3.1 Expression of p53 and p21
Both p21 and p53 are closely associated in cell cycle progression. p53, for 
example, is a transcriptional factor for stimulatation of the synthesis of 
p21Cip1, a Cdk inhibitor that suppresses the activity of Cdk2-cyclin complex 
and hence blocks passage through the G1 checkpoint (Xiong et al., 1993;
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El Deiry et al., 1993; 1994). It is indicated from animal model studies that 
p53 can induce apoptosis but not G1 arrest in p21clp1/WAF1-defiicent mice 
(Brugarolas e ta i, 1995; Deng etal., 1995; Macleod eta!., 1995). Arresting 
the cell cycle in G1 gives defected cells time to repair DNA damage. Thus, 
p21c,p1-deficient mice are susceptible to spontaneous tumour development 
(Martin-Caballero etal., 2001).
Detections of p53 protein levels in benzoate analogues-treated-HT-1080 
cells were conducted by Western blot after 24 hours' exposure to 0.05mM 
and 0.4mM of both calcium 2-hydroxybenzoate. Results indicated that the 
expression of p53 was upregulated at least 0.14-fold more than in the 
control sample (Figure 4.12). Further increase in the expression of p53 
was caused by zinc 2-hydroxybenzoate, where the expression was 
increased 1-fold compared to control (Figure 4.12). It is very interesting to 
note that the expression of p53 in both calcium and zinc benzoate 
treatments was higher at lower drug concentration (0.05mM) than the 
higher one (0.4mM). A similar result was also obtained when HT-1080 
cells were exposed to the 2-acetylbenzoic acid at the same concentrations 
for 24 hours.
Figure 4.13 shows the effect of calcium 2-hydroxybenzoate, zinc 2- 
hydroxybenzoate and 2-acetylbenzoic acid on the expression of p21 in 
treated HT-1080 cells. Calcium benzoate clearly upregulated p21 in HT- 
1080 cells in a concentration-dependent manner. The induction of p21 
expression is higher than 2-acetylbenzoic acid by 2.3-fold, both at 0.4mM 
concentration and higher than control by approximately 0.79-fold.
The effect of zinc 2-hydroxybenzoate at the same concentration also 
upregulated the expression of p21 in a parallel experiment being 
increased by at least 0.4-fold.
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Figure 4.12 Effect of 0.05mM and 0.4mM concentration of calcium 2- 
hydroxybenzoate, zinc 2-hydroxybenzoate and 2-acetylbenzoic acid on 
expression of p53 in HT-1080 cancer cells. Cells cultured under standard 
conditions, arrested with serum-free DMEM medium, treated for 24 hours. 
Western blots data represent megn ±SE of 2 independent gels for 
2HBnCa and 4 gels for 2AcBA.
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Figure 4.13 Effect of 0.05mM and 0.4mM concentration of calcium 2- 
hydroxybenzoate, zinc 2-hydroxybenzoate and 2-acetylbenzoic acid on 
expression of p21 in HT-1080 cancer cells. Cells cultured under standard 
conditions, arrest with 10% serum-free DMEM medium, treated for 24 
hours. Western blots data represent mean ±SE of 2 independent gels for 
2HBnCa and 4 gels for 2AcBA.
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4.6.3.2 Expression of Bax and Bcl-2
In addition, the treatment with these two benzoate analogues at the same 
concentrations (0.05mM and 0.4mM) for 24 hours was used to study the 
effect on the expression of both Bax and Bcl-2. These two proteins are 
transcribed by the same gene family (Bcl-2) that contain both proapoptotic 
proteins (e.g. Bax, Bad, Bak) and antiapoptotic proteins (e.g. Bcl-2, Bcl- 
XL) (Pellegrini and Strasser, 1999). They contribute to regulate the release 
of cytochrome c from mitochondria, which associates with downstream 
caspases to induce apoptosis (Jurgensmeier et al., 1998). Both pro- and 
anti- apoptotic Bcl-2 family members can interact with each other in the 
loss of function. Therefore, the balance of regulating both pro- and 
resulting anti-apoptotic proteins is important in regulating cell decisions on 
life or death (Newton and Strasser, 1998).
Figure 4.14 shows the results of the Western blot analysis, indicating that 
exposure of HT-1080 cells to benzoate analogues for 24 hours caused 
upregulation of Bax in a concentration-dependent manner, compared to 
the control. 0.04mM calcium 2-hyroxybenzoate upregulated Bax by 2.3- 
fold compared to the control sample. Similar increase in the expression of 
Bax was also induced by 2-acetylbenzoic acid at 0.4mM (Figure 4.14). 
The increases in Bax protein due to 0.05mM calcium benzoate and 
0.05mM 2-acetylbenzoic acid were about 0.96-folds for both treatments, 
compared to the control. The effect of zinc 2-hydroxybenzoate showed the 
lowest effect, compared to both calcium 2-hydroxybenzoate and 2- 
acetylbenzoic acid.
In contrast, both 0.05mM and 0.4mM calcium 2-hydroxybenzoate 
downregulated the expression of Bcl-2 compared to the control sample by 
about 21% at both concentrations (Figure 4.15). The effect of 2- 
acetylbenzoic acid on the expression of Bcl-2 protein, however, showed 
an increase of approximately 0.74 and 1.9-fold when HT-1080 cells were 
exposed to 0.4mM and 0.05mM concentration, respectively, for 24 hours 
compared to control (Figure 4.15). In contrast, the expression of Bcl-2 in
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HT-1080 cells after the exposure to zinc 2-hydroxybenzoate was 
upregulated 2-fold for both concentration treatments (Figure 4.15).
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Figure 4.14 Effect of calcium 2-hydroxybenzoate, zinc 2-hydroxybenzoate 
and 2-acetylbenzoic acid at 0.05mM and 0.4mM concentrations, on the 
expression of Bax in HT-1080 cancer cells. Cells were cultured under 
standard conditions, arrested with serum-free DMEM medium, treated for 
24 hours. Western blots data represent means ±SE of 2 independent gels 
for 2HBnCa and 4 gels for 2AcBA.
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Figure (4.15) The effect of calcium 2-hydroxybenzoate, zinc 2- 
hydroxybenzoate and 2-acetylbenzoic acid both at 0.05mM and 0.4mM 
concentrations on the expression of Bcl-2 in HT-1080 cancer cells. Cells 
were cultured under standard conditions, arrest with serum free DMEM 
medium, treated for 24 hours. Western blots data represents the mean 
±SE of 2 independent gels for 2HBnCa and 4 gels for 2AcBA.
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4.6.3.3 Expression of Histones
The effect of benzoate analogues on the expression of histones was also 
assessed in HT-1080 lysates obtained from the same experiment for the 
previous described proteins. Histones play an important role in chromatin 
structure. Approximately 146 base pairs of DNA are wrapped twice around 
a histone octamere, comprising a H3/H4 tetramere and two H2A, H2B 
dimers, to form a nucleosome, which is compacted further by the 
attachment of histone H1. Histones have been found to control gene 
transcription epigenetically (not interfering directly with DNA). They bind to 
DNA via an ionic interaction between the negatively charged phosphates 
on the DNA backbone and the lysine residues, clustered on the highly 
basic amino-termini tails of the core histone proteins (Archer and Hodin, 
1999). Histone acetylation and deacetylation depend on the activity levels 
of the histone acetyltransferase (HAT) and histone deacetylase (HDACs) 
enzymes. Many studies have found an inverse correlation between HDAC 
activity and tumour suppressor gene (TSG) expression, suggesting HDAC 
plays a pivotal role in oncogenesis (Laird and Jaenisch, 1996; Archer and 
Hodin, 1999).
Alterations of chromatin, through histone deacetylation and DNA 
methylation have been found to play an important role in carcinogenesis 
(Laird and Jaenisch, 1996; Archer and Hodin, 1999). Both processes have 
been found to block the expression of tumor suppressor genes, such as 
cell death inducer p53, the universal guardian of the cell cycle in 
mammalian cells, activated if a cell cycle error cannot be repaired by the 
cell repair mechanisms.
Figure 4.16 shows the effect of 0.05mM and 0.4mM calcium 2- 
hydroxybenzoate, zinc 2-hydroxybenzoate and 2-acetylbenzoic acid on 
the regulation of histone proteins. These benzoates upregulate histones at 
least 1.1-fold compared to the control sample. In the case of calcium 
benzoate, results showed no differences between 0.05mM and 0.4mM 
concentrations. However, the effect of zinc analogue on the expression of 
histones showed a concentration-dependent effect, where 0.4mM
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concentration expressed histone more than doubled the expression of 
histone than that induced by 0.05mM of zinc 2-hydroxybenzoate (Figure 
4.16).
The figure also shows the effect of 2-acetylhybenzoic acid on the 
expression of histones at the same concentrations. Results of Western 
blotting showed that lower concentration (0.05mM) of 2-acetylbenzoic acid 
was more effective is upregulating histone than 0.4mM.
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Figure 4.16 Effect of calcium 2-hydroxybenzoate, zinc 2-hydroxybenzoate 
and 2-acetylbenzoic acid, both at 0.05mM and 0.4mM concentrations, on 
the expression of histone in HT-1080 cancer cells. Cells cultured under 
standard conditions, arrested with 10% serum free DMEM medium, 
treated for 24 hours. Western blots data represent mean ±SE of 2 
independent gels for 2HBnCa and 4 gels for 2AcBA.
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4.6.3.4 Expression of Tumour Necrotic Factor (TNF-a)
Two TNF receptors are found on the cell surface: TNF-R1 and TNF-R2. 
The TNF-R1 is expressed in cells binding to TNF-a, which has important 
biological functions including induction of apoptosis and antiviral activity 
(Schulze-Osthoff et al., 1998). 2-acetylbenzoic acid was found to induce 
apoptosis in colon cancer cells through the activation of nuclear factor- 
kappa beta (N F-kB) signalling pathway (Stark et al., 2001). This pathway 
was identified as a target for the antiinflammatory effects of 2- 
acetylbenzoic acid and other NSAIDs (Kopp and Ghosh, 1994; Yin et al.,
1998). TNF-a is able to activate pro-apoptotic proteins including capases, 
resulting in apoptosis, or to activate NF-kB and initiate proliferation or 
differentiation. Therefore, the expression of TNF-a was investigated.
Figure 4.17 shows the results of TNF-a expression in HT-1080 cells when 
exposed to benzoate analogues for 24 hours. Results indicated that both 
calcium and zinc 2-hydroxybenzate upregulated TNF-a by at least 1.23- 
fold compared to the control sample. Furthermore, 2-acetylbenzoic acid 
also increased the expression of TNF-a, but not in a concentration- 
dependent manner, since 0.05mM induced more expression of TNF-a 
than 0.4mM concentration.
4.6.4 Investigation of 2-Hydroxybenzoate Analogues Uptake by HT- 
1080
The aim of this study was also to investigate the uptake of 2- 
hydroxybenzoates by HT-1080 cells. Therefore, both high pressure liquid 
chromatography and atomic absorption were used to detect 2- 
hydroxybenzoic acid and metal ions, respectively. Authentic samples of 2- 
hydroxybenzoic and 2-acetylbenzoic acids were run first to specify the 
retention time for each benzoate, and used as a reference for the same 
molecules that were extracted from treated cells.
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Figure 4.17 Effect of calcium 2-hydroxybenzoate, zinc 2-hydroxybenzoate 
and 2-acetylbenzoic acid, at both 0.05mM and 0.4mM concentrations, on 
the expression of TNF-a in HT-1080 cancer cells. Cells cultured under 
standard conditions, arrested with 10% serum-free DMEM medium, 
treated for 24 hours. Western blots data represent mean ±SE of 2 
independent gels for 2HBnCa and 4 gels for 2AcBA.
HT-1080 cell pellets of 0.4mM calcium 2-hydroxybenzoate and zinc 2- 
hydroxybenzoate-treated samples were digested with nitric acid to free
124
both 2-hydroxybenzic acid and the metal ion in the form of calcium or zinc 
nitrate. The 2-hydroxybenzoic acid samples were extracted with 
chloroform, concentrated to about 1ml, and then analysed by HPLC.
Figure 4.18 shows the HPLC chromatograms for both the authentic 2- 
acetylbenzoic acid (Retention time= 4.5min; Figure 4.18A) and 2- 
hydroxybenzoic acid (Retention time= 6.3min; Figure 4.18B). Figure 4.18C 
shows a mixture of 2-acetylbenzoic acid and 2-hydroxybenzoic acid was 
detected in HT-1080 cells treated with 0.4mM 2-acetylbenzoic acid for 24 
hours. Both peaks have the same retention time of the authentic 
molecules. This resulted from the hydrolysis of the acetate, either 
enzymatically or most likely due to the fact that the ortho acetate group 
forms intrahydrogen bonding which promotes hydrolysis. Other peaks are 
attributed to other cellular compounds or to the metabolites present in the 
cell.
Figure 4.18D also shows a trace of 2-hydroxybenzoic acid (retention time 
= 6.3min) extracted from cells that were treated with calcium 2- 
hydroxybenzoate. In contrast, HPLC chromatogram of zinc 2- 
hydroxybenzoate treatment (Figure 4.17E) did not show any trace of 2- 
hydroxybenzoic acid. This may be attributed to either the low 
concentration of 2-hydroxybenzoic acid, or it may have been metabolised 
inside the cell, as in the other treatment, where the three chromatograms 
(Figure 4.18C-E) of 2 or 3 traces of compounds had the following retention 
times: 4.392, 5.121 minutes (Figure 4.17C); 2.867, 4.350, 5.092 minutes 
(Figure 4.18D), and 2.854, 3.171, 4.333, 5.067 minutes (Figure 4.18E).
In this study, we also examined the presence of both calcium and zinc in 
HT-1080 cells treated independently with calcium 2-hydroxybenzoate and 
zinc 2-hydroxybenzoate at 0.4mM concentration for 24 hours. Table 4.4 
shows that only zinc could be detected using atomic absorption. Although 
zinc was detected, the validity of the atomic absorption results remain 
questionable, due to the insensitivity of this technique to detect traces of 
zinc and calcium.
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Figure 4.18 HPLC chromatograms of (A) authentic 2-acetylbenzoic acid, 
(B) authentic 2-hydroxybenzoic acid, (C) HT-1080 cell extract after 
treatment with 0.4mM 2-acetylbenzoic acid, (D) HT-1080 cell extract after 
treatment with 0.4mM calcium 2-hydroxybenzoate, (E) HT-1080 cell 
extract after treatment with 0.4mM zinc 2-hydroxybenzoate.
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It seems likely that the overall results obtained in this section have shown 
some evidence of the uptake of 2-hydroxybenzoate analogues into HT- 
1080 cells, and hence elicited their biological activities to induce 
apoptosis.
Table 4.4 Detection of zinc and calcium in benzoate treated HT-1080 
cells using atomic absorption.
Treatment/Metal ion Zn (ppm) Ca(ppm)
HT-1080 cell pellet. Cells treated with either zinc 2- 
hydroxybenzoate, or calcium 2-hydroxybenzoate
0.1841 Not
detected
4.7 Summary and Conclusion
This chapter focused on the effect of 2-acetylbenzoic acid, calcium 2- 
hydroxybenzoate and zinc 2-hydroxybenzoate on cell cycle and molecular 
changes in HT-1080 cells. Cell cycle analysis indicated that benzoates 
exerted different effects on the duration of first and second mitosis, as well 
as on the number of mitotic cells observed during the course of the 
experiment. The exposure of HT-1080 cells to 0.8mM 2-acetylbenzoic acid 
or 0.25mM zinc 2-hydroxybenzoate, for example, increased the duration 
for mitosis in HT-1080 by about 2.1 and 1.9-fold, respectively. It is clear 
that zinc 2-hydroxybenzoate was the most effective agent in reducing the 
numbers of first and second mitotic cells in a concentration-dependent 
manner. A similar effect was also observed in HT-1080 cell cycle duration. 
Zinc benzoate was also shown to be the most effective agent to inhibit 
cells' progression to first or second cycle of apoptosis during the 22 hours' 
exposure.
The effect of calcium and zinc benzoate analogues on cell cycle phase 
distributions indicated that neither of the treatments induced a significant 
cell cycle arrest. On the other hand, both calcium and zinc benzoate 
treatments have shown evidence of their apoptotic mode of action. The 
flow cytometric analysis of both Annexin V and caspase-3, for example, 
showed evidence of apoptosis. Both cell cycle analysis and the evidence
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of apoptosis may indicate that the induction of cell death is by a 
mechanism that does not involve a specific phase arrest. To better 
understand the mechanism of action of benzoate analogues on cellular 
population growth and apoptosis in HT-1080 cells, we investigated the 
expression of six proteins that are involved in the downstream molecular 
organisation. These proteins included p53, p21, Bax, Bcl-2, histones and 
TNF-a using Western blot analysis. Results of the experiments are 
summarised as follows and in Table 4.5.
1 2-Acetylbenzoic acid treatments: p53, p21, Bax, Bcle-2, histones 
and TNF-a were upregulated in HT-1080 by both 0.05mM and 
0.4mM 2-acetylbenzoic acid treatments by values ranging from 7% 
to 189% above the control (100%). However, 0.4mM concentration 
down- regulated p21 by 28%. Most treatments were not 
concentration- dependent.
2 Calcium 2-hydroxybenzoate treatment: p53, p21, Bax, histones and 
TNF-a were upregulated in HT-1080 by both 0.05mM and 0.4mM 
calcium 2-hydroxybenzoate treatments by values ranging from 17% 
to 240% above the control (100%). However, both 0.05mM and 
0.4mM concentrations downregulated Bcl-2 by 21%. Most 
treatments were concentration-dependent.
3 Zinc 2-hydroxybenzoate treatments: p53, p21, Bax, histones and 
TNF-a were upregulated in HT-1080 by both 0.05mM and 0.4mM 
Zinc 2-hydroxybenzoate treatments by values ranging from 40% to 
250% above the control (100%). However, 0.4mM concentration 
regulated p53 to the same extent as the control sample (or 100%). 
Most treatments were concentration-dependent.
4 The ratios between Bax (apoptotic promoter) to Bcl-2 (apoptotic 
inhibitor) induced by the three agents were concentration- 
dependent. The regulation of Bax was higher than Bcl-2 in HT- 
1080 cells when they were exposed to 2-acetylbenzoic acid, 
calcium 2-hydroxybenzoate, or zinc 2-hydroxybenzoate.
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5 The ratios between Bcl-2 and p53 showed an increase in 2- 
acetylbenzoic acid treated HT-1080 while they decreased in 
presence both calcium and zinc 2-hydroxybenzoate treatments. 
Furthermore, the Bax/p53 ratios increased in most treatments 
(Table 4.5).
Table 4.5 Optical densities for protein expressions in benzoate-treated 
HT-1080 cells exposed for 24 hours.
Protein 2-Acetyl benzoic 
Acid (%)
Ca 2-hydroxybenzoate
(%)
Zn 2-hydroxybenzoate 
(%)
0.4mM 0.05mM 0.4mM 0.05mM 0.4m M 0.05mM
P53 114 198 135 150 200 259
p21 78 107 179 117 154 140
Bax 289 198 331 195 253 176
Bcl-2 174 290 79 78 302 308
Histone 233 286 340 335 350 211
TNF-a 163 243 306 264 244 223
Bcl-2: Bax 1:1.66 1:0.676 1:4.190 1:2.5 1:0.838 1:0.571
Bcl-2: p53 1:0.66 1:0.68 1:1.71 1:1.92 1:1.51 1:1.89
Bax:p53 1:0.29 1:1 1:0.41 1:0.77 1:0.79 1:1.47
The increase in the upregulation of p53, Bax, histones and TNF-a as a 
result of exposing HT-1080 cells to 2-acetylbenzoic acid induced 
apoptosis measured by Annexin V and caspase-3. These four proteins are 
promoter agents in the induction of apoptosis, which suggests that the cell 
death proceeds through different apoptotic signalling pathways. Another 
principal observation made in these experiments is that, contrary to the 
function of Bcl-2 as an apoptotic inhibitor, its level increased at both 2- 
acetylbenzoic acid concentrations, while p21 decreased in cells 
undergoing apoptosis.
However, the incorporation of calcium 2-hydroxybenzoate (at both 
0.05mM and 0.4mM) induced downregulation of Bcl-2 which participates in 
initiating apoptosis. The expression of other proteins was also increased,
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which substantiates the apoptotic-inducing mechanism of calcium 
benzoate.
Results for the six protein expressions in zinc 2-hydroxybenzoate are 
similar to the effect of 2-acetylbenzoic acid, where Bcl-2 (apoptotic 
inhibitor) increased, while both Annexin V and caspase-3 assays indicated 
that HT-1080 cells died by apoptosis. Finally, it is important to note that 
the pharmacological investigations of the 2-hydroxybenzoate analogues 
showed the presence of these compounds inside HT-1080 cells, as 
indicated by HPLC and atomic absorption spectroscopy.
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Chapter Five
General Discussion 
and Conclusions
CHAPTER FIVE
General Discussion and Conclusions 
5.1 Introduction
In the previous last three chapters, the biological activities of 2- 
hydroxybenzoate analogues on HT-1080 fibrosarcoma cells have been 
demonstrated. The results have identified the cytotoxic effect of zinc 2- 
hyroxybenzoate and its ability to induce various molecular changes in HT- 
1080 cells. Both morphological and molecular studies confirm that 2- 
hydroxybenzoate salts affect HT-1080 fibrosarcoma cells, and indeed 
inhibit their growth by apoptosis. Apoptosis was confirmed by two 
immunoassays: Annexin V and caspase-3 assays using flow cytometry. It 
is important to note that: (1) 2-hydroxybenzoate analogues used in this 
work have not been previously investigated, and (2) low concentrations 
(mostly 0.4mM) were used, even for the 2-acetylbenzoic acid (aspirin) 
compared to the commonly reported concentration of 5-1 OmM (Santini et 
al., 1999; Marra and Liao, 2001). This chapter will shed light on the overall 
effects of 2-hydroxybenzoates on cell cycle components, morphological 
and the molecular changes in HT-1080 cells.
5.2 Growth in vitro of HT-1080 Cells: Research Perspective
The HT-1080 cell line is an epithelial-like adherent cell line, developed 
from a fibrosarcoma isolated from a 35 year-old Caucasian male (Rasheed 
et al., 1974). Fibrosarcoma can infect bone and soft tissues including lung, 
kidney and lymph nodes. This human fibrosarcoma cell line was used in 
this work where enough cells were subcultured and frozen in batches in 
liquid nitrogen for subsequent work. Each batch was then subcultured 2-3 
times depending on the planned experiments. General microscopic 
observation of each batch of HT-1080 cells indicated that they were 
healthy and grew well, and a consistent mode of growth was achieved.
131
Cells reached about 40-50% confluence in about 4 days after the initial 
seeding. To ensure a consistent benzoate effect on cultured cells, HT- 
1080 were cultured for 3 days in a full DMEM medium, followed by another 
day, but in serum-free DMEM, before cells were exposed to the benzoate 
compounds at certain concentration and time points. The purpose of 
culturing cells in a serum-free medium is to synchronise most cells at 
Go/G1 phase at the beginning of the exponential phase of their growth, 
which was determined by a growth curve (see Figure 2.2). There are 
various methods for synchronisation such as physical (gentle shaking) and 
chemical (serum deprivation, chemical agents) methods (Matherly et ai, 
1989; Chen et al., 1996; Nguyen et al., 1999; Albino et al., 2000). The 
physical method includes harvesting cells by gentle shaking, where cells in 
M phase are less attached. In this study, serum deprivation was used, 
where HT-1080 cells were serum starved for 24 hours. Results of the flow 
cytometry indicated that the distribution of G1 phase reached 49.9% when 
HT-1080 cells were grown in serum-free DMEM medium for 24 hours, 
compared with 31.9% in the control experiment (culture medium 
containing 10% serum) (see Figure 4.6).
One of the main aims of this research was to investigate the anticancer 
activities of 2-hydroxybenzoic acid analogues using lower concentrations 
than those reported in the literature for 2-acetylbenzoic acid and its 
benzoate analogues (i.e. 5-1 OmM; Santini et al., 1999; Marra and Liao, 
2001). 2-acetylbenzoic acid, or aspirin, is the most common drug that has 
received a deal of research interest and been actively studied in different 
medical areas including cancer. Various studies have demonstrated that 
2-acetylbenzoic acid and other NSAIDs play significant roles as protective 
agents against various types of cancer such as of the larynx and of the 
oral cavity (Funkhouser and Sharp, 1995; Claudia, 2003). However, 
relatively high concentrations of 2-acetylbenzate analogues (mostly 5- 
10mM) have been used in vitro of culture treatment (Santini et al., 1999; 
Marra and Liao, 2001). Using the high concentration of 2-acetylbenzoic 
acid for an in vitro treatment is not compatible with the commonly
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prescribed 75mg (4 .1 7x1 0^) of aspirin. Xu et al., (1999) indicated that 2- 
acetylbenzoic acid at 10'4 to 10'5M is the therapeutic concentration that is 
commonly achieved to selectively inhibit Cox-2 transcription in fibroblasts, 
and endothelial cells at high concentrations. In contrast, the high 
concentrations used for in vitro experiments exhibit nonspecific inhibition of 
a large number of kinases in cells. Therefore, high concentration of drugs 
can induce side effects. Indeed, Raz (2002) and others (Frantz and 
O’Neill, 1995; Yin et a!., 1998) questioned the use of high 2- 
acetylbenzoate concentrations, and concluded that the anti- tumourogenic 
effect of 2-acetylbenzoate in vivo is due to the inhibition of tumour Cox-2. 
This mechanism, however, may not have substantial relevance to the one 
that mediates the effects of NSAIDs in vitro, due to the high concentration 
of drug being used in in vitro experiments (Raz, 2002). Furthermore, it has 
been reported recently that high aspirin concentration used in cancer 
treatment causes complications to heart function (Patrono et al., 2004). 
Thus, it was decided to use a low concentration (mostly 0.4mM). Indeed, 
we have noticed in this study that high concentrations (up to 8mM) of 
benzoate were required to observe explicit cytotoxicity in calcium 2- 
hydroxybenzoate-treated HT-1080 cells (Figure 2.8), although at lower 
concentrations of calcium 2-hydroxybenzoate (0.4mM), cytotoxic effects 
on HT-1080 cells were clearly seen when morphological and molecular 
investigations were used (see Chapters 3 and 4).
5.3 Appraisal of Cytotoxicity of 2-Hydroxybenzoate Analogues
As indicated in previous chapters, 2-hydroxybenzoates exert 
chemopreventative and chemotherapeutic potentials by virtue of their 
antiinflammatory, antipyretic and analgesic properties (Wong et a!., 1999; 
Husain et al., 2001). These compounds also exert antioxidant activities in 
common with other phenolic compounds (Kikuzaki and Nakatani, 1989, 
Cuvelier etai., 1996; Chen and Ho, 1997; Rice-Evans, 1997; Owen etal., 
2000). Clinical and epidemiological data associated with 2-acetylbenzoic
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acid have shown evidence that nonsteroidal antiinflammatory drugs 
reduced the occurrence and growth of certain tumours such as colon and 
breast cancers (Harris, 1995; Stellman, 1995; Stark, 2001). In this study, 
18 benzoic acid analogues were tested against the HT-1080 fibrosarcoma 
cell line. These benzoates possess a basic structure of an aromatic acid, 
with or without hydroxyl or acetyl functional groups (see Section 1.5). 
These two functional groups (hydroxyl and acetate) give rise to further 
chemical interactions in biological systems, as both benzoates contain 
heteroatoms and oxygen atoms. Furthermore, the conjugated system of 
the aromatic moiety participates to accommodate better conditions for the 
stability of reaction intermediates. The stabilisation of such intermediates 
is often accomplished by reactions with free radicals to hydroxy late the 
aromatic moiety. This gives benzoates the potential for free radical 
scavenging, and thus benzoates exert antioxidant characteristics. The 
benzoate analogues used in this study also carry mono or divalent metal 
ions, such as lithium, sodium, potassium, calcium, magnesium or zinc. In 
addition to their significant roles in biological systems (Hartwig, 2001; 
Truong-Tran et al., 2001; Luchinat, 2003; see also Chapter 1), chemically, 
metal ions bonded to carboxylate, improve the solubility of organic acid 
molecules. The solubility of 2-acetylbenzoic acid, for example, is poor in 
water (3g/L), while its metal ion salts are readily soluble in water. 
Therefore, using different metal ions not only exerts biological effects but 
also improves physical properties which become available for interaction 
with cellular molecules. Both sodium and calcium 2-acetyl benzoate have 
been tested against various cancer cell lines (Santini et al., 1999; Ishihara 
et al., 2003; Lee et al., 2003); however, other benzoates used in this study 
have not been tested before to our knowledge. In particular, the use of 
zinc- containing compounds (which exerted a significant biological 
potential against HT-1080 cells in this study) appears to be novel.
The anticarcinogenic effects of 2-acetylbenzoic acid have been widely 
studied in the large bowel, but the relationship between 2-acetylbenzoic 
acid use and cancer sites outside the large bowel have not been clearly
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elucidated. Pagnate-Hill et al., (1989) showed that there was no 
statistically significant association between 2-acetylbenzoic acid usage 
and risk of cancers of the lung, bladder, kidney, prostate or breast. 
Rosenbuurg et al., (1991) also found no association between 2- 
acetylbenzoic acid usage and risk of cancers of the lung, breast, 
endometrium, ovary, testis, bladder, lymphomas, leukaemias and 
melanoma. Thun et al., (1997) showed that there was no consistent 
association with 2-acetylbenzoic acid usage and cancer of the buccal 
cavity and pharynx, respiratory system, breast, male or female genital 
system, urinary system, brain and other nervous system, lymphatic and 
haematopoietic systems. However, a report from an American Health 
Foundation Workshop referred to various evidence that 2-acetylbenzoic 
acid may exhibit anticancer activities, and found data indicating an 
association between 2-acetylbenzoic acid use and reduced breast cancer 
risk (Stellman, 1995). In this study, the anti-carcinogenic activities of 18 of 
the benzoate analogues was studied in detail on HT-1080 cell.
The response of HT-1080 cells to benzoate analogues was studied to 
elucidate the effect on cell proliferation at different exposure times (12, 24, 
48 and 72 hours) and at different benzoate concentrations (0.025, 0.05, 
0.1, 0.2, 0.4mM). The results obtained from the MTT assay helped to 
identify the most promising targets for further studies. It is interesting to 
note that the effects of 2-hydroxybenzoate analogues except Zinc, were 
not concentration- or time-dependent (at concentration between 0.025 and 
0.4mM). Generally, the biological effects of these analogues were 
biphasic, ranging between cytotoxic and mitogenic. For example, 0.1 mM 
potassium benzoate, 0.05 and 0.1 mM potassium 2-hydroxybenzoate, and 
0.05mM potassium 2-acetylbenzoate reduced HT-1080 population number 
by about 30% when cells were exposed to these compounds for 12 and 24 
hours, and compared to the control experiment (see Figure 2.5). However, 
the incubation of HT-1080 cells for longer periods (48 and 72 hours) 
induced a mitogenic effect, as measured by MTT assay. Similar results 
were obtained when HT-1080 cells were exposed for 6, 12, 24, 48 and 72
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hours at low concentrations (0.025, 0.5 and 0.1 mM) of calcium, 
magnesium, or zinc benzoates, 2-hydroxybenzoate and 2-acetylbenzoate 
analogues (see Figures 2.6, 2.7, 2.9, 2.10). However, both 0.2 and 0.4mM 
concentrations of zinc benzoate, 2-hydroxybenzoate and 2-acetylbenzoate 
analogues were both concentration- and time-dependent when compared 
to the control experiment (see Figures 2.9, 2.10). The three zinc benzoate 
analogues had similar cytotoxicity. In comparison to the reported 
concentration, 5-1 OmM, of 2-acetylbenzoic acid. We have found in this 
study that the minimum effective concentration of zinc 2-hydroxybenzoate 
is 0.2mM, or 25-50-fold less than previously been reported (5-1 OmM; 
Santini et a!., 1999; Marra and Liao, 2001); hence, it may have a 
therapeutic potential. Zinc ion is an essential trace metal for various 
biological processes. Zinc, for example, functions as a cofactor for various 
enzymes, nuclear factors and hormones, hence it influences cell viability, 
proliferation, differentiation and cell death (Keen and Hurley, 1989; 
Falchuk, 1998; Chimienti et al., 2001). Zinc also acts as an antioxidant, 
due to protection of protein sulphydryl groups (Powell, 2000). The 
metabolically active cellular zinc pool is thereby controlled by the 
mechanism of action of the redox unit of the metallothionein/thionein 
couple, which works as a two-cluster network (Maret, 2000).
The results obtained from this study showed that zinc benzoate, zinc 2- 
hydroxybenzoate, and zinc 2-acetylbenzoate inhibited HT-1080 cell 
proliferation by about 90% at 0.4mM, and by about 70% at 0.2mM 
concentrations (see Figure 2.9, 2.10). The cytotoxic effect of zinc 
benzoate analogues on HT-1080 cells was also observed by direct cell 
count using a haemocytometer (see Figure 2.11), and by time-lapse 
tracking images (see Figure 2.13). The results of the three methods were 
consistent, indicating that zinc benzoate analogues have a greater 
cytotoxic effect on HT-1080 cells compared to other benzoate analogues 
(see Chapter 2). The cytotoxic effects of zinc-containing compounds have 
been verified in the literature. Gibson et al., (1985) showed that zinc 
pyrithione reduced the proliferation of hamster kidney cells (BHK 21)
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above 0.1 pg/ml. 0.4mM and 0.8mM Zinc sulphate (ZnS0 4 ) was also toxic 
to epithelial cells of the human intestinal cell line Caco-2 (Scarino et a!., 
1992; Zodl eta!., 2003).
5.4 Appraisal of Apoptotic Potential of 2-Hydroxybenzoate Analogues
Physiological programmed cell death, or apoptosis, has significant virtues 
over necrotic cell death in therapy, and hence one of the strategies in 
designing and developing anticancer drugs is concentrated on compounds 
that can induce apoptosis. Our interest in this project was to investigate 
whether 2-hydroxybenzoate analogues could trigger apoptosis in HT-1080 
fibrosarcoma cells. The MTT and other cell viability assays showed 
evidence of significant potential of cytotoxicity exerted by a number of 2- 
hydroxybenzoate analogues in HT-1080 cells (see Chapter 2). These 
mainly included zinc analogues. However, as indicated in the previous 
section, viability assays may not be powerful enough to reveal the 
apoptotic potential. Therefore, various analytical techniques were applied, 
including microscopic assessment of treated HT-1080 cells. Morphological 
cell changes induced by chemical agents can easily be detected under the 
light and fluorescent microscope, and enhanced with dyes and stains. This 
therefore allows subtle morphological changes to be visualised, and a 
definitive conclusion on the 2-hydroxybenzoate analogues' effect can be 
drawn. Although the morphological characteristics of apoptosis are 
distinctive under the microscope, staurosporine was also used as a 
positive apoptotic control in this study. Generally, results of the 
morphology (see Chapter 3) revealed definitive signs that 2-acetylbenzoic 
acid, calcium and zinc 2-hydroxybenzoates do indeed induce classical 
apoptosis. The morphological results obtained from DAPI, haematoxylin- 
eosin, methyl green pyronin, Annexin V and SEM (see Chapter 3) were 
consistent with the classical apoptotic signs illustrated in the literature, 
including blebbing of the cell membrane, appearance of apoptotic bodies,
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and cell shrinkage (Wyllie, 1981; Smith eta!., 1990; Ruschoff ef a/., 1998; 
Wong et af., 1999; Stark et a!., 2001).
As indicated in Chapters 1-4, apoptosis occurs naturally, and it is part of 
normal physiological events such as embryogenesis (Schutte and 
Ramaekers, 2000). Apoptosis is an integral biological process necessary 
for the development and homeostasis of multicellular organisms (Zou et 
a!., 1997). Both extracellular (like TNF-a) or intracellular (accumulation of 
calcium for example) signalling induce apoptosis (Azmi et a!., 1992; Vaux 
et ai, 1996). Furthermore, several chemical compounds, such as 2- 
acetylsalicylic acid, induce apoptosis in gastric cancer cells (Wong et al., 
1999; Zhou et al., 2001; 1999). Sodium 2-acetylbenzoate, for example, 
induces apoptosis in human myeloid leukaemia cell lines and vascular 
smooth muscle cells (Klampfer et al., 1999; Marra et al., 2000). In this 
study, the apoptotic effect of zinc 2-hydroxybenzoates and 2-acetyl benzoic 
acid were assessed at final concentrations of 0.1 mM and 3.2mM, 
respectively (see Figures 4.10 and 4.11).
Several pathways for the effect of 2-acetylbenzoic acid and its benzoate 
analogues have appeared in the literature. These compounds modulate 
the cellular molecular biology, including mitogen-activated protein kinase 
(MAPK) signalling. 2-acetyl benzoates, for example, inhibit tumour necrotic 
factor (TNF)-induced extra cellular signal-regulated kinase (ERK) 
(Klampfer et al., 1999). Law et a i, (2000) provided the first evidence for 
the effect of 2-acetylbenzoate on the mTOR/p70 pathway. They found that 
2-acetylbenzoate inhibits p70S6K activity and phosphorylation in a p38 
MAPK-independent manner. The effect of 2-acetylbenzoate on caspase 
activation has also been studied in the literature. Pique et ai, (2000) 
indicated that 2-acetylbenzoic acid induces apoptosis through 
mitochondrial cytochrome c release and caspases 9, 3 and 8 in different 
cell lines (Jurkat, MOLT-4, Raji and HL-60). However, the mechanism 
leading to caspase activation remains unknown. Our results also showed 
that 0.4mM zinc 2-hydroxybenzoate and 3.2mM 2-acetylbenzoic acid 
induced apoptosis through caspase-3 activation (see Figure 4.11). The
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apoptotic effects of these compounds were also confirmed flow- 
cytometrically by Annexin V (see Figure 4.10). Caspase-3 is an important 
protein involved in apoptosis of various cells, and the main effector of 
apoptosis (Thornberry and Lazebnik, 1998).
The accumulation of calcium inside the cell subsequently leads to the 
activation of the calcium/magnesium-dependent endonucleases. These 
enzymes are responsible for the induction of DNA fragmentation (Wyllie, 
1980; Walker and Sikorska, 1997). Our results showed that calcium 2- 
hydroxybenzoate and other analogue treatments induced apoptosis (see 
Chapter 3). Generally, cationic metal ions, such as Ca2+, and Zn2+, are 
capable of forming various ionic bonds with a range of cellular molecules 
(with anionic counter ions) under a strict stereochemical and 
conformational set-up. Ionic bonding can occur, for example, with nucleic 
acids, which posses negative charges on the phosphate groups 
incorporated in both RNA and DNA. Proteins also posses negative charge 
capable of bonding with cations. Both aspartate and glutamate, for 
example, are negatively charged, and hence, cations brought into the cell 
may create ionic bonds with proteins containing negatively charged amino 
acid moieties. The elevation of cellular ions by the uptake of calcium or 
zinc 2-hydroxybenzoate could result in significant biological responses, 
such as triggering apoptosis, as revealed in the results. As indicated 
previously, metal ions act as cofactors necessary for protein function. A 
zinc finger, for example, is a small functionally important, independently 
folded domain that requires the coordination of a zinc ion to stabilise its 
structure. Folding of the zinc finger is vital in order for the enzyme to 
maintain its particular DNA, RNA and protein associations (Qian et al., 
1993a; 1993b). A good example of a protein containing zinc finger motifs 
is the Bcl-6 protein. It is a 706 amino acid nuclear protein containing six 
zinc fingers at its C-terminus and acts as a sequence-specific transcription 
repressor. Bcl-6 is expressed in most tissues and in many cell types in 
vitro. Its induction can completely suppress cell growth and triggers both 
cell-cycle arrest and apoptosis (Albagli, 1999). The mechanism by which it
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induces apoptosis has not been elucidated. Elevated concentration of zinc 
ion may assist in the induction of Bcl-6, and consequently apoptosis (see 
also Chapter 1).
Our evidence for apoptosis triggered by 2-hydrohydroxybenzoate 
analogues was based on various techniques, including morphology and 
molecular measurements. Results were obtained from DAPI, methyl 
green/pyronin, haematoxylin and eosin, Annexin V immunolabelling, and 
scanning electron microscopy. The results from these techniques 
substantiate each other, and confirm the apoptotic signs such as blebbing, 
cell rounding and shrinking, as well as the increased presence of RNA in 
the cytoplasm, as shown by pyronin y staining. 0.4mM and 0.8mM 2- 
acetylbenzoic acid, and 0.4mM calcium 2-hydroxybenzoate, as shown by 
all five techniques, induced blebbing, apoptotic bodies, and other signs of 
morphological changes in apoptosis (see Figure 3.4-3.7). The quantitative 
analysis of early apoptosis activated by these two benzoates using 
Annexin-V indicated that both 0.4mM 2-acetylbenzoic acid and 0.4mM 
calcium 2-hydroxybenzoate induced significantly more apoptotic cells 
(16.5% and 25%, respectively) compared to the control samples (see 
Figure 3.5). Potassium and magnesium 2-hydroxybenzoates also induced 
apoptosis at 0.4mM concentration, and were significantly higher than the 
control by about 20.8 and 24.9%, respectively (see Figure 3.8).
A complex relationship exists between magnesium and cancer. There is a 
general notion that magnesium possesses anti-carcinogenic properties 
(Durlach et al., 1990). However, the preventive effects of magnesium exist 
only at the early stages of the carcinogenic process. A magnesium 
deficiency tends to increase the incidence of tumours in humans and 
animals, whilst excessive magnesium promotes the growth of pre-existing 
tumours due to the profound alterations of magnesium homeostasis in 
tumour cells (Hartwig, 2001). Magnesium may interfere with 
carcinogenesis through a variety of biochemical roles in the cell. Increased 
intracellular magnesium may act either as an anticancer or carcinogenic 
agent. This may explain the incidence of increased cell proliferation in
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cells treated with 2-hydroxybenzoic acid magnesium salts. However, it is 
not clear whether only magnesium ions and/or 2-hydroxybenzoate play the 
significant role in promoting these biological activities.
The number of apoptotic cells labelled by Annexin V increased in a 
concentration- and time-dependent manner after treatment with zinc 2- 
hydroxybenzoate. At 0.3mM, the percentage of apoptotic cells was 59% 
compared to the control. This percentage increased to 81.65% when HT- 
1080 cells were exposed to 0.4mM zinc 2-hydroxybenzoate (see Figure 
3.9). At the same concentration (0.4mM), but for a longer exposure time 
(48 hours), all HT-1080 cells were labelled by Annexin V, indicating that 
cells died by apoptosis (see Figure 3.9). The results also showed further 
morphological evidence for apoptosis, specifically through DAPI, methyl 
green/pyronin, haematoxylin and eosin, and scanning electron microscopy 
(see Figures 3.10-3.11).
The Annexin V and morphological evidence for apoptosis induced by zinc 
2-hydroxybenzoate was also confirmed by flow cytometric measurement of 
Annexin V binding to phosphatidylserine. The effect of zinc 2- 
hydroxybenzoate was also concentration-dependent, 0.1 mM induced 
66.6% apoptosis, which increased to 72.3% and to 95.1%, upon 
increasing the zinc 2-hydroxybenzoate concentration to 0.2 and 0.4mM 
respectively. Furthermore, the changes in light scatter due to changes in 
cell morphology when exposed to cytotoxic agent also were used to 
quantify the apoptotic cells flow-cytometrically (Ferlini et al., 1996; Pepper,
1999). The changes in the forward (F) and side (S) scattering 
characteristics (SC) measurements can be used to gate apoptotic cells. 
The quantification of apoptotic cells by light scattering and cells labelled by 
Annexin V showed a strong correlation between the two methods (r2 
=0.99), as calculated by linear regression (Pepper et al., 1997; 1999). The 
results obtained from morphology and flow-cytometric measurement 
(labelled by PI and Annexin V) have clearly indicated that zinc 2- 
hydroxybenzoate induces apoptosis in HT-1080 treated for 24 hours. 
However, it is not clear whether the benzoate salt molecule, benzoate or
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metal ions are responsible for the biological activities inducing apoptosis. 
Results obtained from the calcium or zinc benzoates uptake experiments 
were not enough to demonstrate which part of the 2-hydroxybenzoate is 
responsible for the biological activity. This could be due to either the 
insensitivity of the HPLC and atomic absorption used and/or the low 
concentrations of treated HT-1080 cell samples (see Figure 4.17, and 
Table 4.4). Although the results presented here have demonstrated the 
cytotoxic effect of both calcium and zinc 2-hydroxybenzoate, it is possible 
that the effect may be attributed to the metal ions. Indeed, the simple zinc 
(II) salts, such as zinc chloride (Berger et al., 2004; our laboratory) and 
zinc sulphate (Zodl et al., 2003), reduced cell proliferation in a 
concentration-dependent way. In contrast, the 2-hydroxybenzoic acid was 
found not to be cytotoxic to HT-1080 cells at 0.4mM or less (see Chapter 
2). Apoptosis can be trigged by the elevation of intracellular calcium ion 
which is necessary to activate the calcium/magnesium-dependent 
endonuclease responsible for DNA fragmentation (Wyllie, 1980). On the 
other hand, the increase in intracellular zinc inhibits DNA fragmentation, in 
part by inhibiting the calcium/magnesium-dependent endonuclease 
(Cohen and Duke, 1984; Lohmann and Beyersmann, 1993). Other studies 
have indicated that depletion (by chelating agents) of intracellular zinc in 
many cell types promote apoptosis (Zalewski et al., 1993; Parat et al., 
1997; Ahn et al., 1998) through caspase-3 (Perry et al., 1997) and TNF-a 
(Vaux and Strasser, 1996) upregulation. However, in this study, zinc 2- 
hydroxybenzoate was found to induce apoptosis by upregulating caspase- 
3 at moderate concentrations (0.1-0.4mM; see Figure 4.10; Chapter 4).
5.5 Appraisal of Effect of 2-Hydroxybenzoate Analogues on Molecular 
Expression
In addition to the apoptotic evidence demonstrated by morphological and 
immunocytochemical investigations, some molecular investigations were 
also conducted to establish the mechanism of the apoptotic action for 2- 
hydroxybenzoate analogues. In this study, the expression of various key
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proteins responsible for the regulation of physiological cell death by 
apoptosis was investigated, using Western blot. They included both pro 
apoptotic proteins, such as p53, p21, Bax, and TNF-a, and the anti 
apoptotic proteins, Bcl-2, as well as the expression of histones was also 
investigated. The expression of genes such as caspases, p53, Bcl-2 family 
proteins, and p21 has been demonstrated to occur in the process of 
apoptosis (Huang and Strasser, 2000; Mayer et al., 2003). Caspase-3, 
upon activation, is a significant downstream executioner in apoptosis, 
responsible for the cleavage of a number of substrates such as poly (ADP- 
ribose) polymerase (PARP), D4-GDI, and lamin A (Lee etal., 2003). p21 is 
a downstream gene regulated by p53 gene, and both p21 -dependent and 
independent apoptosis have been identified (Tsao et al., 1998; Yoneda et 
al., 1998; Kuo et al., 2002). Induction of p21 altered the progression of cell 
cycle and arrested cells at the G1 phase through blocking CDK4 activity, 
and promoted the occurrence of apoptosis (El-Deiry et al., 1993). 
Additionally, activation of proapoptotic Bcl-2 family proteins such as Bax 
and Bad or inactivation of antiapoptotic Bcl-2 family proteins such as Bcl-2 
and Mcl-1, have been shown to regulate the intrinsic apoptosis pathway 
(Green, 2000; Reed et al., 2000). Their expression is variable in normal 
and neoplastic human tissues, and their biological significance depends 
on the site of and type of tissue (Soini et al., 1999).
It is evident from the literature that 2-acetylbenzoic acid and other NSAIDs 
induce apoptosis and inhibit cellular proliferation (Sebolt-Leopold et al., 
1999; Wong et al., 1999; Pique et al., 2000; Husain et al., 2001). The 
mechanism of 2-acetylbenzoic acid action is associated with the inhibition 
of cylooxygenase responsible for the synthesis of prostaglandin by 
acetylation of serine-530 in Cox-1 but not Cox-2 (Elder and Paraskeva, 
1998; Shiff and Rigas, 1999 Williams et al., 1999). This explains the anti­
inflammatory effect of 2-acetylbenzoic acid, but how is this related to its 
anti-neoplastic properties? Many tumours contain high concentrations of 
prostaglandins (PGs), which promote angiogenesis, but more importantly, 
cellular proliferation and tumour growth (Munkarah et al., 2002). Although
143
the exact mechanisms by which Cox-2 contributes to carcinogenesis, and 
thus the anti- neoplastic properties of NSAIDs as Cox-2 inhibitors is not 
known, it is probable that increased Cox-2 expression in tumours 
increases prostaglandin and cellular proliferation of the cancer cells by 
default. However, Munkarah (2002) suggested an alternative mechanism, 
and raises the important point that Cox-2 over-expression in tumour cells 
is associated with the reduction in apoptosis, probably mediated through 
an alteration in the balance between Bcl-2 and Bax, resulting in an 
increase in the ratio of Bcl-2 to Bax in these cells, thus inhibiting 
apoptosis. According to Jaattela (1999) and others (Oltvai et al., 1993; 
Sedlak et al., 1995; Reed, 2000), the Bcl-2/Bax ratio reflects cell sensitivity 
to apoptotic stimuli. A high Bcl-2/Bax ratio is linked to poor prognosis and 
a high histological tumour grade (Brambilla et al., 1996; Gazzaniga et al., 
1996) whereas a low Bcl-2/Bax ratio is associated with a favourable 
histological grade and a better patient outcome in combination with a lack 
of relapse and sensitivity to chemotherapy (Aguilar-Santelises et al., 1996; 
Chresta et al., 1996; Gazzaniga et al., 1996). In this respect, the results 
here showed that the ratio of Bcl-2 to Bax decreased upon exposing HT- 
1080 cells to 2-acetylbenzoic acid (1:1.66) or calcium 2-hydroxybenzoate 
(1:4.19) at 0.2mM and 24 hours incubation. Furthermore, the results in this 
study indicated that the ratio increased in a concentration dependent 
manner at 0.05mM and 0.4mM, indicating that apoptosis may be preceded 
via the Bax promoting effect (see Table 4.5; Chapter 4). A study by Zhou 
et al., (2001) confirmed that the induction of apoptosis was mediated 
through Bax over expression without changes in Bcl-2 expression.
In contrast, the ratio of Bcl-2 to Bax increased in the case of zinc 2- 
hydroxybenzoate treated HT-1080 cells at the same concentrations and 
incubation times. Results also indicated that the ratio increased in a 
concentration dependent manner from 1:0.57 at 0.05mM exposure to 
1:0.83 at 0.4mM and both concentrations expressed Bcl-2 more than Bax 
(see Table 4.5; Chapter 4). The effect of zinc 2-hydroxybenzoate on the 
expression of Bcl-2/Bax proteins suggests that HT-1080 cell’s biological
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characteristics have to be explained with other mechanisms that could 
counteract the pro-apoptotic effects of Bax. Fukamachi et al., (1998) 
reported an increase of the Bcl-2/Bax ratio by 1mM cupper sulphate 
treated U937 cells at 4 hours incubation but suppressed hydrogen 
peroxide induced apoptosis. Furthermore, Vaux et al., (1992) reported that 
Bcl-2 did not prevent apoptosis in targeted cells exposed to cytotoxic T 
cells. The results above imply that the mechanism underlining the 
induction of apoptosis exists in multiple pathways. Not all of them 
necessarily involve genetic control but may well share some signals and/or 
intermediate steps.
In addition to the association between Bcl-2 and Bax, the balance between 
Bcl-2 and p53 is important in assessing the apoptotic effect of 2- 
hydroxybenzoates. 2-acetylbenzoic acid increased the Bcl-2:p53 ratio at 
both 0.05mM and 0.4mM. However, both calcium and zinc 2- 
hydroxybenzoates decreased the ratio in treated HT-1080 cells at the 
same concentrations. The same pattern of Bax and p53 protein 
regulations we also observed in HT-1080 cells treated at 0.05mM and 
0.4mM and incubated for 24 hours (see Table 4.5; Chapter 4). Findley et 
al., (1997) found that the Bcl-2 expression was p53-dependent in 18 
pediatric acute lymphoblastic leukemia cells after exposure to ionizing 
radiation. Furthermore, earlier studies also found an inverse correlation 
between the expression of the Bcl-2 and p53 proteins, where Bcl-2 was 
decreased in several breast cancer cells and non-Hodgkin's lymphoma 
(Pezzella etal., 1993; Haidar et al., 1994).
The apoptotic action of 2-acetylbenzoic in gastric cancer cell lines AGS 
(wild-type p53) and MKN-28 (mutant p53) showed the increase of 
caspases-3, Bax and Bad activity (Zhou et al., 2001). In the current study 
the expression of caspase-3 was increased dramatically when HT-1080 
cells were exposed to 0.4mM zinc 2-hydroxybenzoate for 24 hours. In 
contrast, a similar increase in the expression of caspase-3 was obtained 
during the same exposure period by at higher concentration (3.2mM). In 
this respect, the measured apoptosis through caspase-3 activation was
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99.8% for 0.4mM zinc 2-hydroxybenzoate, and 87.05% for 3.2mM 2- 
acetylbenzoic acid (see Figure 4.11).
Caspases play a central role in the execution of apoptosis. The two most 
well studied pathways of caspase activation in cells include a surface 
death receptor and the mitochondrial initiated pathway. There is the 
potential that aspirin may activate the latter, with little or no evidence 
suggesting aspirin can trigger caspase activation through the cell surface 
death receptors. Pique et al., (2000) demonstrated that aspirin is taken up 
into the cell, where it subsequently induces caspase activation through 
cytochrome c release from the mitochondria, preceding the loss of 
mitochondrial membrane potential and the subsequent activation of 
caspases 9, 3 and 8.
Our results clearly indicated that 2-acetylbenzoic acid, calcium 2- 
hydroxybenzoate and zinc 2-hydroxybenzoate have increased the 
expression of p53, p21, Bax, histones and TNF-a in HT-1080 at both 
0.05mM and 0.4mM, and for 24 hours' exposure. However, the effects for 
the expression of these proteins were different in term of concentration. 2- 
acetylbenzoic acid treatments, for example was not concentration- 
dependent, while the effect of most calcium 2-hydroxybenzoate and zinc 
2-hydroxybenzoate treatments was concentration dependent (see Chapter 
4; Figures 4.12-4.16, and Section 4.4).
5.6 Conclusions
The results presented in this thesis indicate that 2-hydroxybenzoates can 
reduce proliferation of HT-1080 cells, most likely through the induction of 
apoptosis. The apoptosis was exclusively confirmed by various 
morphological and biochemical techniques. This thesis also presents 
definitive evidence to show that cell death was trigged by a lower 
concentration (0.4mM) of 2-acetylbenzoic acid than has been commonly 
used in the literature (5-1 OmM). Also, modification of the 2-acetylbenzoic
acid structure has been successful in introducing a new potential 
anticancer drug zinc 2-hydroxybenzoate.
Data presented here indicated that 2-acetylbenzoic acid, calcium 2- 
hydroxybenzoate and zinc 2-hydroxybenzoate at 0.4mM exhibit different 
effects on the expression of investigated proteins (see summary of 
Western blot results, Table 4.4). This may indicate that the three 2- 
hydroxybenzoate analogues exert different mechanisms of action to 
induce apoptosis, although this will need to be further investigated (see 
Chapters 3 and 4). The ratio between Bax (apoptotic promoter) and Bcl-2 
(apoptotic inhibitor) for both 2-acetylbenzoic acid and calcium 2- 
hydroxybenzoate at 0.4mM concentration were 1.7:1 and 4.2:1 
respectively. The interaction between pro- and anti-apoptotic members set 
the threshold that determines whether a cell should die or not (Fleischer et 
al., 2003; Tsujimoto, 2003). Bax and Bcl-2 belong to the Bcl-2 family, 
which encompasses three subfamilies: the anti-apoptotic Bcl-2 (Bcl-2, Bcl- 
XL, Bcl-W, Mcl-1), the pro-apoptotic BH3 (Bad, Bik, Bid, Bik), and the pro- 
apoptotic Bax (Bax, Bak, Bok). These proteins are found in many parts of 
the cell, but their association with mitochondria has become a centre of 
various investigations (Green and Reed, 1998). Bcl-2 family members 
appear to regulate the release of cytochrome c from mitochondria, which 
acts in concert with specific downstream factors, like caspases, to induce 
apoptosis. Thus the induction of apoptosis by 2-acetylbenzoic acid and 
calcium 2-hydroxybenzoate may take place through the downstream 
activities of Bax and caspase-3. Both 2-acetylbenzoic acid and calcium 2- 
hydroxybenzoate also increased the expression of histones, p53, p21 (but 
not in 2-acetylbenzoic acid) and TNF-a proteins at 0.4mM concentration.
In contrast, the apoptotic effect of 0.4mM zinc 2-hydroxybenzoate appears 
to proceed not via the Bcl-2 family pathway, as the ratio of Bax/Bcl-2 
expression was 1:1.2, and both proteins were higher than in the control 
samples. Treatment of HT-1080 cells with zinc 2-hydroxybenzoate also 
induced p21 and p53, histones and TNF-a, which may explain the
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complex cytotoxic effects on the downstream events of apoptotic cell 
death.
Finally, it is still not clear whether the metal ions, the 2-hydroxybenzoate, 
or the combination of the two are causing the apoptosis in HT-1080. 
Unfortunately, attempts to clarify this point by both HPLC and Atomic 
Absorption spectroscopy did not reveal any answer, owing to both 
instrumental insensitivity and low concentrations of both the 2- 
hydroxybenzoates and the metal ions, respectively.
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Appendices
APPENDIX A
A1 - A3 HT-1080 Cells' Response to Monoaromatic Acids: Cell 
Growth and Cell V iability
Data in the following histograms represent the mean ±SE of 
means of three replicates. Cell viability measured by MTT assay.
A1.1 Cell viability (%) by benzoic acid and benzoate analogues after 12 
hours' incubation
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A1.3 Cell viability (%) by benzoic acid and benzoate analogues after 48 
hours' incubation.
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A1.4 Cell viability (%) by benzoic acid and benzoate analogues after 72 
hours' incubation
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potassium 2-acetyl benzoate; 2-AcBnMg = magnesium 2-acetylbenzoate; 2-AcBnCa 
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A4. One-way ANOVA for Figure 2.8D, Chapter 2: Viability (%) (2-acetylbenzoic acid, 
calcium 2-acetylbenzoate, calcium 2-hydroxybenzoate) versus Concentration (6 mM 
and 8 mM).
Analysis of Variance for viability
Source DF SS MS F P
Treatment 5 2486.6 497.3 37.87 0.000
Error 18 236.4 13.1
Total 23 2722.9
Individual 95% CIs For Mean
Based on Pooled StDev
Level N Mean CfDpv -____+__ _ __4 .___ __ 4 _____OIL/CV
1 4 53.589 3.660 ( - * - )
2 4 40.169 2.088 ( - * - ■)
3 4 60.464 4.395 ( - - * - )
4 4 36.475 2.624 ( - * - >
5 4 48.221 2.114 (- * - )
6  4 30.775 5.510 (---*» )
.+ + +--------
Pooled S tD ev= 3.624 36 48 60
Fisher's pairwise comparisons
Family error rate = 0.0109
Individual error rate = 0.00100
Critical value = 3.922
Intervals for (column level mean) - (row level mean)
1 2 3 4 5
2 3.370
23.469
3 -16.925
3.174
-30.345
-10.246
4 7.065
27.164
-6.355
13.744
13.940
34.039
5 -4.681 -18.101 2.194 -21.796
15.417 1.998 22.293 -1.697
6 12.765 -0.655 19.640 -4.350 7.397
32.863 19.444 39.739 15.749 27.495
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APPENDIX B 
Immunolabelling HT-1080 Cells with Annexin-V
B1 One-way ANOVA: +ve Annexin-V /Ca versus Treatments (Control, 2- 
acetylbenzoic acid and calcium 2-hydroxybenzoate) (see Figure 3.5, 
Chapter 3)
Analysis of Variance for +ve/C a
Source DF SS  M S  F P
Tretm ent 2 21 26 .4  10 63 .2  75 .86 0 .000
Error 21 2 9 4 .3  14.0
Total 23  24 20 .7
Individual 95%  CIs For M ean
Based on Pooled S tDev
Level N Mean S tDev -+ ----------- + ----------- +— +
1 8 2.560  1 .289 ( - * — )
2 8 17 .313 4 .8 64  (— * - )
3 8 25.281 4 .0 89  ( - -*->
-+  + + +
Pooled S tD e v =  3 .744  0.0  8.0  16.0 24 .0
Fisher’s pairwise comparisons 
Family error rate = 0.221  
Individual error rate = 0 .100
Critical value = 1.721
Intervals for (column level m ean) - (row level m ean) 
1 2
2 -17 .974  
-11.531
3 -25 .9 43  -11 .1 90
-19 .5 00  -4 .747
B2 One-way ANOVA: +ve Annexin-V /K versus Treatments (Control, 2- 
acetylbenzoic acid, and potassium 2-hydroxybenzoate) (see Figure
3.8, Chapter 3)
Analysis of Variance for +ve/K
Source DF SS M S F P
Tretm ent 2 1502 .9 75 1 .4  4 6 .93  0 .000
Error 21 336.3 16.0
Total 23 1839 .2
Individual 95%  CIs For Mean
Based on Pooled S tD ev
Level N Mean StDev - + + Yn„T
1 8 2.560 1.289 (— ■* - )
2 8 17.313 4.864 ( - * - )
3 8 20 .825 4 .766
-4
( - * - )  
----------+----------- ‘
Pooled S tD e v =  4 .002  0.0  7.0  14.0 21 .0
Fisher's pairwise comparisons 
Family error rate = 0.221 
Individual error rate = 0 .100  
Critical value = 1.721
Intervals for (column level m ean) -  (row  level m ean)
1 2
2 -18 .196  
-11 .3 09
3 -21 .7 08  -6 .956
-14 .8 22  -0 .069
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B3 One-way ANOVA: +ve Annexin-V /Mg versus Treatments (Control, 2- 
acetylbenzoic acid, and magnesium 2-hydroxybenzoate) (see Figure
3.8, Chapter 3).
Analysis of Variance for +ve/M g
Source DF S S M S F P
T retment 2 2 0 65 .0 10 32 .5  41 .7 3  0 .000
Error 21 519 .6 2 4 .7
Total 23 25 84 .6
Individual 95 %  C Is For M ean  
Based on Pooled S tD ev  
Level N Mean S tD ev —+----------- + ----------- + ------------+—
1 8 2 .560  1 .289  (— * - )
2 8 17 .313 4 .8 64  ( - * — )
3 8 24 .901 6 .9 93  (— *— )_+ + +-------+—
Pooled StDev = 4 .974  0 10 20  30
Fisher’s pairwise comparisons 
Family error rate = 0.221  
Individual error rate = 0 .100  
Critical value = 1.721
Intervals for (column level m ean) -  (row  level m ean)
1 2
2 -19 .0 33  
-1 0 .4 72
3 -2 6 .6 22  -11 .869
-18 .061 -3 .308
B4 One-way ANOVA: +ve Annexin-V /Zn versus Treatments Control, 2- 
acetylbenzoic acid, and zinc 2-hydroxybenzoate) (see Figure 3.9, 
Chapter 3)
Analysis of Variance for +V e/Zn
Source DF SS  M S F P
T retment 2 14823 .6  7 4 11 .8  128 .75  0 .000
Error 21 1208 .9  57 .6
Total 23 16032.5
Individual 95 %  CIs For Mean
Based on Pooled S tDev
Level N M ean S tD ev - + ----------- +---------
1 8 2 .5 6 0  1 .289  ( - * - )
2 8 17 .313  4 .8 64  ( - * - )
3 8 6 1 .0 8 5  12 .140
_+ + + +—
Pooled StD ev = 7 .587  0 20  40 60
Fisher’s pairwise comparisons 
Family error rate = 0.221  
Individual error rate = 0 .100  
Critical value = 1.721
Intervals for (column level m ean)-(row  level m ean) 
1 2 
2  -2 1 .2 8  
- 8.22
3 -6 5 .0 5  -50 .3 0
-5 2 .0 0  -37 .2 4
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APPENDIX C
Supporting Data fo r Chapter 4
C1 -  C3 Flow Cytometric Analysis of Cell Cycle fo r HT-1080 Cells at 
2, 6,12 and 24 hours.
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C4.1 Apoptosis measurement using Annexin-V labelling of zinc 2- 
hydroxy benzoate-treated HT-1080 cells
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C4.2 Apoptosis measurement using Caspase-3 activity assay of zinc 
2-hydroxybenzoate-treated HT-1080 cells 
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C5 Western Blot: Protein concentrations and antibodies dilutions. 
Table A1 Protein analysis of albumin standard curve.
pg/100pl R1 R2 R3 R4 R5 R6 R7 R8 Average SE
0 0.051 0.06 0.057 0.059 0.052 0.048 0.055 0.073 0.057 0.0077
50 0.059 0.068 0.067 0.067 0.058 0.056 0.064 0.081 0.065 0.0079
100 0.065 0.074 0.071 0.071 0.065 0.06 0.071 0.097 0.072 0.011
150 0.07 0.079 0.078 0.077 0.072 0.066 0.075 0.095 0.077 0.0087
200 0.08 0.085 0.084 0.085 0.075 0.071 0.08 0.098 0.082 0.0081
250 0.087 0.1 0.091 0.094 0.086 0.077 0.088 0.105 0.091 0.0087
300 0.095 0.106 0.105 0.101 0.099 0.09 0.099 0.113 0.101 0.0071
Table B1 Protein analysis of proteins in HT-1080 cell lysate.
R1 R2 R3 R4 R5 R6 Average STDER
Control - 0.15 0.156 0.149 0.149 0.154 0.1516 0.003
2AcBA 0.05 0.210 0.191 0.214 0.221 0.228 0.194 0.2096 0.015
2AcBA 0.4 0.147 0.155 0.143 0.14 0.156 0.143 0.1474 0.007
2HBnCa 0.05 0.178 0.165 0.203 0.173 0.178 0.171 0.1780 0.013
2HBnCa 0.4 0.218 0.232 0.227 0.212 0.208 0.213 0.2184 0.009
2HBnZn 0.05 0.224 0.208 0.231 0.211 0.233 0.235 0.2236 0.012
2HBnZn 0.4 0.183 0.184 0.181 0.193 0.178 0.177 0.1826 0.006
Table C1 Protein concentrations of HT-1080 cell lysate per fixed volume.
Average (A575nm) x = y-0.0569/0.0001 Mass (mg/10ml of concentrated sample)
2HBnZn 0.05 0.224 365.67 10604.333
2HBnZn 0.4 0.183 229.00 6641.000
2HBnCa 0.05 0.178 213.67 6196.333
2HBnCa 0.4 0.218 348.33 10101.667
2AcBA 0.05 0.210 319.00 9251.000
2AcBA 0.4 0.147 111.67 3238.333
Control 0.152 125.67 3644.333
1 0  ml of stock solution diluted to 100 with lysate buffer.
